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The immune system is a tightly controlled and extremely complex system with the ability 
to distinguish between dangerous and non-dangerous elements, self and non-self, in order to 
mount effector responses. Its main effector responses are against pathogens, but the immune 
system is also a principal actor in a myriad of different processes in health and disease, including 
cancer, pregnancy establishment and tissue healing, amongst others. There are two major 
components of the immune system that are closely inter-related: the innate branch and the 
adaptive branch. The innate immune system is a non-specific defense system: by recognizing 
danger signals through Toll-like receptors (TLR), amongst other receptors, it produces a powerful 
inflammatory response that prevents or limits the development of infections by virtually all 
potentially pathogenic microorganisms. The epithelium, neutrophils, macrophages, monocytes 
and dendritic cells (DC) are the major actors of the innate immune system. Depending on the 
species, the innate immune system may be the only system to deal with infections, such as in 
invertebrates; however, in vertebrates, the innate immune system is the first step. Following this 
first response, it will enhance antigen-specific responses characteristic of the adaptive immune 
system, both by attracting cells of the adaptive immune system (mainly lymphocytes) and by 
presenting them the processed antigens to induce their activation. Adaptive responses are 
effector responses of antibody secreting B cells and cytotoxic or helper T cells, which will then 
contribute to the generation of memory, that will allow a rapid secondary immune adaptive 
response when the same antigen is reencountered [1,2].  
Defects in the function of the immune system, congenital or acquired, lead to disease: 
inborn or genetic errors of the immune system can induce immunodeficiency. In the other hand, 
secondary/acquired defects of the immune can also lead to immunodeficiency, including 
treatments such as cancer chemotherapy or biological drugs targeting the immune system and 
pathogens such as human immunodeficiency virus. Clinical spectrum of immunodeficient 
individuals is broad since it depends on the nature of the immunodeficiency, from susceptibility 
to single pathogens to susceptibility to a wide range of microorganisms, with or without associated 
malignancy and immune dysregulation.  
 
1.1.Primary immunodeficiency 
Primary immunodeficiencies (PID) are caused by inborn errors of the immune system 
generating susceptibility to infections, autoimmunity and malignancies. Most of PID are caused by 
monogenic defects with classical Mendelian inheritance: autosomal recessive (AR), dominant (AD) 
or X-linked. Recently, with the use of next generation sequencing technologies (NGS), multi-gene 
or somatic causes of PID are being increasingly described [3]. Study of PIDs is an expanding field: 
new PID-causing genes or new phenotypes of known genes are constantly being reported (Figure 
1). Currently there are 357 known genes described to be causative of PID (collected by the 





Figure 1 Number of inborn errors of immunity described by the International Union of 
Immune Societies since 1979. Adapted from Picard C et al, JCI, 2018 [4] 
Although individually rare, incidence of PID as a group is thought to range between 
1:2,000 and 1:10,000 live births [5]. In countries with high consanguinity rates (such as the Middle-
East where approximately a 65% of unions are consanguineous), the incidence of AR PIDs is 
obviously higher [6]. PID are chronic multiorgan disorders with a high burden of disease, that can 
be minimized if specific treatment is started early in the course of the disease, such as antibiotic 
prophylaxis, immunoglobulin replacement therapy, hematopoietic stem cell transplantation 
(HSCT) or gene therapy. Early diagnosis and early treatment have, therefore, a huge impact on 
patient’s prognosis. 
The concept of a PID has dramatically changed over the last years. Classically, PIDs were 
characterized by chronic or recurrent life-threatening infections starting during childhood, with a 
susceptibility to a broad range of infections. Severe Combined Immunodeficiency (SCID), Chronic 
Granulomatous Disease (CGD) or Common Variable Immunodeficiency (CVID) are hallmarks of 
classical or “typical” PIDs. However, recent investigations in the last 10 years have described a 
new type of PID, named “atypical” PID. This atypical PID can confer susceptibility to a narrow range 
of pathogens (even just one) or manifest with autoimmune events without infections, starting 
even in adulthood. Prognosis of “typical” PID patients is usually poor, as patients worsen with age 
without treatment; instead, some atypical PID etiologies improve with age, implying that the 
adaptive immunity can “learn” to overcome the infections. Also, typical or conventional PID 
usually have an inherited recessive familial phenotype with complete penetrance, while new PID 
are often AD, can be spontaneous, have incomplete penetrance or can be originated from somatic 









Table 1. Clinical differences between classical and atypical primary immunodeficiencies (PID) 
 Classical PID “Atypical” PID 
Age of onset Infancy - childhood 




Wide range of pathogens 
Failure to thrive 
Low number of infections 
Low number of pathogens 
Otherwise healthy children 
Prognosis 
High mortality 
Worsens with age 
High mortality 
Improves after adolescence 
Genetics Monogenic (AD, AR, XL) 







Chronic granulomatous disease 
Complement defects 
Toll-like Receptors defects 
IFN-γ and IFN-α defects 
 
The discovery of atypical PIDs has greatly contributed to our understanding of the function 
of the immune system. Single gene mutations conferring susceptibility to individual pathogens in 
otherwise healthy patients are considered by some to be “experiments of nature”: their study has 
helped understand how the immune system battles with different types of pathogens, though the 
identification of specific and non-redundant pathways responsible for the host-immunity to 
particular pathogens [8,9]: some examples are the interleukin (IL)-12/interferon (IFN)-γ pathway 
for anti-mycobacterial immunity or TLR3 pathway in central nervous system immunity against 
herpesvirus [10]. The discovery of this type of genetic infectious susceptibility gave support to the 
development of the genetic theory of infectious disease. 
 
1.1.1.PID classification 
The immune system is a broad and highly specialized network. Defects in different genes 
or gene-pathways give rise to different clinical manifestations. To try to simplify the broad and 
diverse forms of PID; they have been categorized based on the function of the immune system 
most represented. Given the continuous discovery of new etiologies, the IUIS revises the PID 
classification every 2 years since 1970; the last update from August 30, 2017 [4] includes 357 genes 
classified in 9 categories:  
1. Immunodeficiencies affecting cellular and humoral immunity,  
2. Combined immunodeficiencies with associated or syndromic features 
3. Predominantly antibody deficiencies  
4. Diseases of immune dysregulation 
5. Congenital defects of phagocyte number or function 
6. Defects in intrinsic and innate immunity 
7. Autoinflammatory disorders  
8. Complement deficiencies 




PID phenocopies are a new category of disorders, which are caused by two main 
mechanisms: (a) somatic mutations (mutations only present in specific cell types as opposed to 
germline mutations) and (b) auto-antibodies (majorly against cytokines) mimicking primary 
immune deficiencies. One example of this last group is the adult onset immunodeficiency 
mimicking Mendelian Susceptibility to Mycobacterial Disease (MSMD; OMIM 209950) caused by 
the presence of anti-IFN-γ autoantibodies[4,11].  
In any case, PIDs are still underdiagnosed diseases: although awareness of PID among 
clinicians is increasing, there is still a proportion of patients which are not being diagnosed, mostly 
because of the lack of awareness in some geographic areas and in some medical specialties, but 
also because of the technical and economic difficulties to perform genetic and functional tests to 
diagnose a PID in a given patient. Also, the rapid advance of the discovery of new phenotypes is 
broadening the spectrum of PID. Therefore, training of clinicians and laboratory personnel is of 
outmost importance to better diagnose PID patients and, therefore, to decrease morbi-mortality 
of the disease.  
 
1.2.Secondary immunodeficiency 
Defects in the function of the immune system causing immunodeficiency can be 
secondary or acquired, reversible or not. Although the most known form of acquired 
immunodeficiency is the Acquired Immune Deficiency Syndrome (AIDS), caused by a non-
controlled Human Immunodeficiency Virus (HIV) infection, severe malnutrition is currently the 
most prevalent form of secondary immunodeficiency in the world. Secondary immunodeficiencies 
occur by many different causes:  
1. Severe malnutrition: caused by lack of protein intake or extreme protein loss [12]. Other 
forms of malnutrition such as severe micronutrient deficiencies can also lead to some 
form of immunodeficiency [13]. 
2. Viral infections: HIV infection, if untreated, leads to a state of immunodeficiency in which 
opportunistic infections and malignancy can be lethal. Besides, other infections such as 
measles virus, cytomegalovirus or influenza virus may induce transitory states of 
immunodeficiency [12]. 
3. Malignancies: both by the disease itself (i.e. chronic lymphocytic leukemia and multiple 
myeloma) and/or because of treatment’s secondary effects [12,14]. 
4. Iatrogenic: Immunosuppressive or immunomodulatory drug treatment, including biologic 
drugs targeting immune-system molecules and splenectomy (patients whose spleen has 
been removed are more susceptible to Streptococcus pneumoniae and have higher 
probability of developing sepsis). 
5. Age: prematurely born neonates and old age people have altered immune responses 
leading to infection susceptibility. 
6. Metabolic diseases: such as diabetes mellitus in which phagocytosis, chemotaxis and 
proliferation to mitogens may be impaired.  
7. Defects of the epithelial barrier: by trauma, surgery or burn.  
8. Environmental causes such as ultraviolet light, ionizing radiation, high altitude, chronic 




1.2.1.Secondary immunodeficiency caused by biologic drugs targeting immune-system molecules 
The use of therapeutic antibodies targeting immune system molecules has dramatically 
changed the treatment of different diseases such as inflammatory bowel disease (IBD), rheumatic 
disease, cancer (both hematological and solid tumors), allergic and infectious diseases. Antibodies 
are secreted by B cells and are antigen-specific; they have a constant region (Fc) that defines the 
isotype, and a variable region that confers its specificity. The first therapeutic use of antibodies 
was approximately in 1890, with the use of serum from immunized animals for the treatment of 
some infections [15,16]. However, after the discovery of antibiotics by Fleming in 1928, being a 
cheaper and safer treatment, this practice was abandoned [15]. Afterwards, since 1976, when the 
first monoclonal antibody (mAb) was synthetized [17], the possibility of producing specific 
antibodies for therapeutic purposes was launched [18]. After this initial discovery, the use of 
murine mAbs for human therapy had disappointing results due to human anti-murine antibodies 
responses. However, the development of chimeric (constant fraction being from human origin and 
variant regions being murine sequences), humanized (all but the complementarity determining 
region being from human origin) and totally human antibodies overcame this limitation and paved 
the way for their safe and effective use in humans [19–21]. Although the first murine mAb for 
treatment was the anti-CD3 muronomab (OKT3) for transplant rejection therapy [22], it was not 
until 1997 when the first mAb for treatment of malignancy (anti-CD20 rituximab) was approved 
by the Food and Drug Administration (FDA) [23]. Nowadays, more than 60 antibodies have been 
approved for their use in humans [18,24].  
Recently, it has been hypothesized that biologic drugs targeting immune system 
molecules can lead to phenotypes resembling PID, depending on the inhibited or modulated 
pathway by the mAb [25,26]. This theory is supported by the identification of PID phenotypes 
caused by naturally occurring auto-antibodies in the context of an autoimmune disorder: for 
example, anti-IL-17 auto-antibodies presence mimics chronic mucocutaneous candidiasis caused 
by congenital defects of IL-17A, anti-IFN-γ autoantibodies generates the same phenotype 
observed in patients with mutations in IFN-γ receptors, anti-IL-6 resembles Signal Transducer 
Activator of Transcription 3 (STAT3) deficiency and anti-granulocyte and monocyte colony 
stimulating factor causes pulmonary alveolar proteinosis as CSF2RA deficiency [27–29]. These 
forms of PID are named PID phenocopies, as mentioned in chapter 1.1.1. 
Although the observed phenotype after mAb therapy can resemble its corresponding PID, 
there are factors to be considered. PID defects are present in the individual since birth (even 
before), whereas treatment with mAbs is usually used in adults, whose immune system is 
completely developed. Besides, germline mutations leading to immunodeficiencies are present in 
all cell types and the effect of a certain mAb can be restricted to some cell types or tissues. For 
these reasons, clinical outcome in mAb therapy is usually a milder version of the phenotype 
observed in PID. However, there are some confounding factors including disease stage, immune 
status, duration of treatment, concomitant medication, age, ethnicity and environmental 
exposure to infectious agents, amongst others, that modify the phenotype and can lead to more 
severe phenotypes that the corresponding PID [25,26].  
Currently, there are biologic treatments targeting both molecules of the adaptive and 
innate immune system, mainly for the treatment of autoimmune or inflammatory diseases, cancer 




time (B cell lymphoma, autoimmune disorders, graft rejection), with small intervals or at high 
doses, can produce hypogammaglobulinemia, resembling primary antibody deficiencies [30,31]. 
Antibodies targeting molecules of the IL-12/23 – IFN-γ pathway, which are being recently used, 
including antibodies against IL-12p40, CD40, IFN-γ [26] and Janus associated kinase (JAK) inhibitors 
[32], can produce an increased susceptibility to mycobacterial and viral infections [32–35].  
Secondary immunodeficiencies related to the use of anti-Tumor Necrosis Factor (TNF)-α 
antibodies and their relationship with mycobacterial infections will be extensively developed in 
the 4th section of the introduction. 
2. MSMD as a paradigm of the genetic infectious disease theory 
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2. Primary immunodeficiencies as a paradigm of the genetic infectious disease 
theory 
 
Since infection has been, and already is, the principal cause of death in the world, the 
understanding of how and why have been major goals. There are four major theories trying to 
explain the basis for the development of infectious diseases: the genetic and immunological 
theories of infectious disease, which rely on host factors, and the ecological and microbiological 
theories, which rely on environmental factors. These theories are complementary and 
overlapping, and have been developing in parallel with the scientific knowledge advance [36]. 
Microbiological or germ theory arose in the late XIXth century after the works performed 
mainly by Pasteur and Koch. It stated that infectious diseases are caused by microorganism’s 
infection, and that these microorganisms are as well sufficient and necessary for the development 
of the disease. Pasteur’s [37] and other’s observations [38,39] were not sufficient for the general 
acceptance of this theory [40–43]. It was not until the observation of tuberculous bacilli made by 
Koch [44], that germ theory was accepted, giving rise to the Koch-Henle postulates: “(1) The 
parasite occurs in every case of the disease in question and under circumstances which can 
account for the pathological changes and clinical course of the disease. (2) It [the microorganism] 
occurs in no other disease as a fortuitous and nonpathogenic parasite. (3) After being fully isolated 
from the body and repeatedly grown in pure culture, it can induce the disease anew” [45].  
However, the microbiological theory encountered problems with the variability observed in 
infectious disease [36]. (Figure 2) 
 
Figure 2. Studio portrait of Louis Pasteur (1822-1895) by Félix Nadar (before 1895), left panel; and photo 





Ecological theory of infectious disease was strongly supported and developed by Dr. 
Dubos during the 1950’s. It questioned the statement of germ theory defending that pathogens 
were not sufficient for the establishment of infectious disease; it proposed that “pathogens are 
the agent of infection but the instigator of the disease is an unrelated disturbance of the host” 
and “whether the man lives in equilibrium with microbes or became the victim depends upon the 
circumstances which he encounters them” [46]. Those “circumstances” include climatological 
variants (cold, humidity, …[47]), metabolic state (malnutrition [48], uncontrolled diabetes [49],…) 
or co-infections with other pathogens [50]. The ecological theory of infectious disease does not 
invalidate the other theories but encompass them by considering that extrinsic factors modulate 
the relation between the pathogen and the host.  
The immunological theory appeared trying to explain the differences between individuals 
upon an infection with microorganisms. It started with Pasteur being again a ground-breaker with 
the use of attenuated microbes for the protection from severe infections [51,52].  With the use of 
vaccines and serotherapy [15,16], the common thought was that variability in the response to 
normally lethal infections was due to individuals’ attenuated, in terms of quantity or virulence, 
previous exposure [36]. However, it was after the discovery of the antigen specificity of antibodies 
by Paul Ehlrich [53,54] that this theory gained significance. With this fact, the experience gained 
by the adaptive immune system seemed to determine the host response to pathogens. This theory 
explained the variability observed after infection reactivation but failed to explain the great 
variability after primary infections. The discovery of inapparent infections, by Charles Nicolle, in 
which pathogens were present in asymptomatic individuals that were able to transmit the disease 
[55] was not easily explained by the immunological theory of infections.  
After these theories and their limitations, genetic theory appeared, stating that the host’s 
genetic background determined the outcome of a microorganism infection, either at population 
[36,56] or clinical levels [36,57]. Further studies gave support to these theories including, i) the 
differential mice susceptibility to infections depending on the studied strain [58–63], ii) tween 
studies in tuberculosis [64], iii) the observation of the protection to malaria infection by the 
presence of a relatively common allele causing sickle cell trait at a population level (showing 
genetic control of a disease-course) [65,66] and the description for the first time of a primary 
immunodeficiency, Bruton’s disease [67]. Initially the two currents of genetic theory (population- 
and patient-based) were growing separately.  
2.1. The unified genetic theory of infectious disease  
Until middle nineties, despite the convincement that genetic background played a major 
role in infection outcomes, the division between the population- and clinical-based approaches 
continued to exist. Population-level studies showed association between a common background 
including many genes to one single infection while PIDs were the example of the opposite (i.e. one 
defective gene conferring susceptibility to many infections, named “one gene, multiple 
infections”). It was not until the description of mutations conferring susceptibility to a unique type 
of pathogens (“one gene, one infection”), named “atypical” primary immunodeficiencies 
(described in the first section), then the two currents of genetic theory unified. The first entities 
in which single gene mutations were found to confer susceptibility to one type of pathogen were 
infections by Neisseria in complement deficient patients [68], patients with mutations in SH2D1A 
2. MSMD as a paradigm of the genetic infectious disease theory 
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causing X-linked lymphoproliferation after Epstein-Barr virus (EBV)  infection [69,70] and the first 
genetic descriptions of MSMD by mutations in IFNGR1 [71,72]. 
After these discoveries, the unified theory of genetic diseases was finally established. It 
stated that “life-threatening childhood infections are due to single-gene inborn errors of 
immunity in the course of primary infections, […] symptomatic reactivation and secondary 
infections in young adults may result from the impact of a major locus, whereas in older adults 
the cause may be more polygenic” [36], first proposed by Jean-Laurent Casanova and Laurent Abel 
in 2007 [73] and nicely reviewed afterwards [7,36,73,74]. 
The unified genetic theory of infectious disease is “a reconciliation” with the old thoughts 
of hereditable infections that were discredited after the advent of the germ theory, trying to 
explain why not all individuals respond similarly to infections. Of note, until the discovery of Koch 
bacilli in 1882, tuberculosis (TB) was thought to be a hereditary disease [64,75]; more than a 
century after it has been shown that genetic background is of outmost importance for clinical 
development of tuberculosis [76–79] and, what is more, that in some cases severe infections by 
Mycobacterium tuberculosis (Mtb), especially during childhood, are due to PID caused by single-
gene defects in T cell function, oxidative burst [78,80] or IFN-γ responses [81–95]. In conclusion, 
since 2010, the genetic theory of infectious disease states that any more than usual severe 
primoinfection in pediatric patients might underlie an inborn error of immunity or PID.  
2.2.Mendelian susceptibility to mycobacterial disease 
Some years after the initiation of broad vaccination with Bacille-Calmette Guerin (BCG), 
infectious secondary effects including both localized (BCGitis)[96–102] or disseminated (BCGosis) 
[103–108] were reported over the world, some ending in the death of the patient [105,106,108]. 
After the observation of familial pattern of susceptibility to develop infections [105], in the middle 
sixties, BCGosis after vaccination was associated with HIV infection [109–111] and PID [110–114], 
mainly T cell defects (SCID) and CGD [106,110–115] or were labeled as “idiopathic” if the patient 
was otherwise healthy and without apparent immune alterations [110,111]. However, these 
immune deficiencies did not explain all the phenotypes observed. In fact, BCGitis and/or BCGosis 
cases were reported in otherwise healthy individuals without immunological defects detectable 
with the ordinary tools [108,116]. The case reported by Heyne et al of two siblings with 
generalized BCG infection and enteric salmonellosis in 1978 was the first time in which BCG 
susceptibility was linked to the innate system: “No known immunodeficiency disease could be 
correlated with this familial syndrome of increased susceptibility to intracellular vital microbes. A 
defective function of the patient’s macrophage system is suspected” [116].  
Jean Laurent Casanova et al theorized that those “idiopathic” infections after BCG 
vaccination respond to an heritable immunodeficiency [110,111] and Levin et al were also for the 
run of the locus of susceptibility to mycobacterial disease [117]. Later in the same year, the two 
groups simultaneously reported on the same issue of the New England Journal of Medicine 
mutations in the IFNGR1 gene as the first genetic etiology of Mendelian Susceptibility to 
Mycobacterial Disease, known with the acronym MSMD [71,72].  
MSMD is a PID characterized by a selective predisposition in otherwise healthy individuals 
to disease after exposure to BCG vaccines or environmental mycobacteria [95,118]. It is included 




[4,11] . It is one of the most studied “atypical” PID. MSMD is caused by inborn errors impairing 
the final killing of intra-macrophagic pathogens. Immunity to these pathogens, whose major 
representative are mycobacteria, relies on the IFN-γ circuit or IL-12/IFN-γ axis [95,118], which is 
deeply reviewed in section 3.1.  
Currently 10 causal genes have been described, whether affecting IFN-γ production, such 
as IL12RB1 [81,119,120], IL12B [89,121], ISG15 [90,122], NEMO  [123], IRF8 [124], and TYK2 [125], 
or cellular responses to it, such as IFNGR1 [72,91,93,119,126,127], IFNGR2 [128,129], STAT1 
[94,130,131], IRF8 [124] and CYBB [92,123,132]. There are currently 19 different genetic etiologies 
of MSMD deficiency involving either the impact of the mutation (null or hypomorphic), the mode 
of transmission in the family (dominant or recessive), the expression of the mutant allele (absent 
or detectable), or the function affected by the mutation (one domain or another, in the case of a 
detectable protein) [95,125]. This number is likely to increase in the coming years. With so many 
forms of MSMD, the clinical boundaries of the syndrome and each genetic etiology are not yet 
fully defined. 
 
2.2.1.Clinical spectrum of Mendelian susceptibility to mycobacterial disease  
Patients affected with MSMD are usually otherwise healthy and can present a wide range 
of severity of the disease, from local and recurrent to disseminated and lethal. Severity of the 
disease depends on the type of underlying defect (complete or partial). MSMD usually, but not 
always, manifests in childhood [95]. Besides, one of the main issues in MSMD is the incomplete 
penetrance observed in IL-12Rβ1 deficiency and partial IFN-γ receptor (IFN-γR) deficiencies mainly 
[81,91,95].  This incomplete penetrance opens the door for the study of modifying factors 
explaining the different susceptibility of individuals with the same mutation but different clinical 
outcomes. Clinical phenotype and general features of the different MSMD etiologies was 
thoroughly reviewed by Bustamante et al in 2014 [95]; an updated summary is showed in the 
following subsections. 
Clinical manifestations of MSMD comprise atypical mycobacteria infection, being BCG 
after infant vaccination the most common [95,133] or environmental mycobacteria (EM). Some 
patients are also susceptible to Mtb [78]. Besides mycobacteria, there is a wide range of disease-
causing organisms that includes other intra-macrophagic infections such as salmonella or listeria, 
fungi (especially Candida spp.), parasites as Leishmania [134] or virus in combination with 
mycobacteria as cytomegalovirus (Table 2).  
 
Table 2. Current MSMD warning signs.  
Age at 
presentation 
Usually in childhood, also in adolescence and adulthood 
General state Otherwise healthy individuals 
Infectious 
spectrum 
Invasive or recurrent infections by:  
Mycobacteria: 
BCG infection (Mycobacterium bovis vaccine strain)  
Environmental mycobacteria (M. chelonae, M. fortuitum, M. 
mageritense, M. peregrinum, M. smegmatis, M. scrofulaceum...) 
Mycobacterium tuberculosis 
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Intramacrophagic bacteria (alone or in combination with mycobacteria): 
Salmonella spp. 
Listeria monocytogenes /Nocardia spp. /Klebsiella spp.  
Fungi (in combination with mycobacteria) 
Candida spp.  
Histoplasma capsulatum/Paracoccides brasilensis /coccicoides 
spp.  
Parasites (alone or in combination with mycobacteria, rare):  
Leishmania spp. 
Toxoplasma gondii 
Virus (in combination with mycobacteria, rare) 
Cytomegalovirus, human herpes virus 8, parainfluenza virus type 
3, respiratory syncytial virus and varicella zoster virus.  
Other Family history of invasive or recurrent mycobacterial infection 
Undetectable or very low IFN-γ production in Interferon-Gamma Release 
Assays (i. e. QuantiFERON-TB Gold In-Tube) 
 
Interestingly, specific clinical manifestations have been associated with specific gene 
defects: the correlation of pathogens and/or clinical forms with all described genetic etiologies of 
MSMD was broadly reviewed by Bustamante et al [95]. Briefly, patients with IFN-γ production 
defects caused by mutations in IL12RB1 and IL12B (encoding IL-12Rβ1 and IL-12p40 respectively) 
commonly suffer from disease caused by Salmonella (recurrent or not) and, although to a lesser 
extent, from Candida. Some patients with severe TB have been diagnosed with IL-12Rβ1  defects 
[78,82]. These patients do not usually present viral infections. In parallel, the presence of 
multifocal osteomyelitis should raise the suspicion of a partial AD IFN-γR1, partial AR, or STAT1 AD 
loss of function (LOF) [131,135–141]. Patients with complete deficiency in IFN-γR1 and IFN-γR2, 
abolishing IFN-γ response, are more prone to viral disease such as cytomegalovirus, respiratory 
syncytial virus and varicella virus Zoster, among others [95]. Treatment of patients with MSMD 
ranges from HSCT for the most severe forms [72,142], to exogenous human recombinant IFN-γ 
(hr-IFN-γ), in addition to antibiotics, for the milder forms. 
2.2.1.1. IL-12Rβ1 defects 
AR defects in IL12RB1 gene are the most common cause of MSMD, they were first 
reported 1998 [143,144]. IL-12Rβ1 is a common chain of two cytokine receptors, when combined 
with IL-12Rβ2 it binds IL-12p70 and when combined with IL-23R binds IL-23. It is expressed on 
activated T cells and NK cells [145].  More than 200 patients with IL-12Rβ1 deficiency have been 
reported [95,146–155] with complete loss-of-function of mutations including nonsense, missense, 
splice site mutations, small and large deletions, insertions and duplications 
(www.LOVD.nl/IL12RB1). With exception of two described mutations, all mutations give rise to 
the absence of protein expression [95,155,156].  
The clinical phenotype was initially thought to be mild [157], but it has been showed to be 
very variable, ranging from asymptomatic condition in adult individuals to death at early ages 
[81,95]. Atypical mycobacterial infections are the most common, especially after BCG vaccination; 
recurrence or EM disease after BCG vaccination are rare, suggesting altered primary anti-
mycobacterial responses, but not secondary. Another clinical typical feature, observed in more 
than one third of IL-12Rβ1 deficient patients, is invasive salmonellosis. Besides, mucocutaneous 




g. Klebsiella), fungal (e. g. Histoplasma spp.) and parasitic (e. g. leishmaniasis) infections have been 
sporadically reported; malignancy is described in just one patient [95,150]. IL-12Rβ1 defect is one 
of the etiologies with the most incomplete clinical penetrance, being 0.64 at 5 years and 0.79 at 
20 years [81,95].  
2.2.1.2. IL-12p40 defects 
Mutations in IL12B were discovered the same year than in IL12RB1 [95,121], being the 
first discovered inherited cytokine defect. As happens with IL12RB1, encoding for the common 
chain of IL-12 and IL-23 receptors, IL12B encodes for IL-12p40, a subunit of both IL-12 and IL-23. 
More than 50 patients have been identified, all from 5 countries: India, Iran, Pakistan, Saudi Arabia 
and Tunisia. All patients have complete LOF defects that cause the absence of the protein. 
Clinically, IL-12Rβ1 and IL-12p40 deficiency are phenocopies, with the same type of infections 
described. There is also incomplete penetrance, that reached 50% at one year old [89,95].  
2.2.1.3. IFN-γR1 deficiency 
IFN-γR1 is the chain of the IFN-γ receptor responsible of IFN-γ binding. AR null mutations 
in IFNGR1 were the first genetic MSMD etiology to be identified [71,72,95]. Different mutations 
lead to different patterns of receptor’s expression and levels of clinical affectation [91,95]. 
Complete defects of IFN-γR1 cause severe disease with infections characterized by early-onset 
(before three years-old), with commonly disseminated and life-threatening infections by BCG and 
EM and, also, Mtb infections have been observed. Besides mycobacterial infection, viral infections 
have been described, 3 patients have been reported with malignancies [95,158,159] and 
hemophagocytic lymphocytosis have also been observed [95,160]. Partial IFN-γR1 deficiency (both 
AR and AD) patients develop a milder clinical phenotype, with osteomyelitis as a typical disease 
presentation [91,95]. Infection with Mtb has also been observed in one patient; infections with 
other intracellular bacteria, viruses and parasites were sporadically observed [93,95].  
2.2.1.4. IFN-γR2 deficiency 
IFN-γR2 is the subunit of the IFN-γ responsible of transmitting the signal, first described in 
1998 [95,161]. Similar to IFN-γR1 defects, there are AR complete defects with presence or not of 
the protein and AR or AD partial defects with protein expression. Complete defects with protein 
expression are related to glycosylation events, as the one caused by T182N mutation, in which the 
defective response to IFN-γ is caused by the creation a novel N-glycosylation site. IFN-γR2 
deficiency is less common than IFN-γR1 deficiency. Clinical presentation is similar to AR complete 
defects of IFN-γR1, with early onset life-threatening infections and other infections although BCG 
is infrequently involved [95]. Partial AR IFN-γR2 is also rare and related with infections caused by 
BCG, other EM; besides 2 of the 6 described patients developed osteomyelitis. There is only one 
mutation causing an AD partial disease and there have been described cases of haploinsufficiency 
with milder clinical phenotypes and a very low clinical penetrance [95].  
2.2.1.5. AD STAT1 deficiency 
STAT1, along with JAK family members 1 and 2, mediates the response to type I and II IFN 
[95,162]. AR complete forms of STAT1 deficiency lead to life-threating viral and mycobacterial 
infections with abolished responses to both IFN-γ and IFN-α; patients with partial AR STAT1 
deficiency have a milder phenotype that also comprises mycobacterial and viral susceptibility 
[95,130]. On the other hand, AD STAT1 mutations were first described in 2001 and have a 
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dominant negative effect only in IFN-γ signaling and give susceptibility to mycobacterial disease; 
because of that AD STAT1 mutations are considered MSMD-causing. Effects are partial thus 
explaining the milder clinical phenotype, with mycobacterial infections caused majorly by BCG and 
Mycobacterium avium. Similar to partial defects of IFN-γ receptors, multifocal osteomyelitis is 
often seen. Like in the other cases of partial defects, clinical penetrance is incomplete 
[95,130,131,162].  
2.2.1.6. AD Interferon Regulatory Factor 8 deficiency 
Interferon Regulatory Factor (IRF)8 is one of the nine members of the IRF family of 
transcription factors, involved in the regulation of the expression of IFN stimulated genes (ISG). 
Concretely, IRF8 is expressed in macrophages and DCs and is important for myeloid cell 
development. AR mutations in IRF8 lead to a life-threatening disease only described in one patient 
[95], with disseminated BCG disease, oral candidiasis and severe respiratory infections that 
needed antibiotic and antifungal therapy in combination with HSCT. There is another described 
patient with a compound heterozygosis mutations with recurrent viral infection, 
granuloproliferation, and intracerebral calcification [163] On the other hand, the two described 
patients with AD partial defects showed BCGosis as the unique infectious disease, for that reason, 
this type of defects were considered to be MSMD-causing. Absent myeloid dendritic cells CD11c+, 
potent producers of IL-12, are characteristic of this defect [95,124,163–165].  
2.2.1.7. ISG15 deficiency 
ISG15 is an interferon-induced ubiquitin-like protein that modifies its substrate in a 
process that resembles ubiquitination. It is secreted by different proteins and synergistically with 
IL-12 induces strongly IFN-γ production by lymphocytes. AR mutations in ISG15 were first reported 
in 2012 and lead to BCG disease and intracranial calcifications with or without epileptic seizures 
and an increase type I IFN immunity and autoinflammation [90,95,166]. 
2.2.1.8. X-linked recessive Nuclear Factor-kappa B Essential Modulator deficiency 
Nuclear Factor-kappa B Essential Modulator (NEMO) is encoded by the IKBKG gene and is 
a regulatory subunit of the inhibitor of NF-κB kinase. Null mutations totally abolish NF-κB 
activation dependent of NEMO and cause X-linked dominant incontinentia pigmenti in females, 
males being not viable. Hypomorphic mutations that impair but not abolish NF-κB activation cause 
X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency syndrome in males, 
conferring susceptibility to pyogenic bacteria, mycobacteria and viruses, being pneumococcal 
disease the classical warning signs [27,95]. There are two specific mutations in IKBKG that cause 
exclusively MSMD (no viral or pyogenic infections), interfering with the CD40-NEMO-NF-κB 
signaling pathway, important for anti-mycobacterial immunity. Affected patients developed 
disseminated infection mostly from Mycobacterium avium; besides, Mtb and Haemophilus 
influenzae type b were detected at least in one patient [95,167].  
2.2.1.9. X-linked CYBB deficiency 
CYBB encodes for gp91phox, an essential protein of the nicotinamide adenine dinucleotide 
phosphate oxidase complex, expressed majorly in phagocytes. Mutations in CYBB give rise to the 
most common form of CGD, these patients have recurrent and life-threatening infections by 
bacteria (Staphylococcus) and fungi (Aspergillus) and can also present with BCG disease after 




macrophages and B cells, thus causing MSMD with BCG disease and tuberculosis, without 
recurrences [92,95,123,168].  
2.2.1.10. TYK2 deficiency 
There is a form of TYK2 deficiency that leads to viral, fungal and mycobacterial infections 
with hyperIgE syndrome, consisting in atopy, high levels of circulating IgE and recurrent 
mucocutaneus staphylococcal infections; because of this complex clinical course, it is not 
considered a form of MSMD [169]. However, in 2015 a form of TYK2 deficiency with viral and 
mycobacterial infections without hyperIgE syndrome was classified as a genetic etiology of MSMD. 
There are only 7 patients described, who presented with impaired responses to IL-12 and type I 
IFNs and suffered mainly from mycobacterial infections, both after BCG vaccination and TB as well 
as cutaneous viral infections [125].  
 
2.2.2. MSMD diagnostic procedures 
Children or adults without any other haemato-immunological conditions, HIV infection or 
immunosuppressive drug exposure (including anti-TNF-α) [78,80,170–172] who develop recurrent 
or severe/disseminated mycobacterial infectious disease caused by BCG, EM, Mtb, or Salmonella 
alone or in combination with other intracellular pathogens or viruses should be suspected of 
having MSMD. MSMD diagnosis comprises complex functional tests that need to be performed in 
specialized immunology laboratories. We have extensively reviewed the reported methodology 
used for MSMD diagnosis [173], included in Annex 1.  
Briefly, evaluation of cytokine production is the gold standard for study of IFN-γ circuit 
integrity, and was developed by Feinberg et al [119]. This assay is based in the measurement of 
IL-12p40, IL-12p70 and IFN-γ after whole blood or peripheral blood mononuclear cells (PBMCs) 
stimulation. Stimulation conditions comprise live BCG stimulation leukocyte with or without hrIL-
12p70 or hr-IFN-γ co-stimulation for 18 h (for IL-12 measurement) or 48 h (for IFN-γ and IL-12 
measurements). Although powerful, this technique has several limitations: (1) the intrinsic 
variability observed yet in healthy controls; that hampers interpretation of results (2) if fresh 
whole blood is used, it should be performed during the first 48h after extraction and (3) the use 
of BCG stimulation can be limiting in diagnostic laboratories following ISO 15189 regulations. In 
an attempt to solve limitations different strategies have been developed, including the 
performance of the test in cryopreserved cells to eliminate time-from-extraction limitation and 
the use of phytohemagglutinin (PHA) and lipopolysaccharide (LPS) as stimuli to avoid the use of 
BCG.  
Quantitation of IFN-γ levels in plasma is a fast an easy technique for detection of IFN-γR 
deficiencies, since high levels of this cytokine are a sign for these defects, especially of complete 
defects [174]. Cytometric evaluation of the presence of the different receptors of the axis (IFN-
γR1, IFN-γR2 and IL-12Rβ1) is also a very useful tool to detect defects in these proteins leading to 
altered or absent protein expression [81,91,95]. However, receptors’ presence does not exclude 
a defect, since there are forms (especially in IFN-γR) in which non-functional proteins are 
expressed [81,91,95,126,127,129,175,176]. Finally, cytometric evaluation of receptors’ 
downstream signaling after specific stimulation (STAT1 phosphorylation after IFN-γ and IFN-α 
stimulation [128,130,131,175,177–180] and STAT4 phosphorylation after IL-12 stimulation 
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[156,176]) can help detect these defects and STAT1 defects with affected phosphorylation 
[130,131,179,180] (Figure 3).  
 
Figure 3. Diagram of the laboratory analysis of MSMD defects with examples. IFN-γ 
receptors and STAT1 phosphorylation detection is performed in whole blood assay. IL-
12Rβ2 detection is performed in PBMCs after 72h stimulation with PHA. STAT4 
phosphorylation detection is performed in PBMCs after 72h stimulation with PHA and 
at least 48h of culture in presence of IL-2 or PHA + IL-2. A healthy control representative 
for each technique is shown. Cytokine production is detected after 18h (for IL-12p70 in 
some cases) and 48h (for IFN-γ specially) culture with, in the gold standard, BCG with or 
without IFN-γ or IL-12p70 co-stimulation. Control cohort is shown. From Esteve-Solé et 
al, Critical Reviews in Clinical Laboratory Sciences, 2018 [173]. 
Genetic diagnosis of MSMD is of outmost importance, since it will condition the treatment 
of the patient and will allow familial genetic counseling. When functional defects suggest a specific 
defect Sanger sequencing is the option of choice. NGS technology, both in the form of gene panels 
or whole exome sequencing (WES), can be also useful to screen for all genetic etiologies 
simultaneously. In a more research-like setting, whole genome sequencing (WGS) is used to detect 
new disease-causing variations in non-protein coding regions of the genome.  
In summary, MSMD is a paradigmatic PID of the genetic theory if infectious diseases, caused by 
a primary or inborn defect in the function of the IL-12/ IFN-γ axis, mainly manifested by a high 
susceptibility to intra-macrophagic infections. Many aspects of MSMD syndrome remain still 
unresolved, and are current areas of research, such as the identification of other infectious 





3. Immunity to intra-macrophagic infections  
Macrophages and neutrophils are the first line of defense against invading 
microorganisms. Some pathogens have evolved to overcome this first barrier and live and 
replicate inside these cells. Microorganisms with intracellular, concretely intra-macrophagic, 
lifestyle are both eukaryotic, as Candida spp¸ Cryptococcus neoformans [181,182] or Leishmania 
spp [183] among others) and prokaryotic (Mycobacterium spp [184], Salmonella spp [185], 
Yersinia pestis [181], among others). Mtb and Leishmania spp are two of the most relevant 
pathogens within intra-macrophagic infectious agents, causing disease with global relevance. 
Common strategies between pathogens living inside macrophages include the capacity to 
inhibit phagosome maturation and fusion with lysosome or the inhibition of apoptosis in favor of 
necrosis. Crosstalk between adaptive and innate cells of the immune system is then crucial to 
destroy these microorganisms or form the granuloma that will contain it. Principal players are the 
macrophage itself, followed by its activation through the action of specific cytokines, such as IFN-
γ and TNF-α.  
 
3.1. The importance of IL-12/IFN-γ axis  
Although different systems are involved in defense to intra-macrophagic pathogens, the 
IL-12/IFN-γ pathway plays a key/non-redundant role. After bacilli/us phagocytosis, pattern 
recognition receptors are important sensors of mycobacteria, starting a protective response; 
however, their role in generating this response is apparently redundant [186,187]. Antigen-
presenting cells (APC) are then activated and produce TNF-α, ISG15 and IL-12p70. Cytokine 
secretion by APC promote IFN-γ production by Th cells and differentiation into Th1 cells. This 
creates a positive loop between the T cell and the APC, which enhances the former’s microbicidal 
capacity through reactive oxygen intermediates (ROI) production [90,188–191]. (Figure 4), 
 
Figure 4. IL-12/IFN-γ axis. After intracellular microorganism phagocytosis, macrophages and 
dendritic cells get activated and secrete IL-12p70 and ISG15. These cytokines activate T lymphocytes 
and NK cells. Activated T lymphocytes secrete IFN-γ that will further activate the macrophage and 
promote IL-12p70 and TNF-α secretion as well as impulse the oxidative burst. Besides, CD40L-CD40 
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interaction will also promote an increase in IL-12p70 production by the NEMO pathway. The creation 
of this positive loop is necessary to clear the intracellular infection. Known MSMD defects are 
marked in bold. Red circles in transcription factors STAT1 and STAT4 represent phosphorylation.  
The JAK – STAT axis is common for different cytokine signaling, which is conserved though 
evolution from lower organisms such as the Dictyostelium to mammals [192,193]. The JAK family 
receives its name by analogy to the two-sided god Janus because of the presence of two domains: 
the kinase domain and a domain with high similarity to kinases (pseudo-kinase domain) [194]. It 
has four members in mammals (JAK1, JAK2, JAK3 and TYK2). These are non-receptor tyrosine 
kinases and they share the same structure: a FERM domain mediating the interaction with 
upstream receptors and promoting kinase function, a SH-2 like domain that also mediates the 
interaction with upstream receptors, and a pseudokinase domain that limits kinase response and 
the kinase domain [193]. STAT proteins are classical transcription factors that directly interact with 
DNA. There are seven STAT proteins described in mammals (STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b, STAT6). Like JAKs, STAT proteins share a common structure: an N-terminal domain 
involved in protein-protein interactions, a coiled-coil domain also involved in protein-protein 
interactions and nuclear localization, the DNA-binding domain that directly interacts with DNA 
and has nuclear import-export signals, a linker domain that promotes transcriptional activity, a 
transactivation domain containing the tyrosine residues that can be phosphorylated and the C-
terminal domain with serine residues that can also be phosphorylated [192,193,195]. 
Multiple cytokines use a specific combination of JAKs and STATs that lead to different 
cellular responses following the same mechanism of action. Different cytokines and JAK-STAT 
combinations are showed in Figure 5. Despite after each cytokine ligation a ‘preferred’ 
STAT/STATs are activated, there is still “promiscuity” and other STATs may be also activated.  
Ligand binding to cytokine receptors induces an aggregation of the associated JAKs allowing their 
transactivation. Activated JAKs phosphorylate tyrosine residues in the receptor, thus creating SH2-
binding domains that serve as docking sites for STAT molecules. Then, STATs become 
phosphorylated in a tyrosine residue in the C-terminal end, permitting their homo- or 
heterodimerization and translocation to the nucleus, where they will bind to response elements 
of cytokine-dependent genes. STATs transcription factor activities include promoter binding and 
activation or repression; besides, they also have activity in distal binding events in enhancers, 
epigenetic hotspots and non-coding loci. What is more, it has been observed that STATs colocalize 
and work together with other transcription factors. Although less studied, there are other non-
canonical pathways of signaling of the JAK-STAT axis that do not include tyrosine phosphorylation 
or kinase activities [9,192,193,195,196]. Both IFN-γ and IL-12p70, the two major cytokines for 
intracellular pathogen immunity, signal through the JAK-STAT axis, while TNF-α, also crucial for 
intracellular pathogen immunity, signals using a different downstream cascade that will be further 





Figure 5. Cytokines and JAK-STAT pathway. Preferred JAK-STAT combinations for 
different cytokines and molecules. GM-CSF: granulocyte and monocytes colony stimulation factor, 
EPO: erythropoietin, TPO: thrombopoietin, GH: growth hormone. Adapted from O’Shea et al [195] 
IL-12p70 is a heterodimer composed of a p40 subunit, shared with IL-23, and a p35 
subunit. IL-12p70 is recognized with different affinities for its receptors, IL-12Rβ1 and IL-12Rβ2. 
They both belong to the gp130 subgroup of the cytokine receptor superfamily, with a high 
percentage of homology. When presenting as mono-dimers or oligomers, the receptors alone 
have low affinity for IL-12p70 (𝐾𝑑 ≈ 3 − 6𝑛𝑀), becoming a high-affinity receptor (𝐾𝑑 ≈ 55𝑝𝑀) 
when they heterodimerize. IL-12Rβ1 binds IL-12p40 and is associated with JAK2; on the other 
hand, IL-12Rβ2 binds IL-12p35 and is associated with TYK2. After IL-12p70 binds to the IL-12 
receptor (IL-12Rβ1-IL-12Rβ2 dimer), TYK2 and JAK2 come closer and JAKs are trans-
phosphorylated, thereby phosphorylating their receptor chains; STAT4 binds to phosphorylated 
IL-12Rβ2, becomes auto-phosphorylated into tyrosine 693, and homodimerizes. Then, STAT4 
homodimers translocate to the nucleus, where they bind to the IFNG promoter, inducing its 
transcription [152,197–199]. In parallel, secreted free ISG15 (from APCs) also promotes IFN-γ 
production by T-cells and CD3-CD56+ NK cells, which are considered the key ISG15-responder 
leukocytes [90,200]. Thus, ISG15 and IL-12p70 act synergistically to induce IFN-γ production 
activating both NK and Th cells [201].   
IFN-γ response in APCs, especially in macrophages, is mediated by its binding to IFN-γR1 
and IFN-γR2. IFN-γR are members of the class II family of cytokine receptors. Differently to what 
is observed in the two chains of the IL-12 receptor, the two chains of the IFN-γR do not share a 
significative amount of homology. IFN-γR1 is associated with JAK1 by the box1 motif (266LPKS269) 
and has a high affinity for IFN-γ homodimers and has the binding motif for STAT1. On the other 
hand, IFN-γR2 is associated with JAK2 by the box 2 motif (263PPSIPLQIEEYL274) and has stabilization 
and signal transmission functions. After IFN-γ homodimer binding to two IFN-γR1 chains, two IFN-
γR2 chains are recruited, bringing JAK1 and JAK2 closer. JAK1 and JAK2 then cross-phosphorylate 
and phosphorylate IFN-γR1, creating a docking site for STAT1 (440YDKPH444) by its SH2 domain. 
After binding, STAT1 is activated by phosphorylation of tyrosine 701 causing its dimerization, 
STAT1 forms the γ-activated factor (GAF) that translocates to the nucleus where it binds to γ-
interferon-activated site (GAS) of ISGs, promoting their expression. This binding site has been 
identified in the regulatory regions of more than 200 genes. STAT1 activation causes, among other 
responses, an increase of the TNF-α and IL-12 secretion, thus creating a positive loop [9,202–205]. 
MSMD is caused by monogenic defects in different points of this circuit (Figure 4), impairing the 
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production of (or the response to) IFN-γ, disrupting protective immunity to mycobacterial 
infection.  
3.2.Tuberculosis  
TB is the clinical manifestation of Mtb infection. It can be localized in the lungs (pulmonary 
TB) or in other parts of the organism (extra-pulmonary TB). It is a global problem, with more than 
10 million affected people per year. Nowadays, it is the ninth cause of death globally and the first 
cause of death from a single infectious agent, with approximately 1.6 million deaths in 2016. 
Besides, HIV coinfection is one of the biggest problems of TB, representing 29% of the total TB 
deaths of HIV-coinfected individuals. The World Health Organization (WHO) has TB burden 
reduction as one of its general objectives, with a global TB program since 1995 [206].  
Although TB is a global problem, TB burden mostly occurs in low or middle-income 
countries (incidence ranging from 10 per 100,000 population in high-income countries to 500 per 
100,000 population in countries such as Democratic People’s Republic of Korea, Lesotho, 
Mozambique, the Philippines and South Africa). Most of the incident cases in 2016 occurred in 
South-East Asia (45%), Africa (25%) and Western Pacific (17%). Almost a 20% of the incident cases 
(2 million people) of TB are attributable to malnutrition. The vast majority of TB-related mortality 
occurs in the African and South-East Asian region (Figure 6), despite mortality has decreased a 
37% since 2000 [206]. There is currently no effective vaccine protective for pulmonary TB, but 12 
TB vaccines are being tested in clinical trials [206].  
 
Figure 6. Estimated tuberculosis and mortality rates in 2016. Data from World Health Organization 
Global Tuberculosis Report, 2017. 
Mtb causes disease only in a fraction of the infected individuals. After exposure to Mtb 
almost a 90% of individuals get infected, of those, 5% develop primary tuberculosis within two 
years of infection. Primary TB usually is mostly observed during childhood (Figure 7), during which 
can have an extrapulmonary location. The rest of infected individuals who do not develop disease 
are considered to have latent TB infection. Of these, only 5 to 10% will develop active pulmonary 
TB as a reactivation; this type of disease is typically observed in adult patients years after the initial 




association in the development of the disease and associated mortality, before the description of 
the Koch bacilli, tuberculosis was thought to be a hereditary disease.  
 
Figure 7. Epidemiology of pediatric tuberculosis. Data from World Health Organization Global 
Tuberculosis Report, 2017. 
Reports from the pre-therapy era have been clue for the description of the infection’s 
natural history. Since TB is an airborne disease, when bacilli reach a terminal airway, the alveolar 
macrophages phagocyte it. If the bacilli resist phagocytizing, it multiplies inside the macrophage 
until necrosis occurs. After necrosis, bacilli are released to the extracellular milieu and are re-
phagocyted. Virulent mycobacteria have developed mechanisms to avoid destruction after 
phagocytosis, implying the need of an adaptive immune response to stop progression [207].  The 
first localized pneumonic inflammatory focus is called the parenchymal focus (Ghon sign): both 
the Ghon focus and the infected lymph nodes are called the primary complex [208,209]. Primary 
progression is variable and is commonly seen in children. Reactivation of latent tuberculosis 
infection is seen after local or systemic immunosuppression, although it is also seen in 
immunocompetent hosts. Reactivation usually takes place in the upper lobes and a process of 
liquification occurs, favoring the extracellular growth of the bacilli and increasing the 
inflammatory response, resulting in alveolar damage and cavity formation in the lung [207,210]. 
Pulmonary TB is characterized by persistent cough, weight loss or failure to thrive, fatigue and 
reduced playfulness in children [208]. 
Figure 8. A schematic of the natural history of 
human infection by Mycobacterium tuberculosis. 
About 5% of infected individuals develop clinical TB 
within 2 years of infection; this ‘primary’ TB is 
particularly common in children, and could be 
associated with extrapulmonary disease. The 
remaining persons infected with Mycobacterium 
tuberculosis develop latent TB infection. Only a 
minority of subjects with latent TB infection (approx. 
5–10%) develop clinical TB during their lifetime, 
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typically owing to reactivation of the original infection Adapted from Abel et al, Philos Trans R Soc Lond B 
Biol Sci, 2014 [76] 
Pediatric TB represents almost a 7 % of new cases notified in 2016. Most of TB-related 
deaths in children occur during the first 4 years of life [206]. A clear majority of progressing 
children do so within the first 12 months after exposure, especially very young children. Clinically, 
lymph node disease is a common form of primary TB, cervical lymphadenitis is also common and 
if left untreated, leads to a prolonged and relapsing course. Progression of lymph node disease in 
the thoracic area may be dangerous if penetrating other anatomical structures, giving rise to 
pneumonia, unilateral diaphragmatic palsy and chylothorax formation. On the other hand, 
dissemination of the disease and tuberculous meningitis are life-threatening forms of primary TB, 
especially seen in young and immunocompromised children [209]. Extrapulmonary TB can affect 
any organ of the body, thus presenting with a variety of clinical manifestations. It specially spreads 
to the spleen, bone, kidney and cerebral cortex. Symptoms of miliary disease include prolonged 
pyrexia, lassitude, anorexia and weight loss [208].  
Diagnosis of Mtb infection is still a challenge, especially in low-income countries. Different 
diagnostic techniques have been developed for the detection of Mtb, both in active (direct tests) 
or latent (indirect tests) infection [211]. For the detection of active infection three approaches 
have been made: (1) sputum smear microscopy, (2) culture based methods and (3) molecular tests 
[206,211]. These tests are performed with a variety of body fluids or tissues from the patient. (1) 
Sputum smear microscopy was developed more than 100 years ago and is the most widely used 
test [211,212]; it has a high specificity but moderate sensitivity. It is popular because it is 
inexpensive and rapid. (2) Culture is the most sensitive method and the gold standard for TB 
diagnosis, as it can be partly automatized or performed by microscopic evaluation in low-income 
countries. This technique can be coupled to drug sensitivity tests. However, performance of these 
tests in low-income countries can be conditioned by staff and water/electricity supply limitations. 
In children, positive cultures are less frequently observed than in adults in pulmonary TB due to 
children’s difficulty to generate sputum. (3) Molecular detection of Mtb has changed TB diagnosis. 
Many nucleic acid amplification tests have been developed with a good sensitivity and specificity 
in pulmonary TB patients, which decrease in non-respiratory samples. The GeneXpert MTB/RIF 
assay is a closed system that performs real-time PCR and can give results in less than 2 hours; 
sensitivity is almost as good as culture (also in extrapulmonary tuberculosis) with good specificity. 
The use of this technique is endorsed by WHO and its use has increased the proportion of TB 
patients with bacterial confirmation [211,212]. Again, application of this test in low-income 
countries is difficult because of economical and supply limitations.  
Indirect tests are useful to detect individuals with latent TB infection. The most commonly 
used test because of its reduced costs is the tuberculin skin test (Mantoux test). Purified protein 
derivative (PPD) consists of a mixture of proteins found in Mtb but also in BCG. PPD is injected 
intracutaneously, when an intradermal infiltration of 5mm in children (or immunocompromised 
hosts) or 10 mm in adults is observed, the test is considered positive. This test has a low sensitivity 
and specificity, especially because of the cross-reactivity with BCG exposure. IFN-γ release assays 
detect the production of IFN-γ after the stimulation of patient’s cells with Mtb complex specific 
antigens, absent in BCG. These tests have better sensitivity and specificity than tuberculin skin 




Although advances had been made during the last years, more studies are needed to improve the 
diagnosis of latent TB infection.  
Since the development of the first effective treatment in 1940, more than 15 drugs have 
been developed for the treatment of Mtb. For drug-susceptible cases the treatment lasts 6 
months, with four first-line drugs: isoniazid, rifampicin, ethambutol and pyrazinamide (just 40 
$/individual) and 85% of individuals respond to this regimen. If resistances are found, the 
treatment is longer (20 months) and has increased costs (2000-5000 $/individual), also with 
increased toxicities. Currently there is a tendency towards a reduction in the treatment length, 
lasting 9 to 12 months if there is no resistance to second line drugs, reducing the costs to 
approximately 1000 $). Resistance is a real problem: rifampicin resistance (RR) is growing: 41% of 
all new reported cases in 2016 were resistant, and an increase of 10% from 2015 has been 
observed [206]. There are three grades of TB resistance: rifampicin resistant, multi-drug resistant 
(MDR, isoniazid and rifampicin resistant) and extensive-drug resistant (XDR, MDR + at least one 
fluoroquinolone and a second-line injectable agent). Nowadays combination of phenotypic and 
genotyping testing methods to evaluate resistance to these drugs are available [206,211,212]. 
 
3.2.1.Immunity to tuberculosis 
Immunity to tuberculosis is complex and incompletely characterized, however it is clear 
that macrophages, CD4+ T-cells, IL-12, IFN-γ and TNF-α play a critical role. Current knowledge on 
tuberculosis immunity has been extensively reviewed. Briefly, on entrance, Mtb bacilli are 
phagocyted by macrophages and neutrophils thanks to their antigen uptake machinery [213–215]. 
The role of neutrophils in mycobacterial infection is up for debate, since it is not clear if their 
action is beneficial or detrimental for the host [216]. Macrophages are innate cells specialized in 
the engulfment and destroy of pathogens [217]; one of the virulence factors of Mtb is its ability to 
inhibit the phagosome maturation and its fusion with the lysosome, thus preventing its 
destruction [213–215]. Besides, dendritic cells get activated both by direct mycobacterial infection 
and by bystander activation to act as APCs; however, the mechanisms are not totally clear [213–
215,218]. Activated/infected macrophages and dendritic cells migrate to the lymph node, where 
they will produce IL-12. This production of IL-12, besides other molecules, prime Th cells to 
develop into Th1 IFN-γ producing CD4+ T-cells, which will migrate to the lung to perform their 
action [213–215,218]. 
IFN-γ-mediated activation is a key factor for Mtb growth restraining. The main action of 
IFN-γ, in synergy with TNF-α, is the activation of the infected macrophage, thus promoting the 
maturation of the phagosome and autophagy to induce mycobacterial destruction. TNF-α is 
important for the construction and maintenance of granuloma and for inflammation. Besides, it 
induces the inducible nitrogen oxide synthase (iNOS) production and activity, resulting in the 
production of ROI, thus helping in the final killing of the mycobacteria. Nonetheless, in most cases 
the macrophage is not completely capable of destroying the mycobacteria [213–215]. Stimulated 
macrophages that differentiate into multinucleated giant cells are the central mass of the 
granulomas, along with other infected macrophages, epithelioid cells, foamy macrophages and 
neutrophils. T (specially CD4+ cells) and B cells surround this inner mass and are covered by a 
fibrotic capsule. The center of the granuloma contains an hypoxic and hostile environment for the 
pathogen’s growth, hence limiting the infection and leading to “dormant bacilli” [213–215,219]. 
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Of note, if there is a real dormancy or a dynamic equilibrium of infection-reinfection due to 
recirculation of the bacilli, is nowadays up for debate [207,220]. 
Although IFN-γ producing CD4+ cells are the main actors of adaptive immunity to Mtb, 
there are other adaptive cells implied. CD8+ cells also produce IFN-γ and secrete molecules 
(perforin and granulysin) that can directly lyse the mycobacteria. Besides, as the outer membrane 
of Mtb is covered with glycolipids, atypical CD1+ T cells have an important role by producing IFN-
γ and are thought to possibly be one of the first barriers of defense in the lung after macrophage 
activation [213–215,221]. Gamma-delta T cells recognize phospholigands (antigens containing 
phosphates), including prenylpyrophosphates that are abundant in mycobacteria. After 
stimulation, these cells produce IFN-γ and express granule-dependent mycobactericidal activity 
[213–215,222]. Although the role of B cells has not been thoroughly studied, they are also thought 
to play a role in Mtb pathogenesis. B cells could promote protection against Mtb by antibody 
production, antigen presentation and cytokine production [223]. 
There is a dynamic balance between the bacilli and the host, related to a balance between 
regulatory and effector immune responses. Besides the vigorous immune response displayed after 
Mtb infection, the activation of the inhibitory machinery is important to avoid hazardous immune 
responses. An excessive response could lead to destruction of the pulmonary tissue. The anti-
inflammatory machinery (T regulatory (Treg) cells, IL10 production, exhaustion…) inhibits the 
effector response, but also protects and heals the host tissue from the immune response. When 
the balance is broken, the disease appears. If the crosstalk between the innate and adaptive cells 
is not optimal, the bacilli can scape and invade other organs, leading to extrapulmonary TB [213–
215,224].  
 
3.2.2.Mtb infection in the immunocompromised host 
There are some acquired conditions predisposing to tuberculosis. Malnutrition is a potent 
immunosuppressive agent, considered responsible of 20% of the new cases of TB during 2016. 
Also is HIV coinfection, since 10% of the new cases of TB occur among HIV infected individuals, 
having an increased mortality [206]. HIV infection, if untreated, causes a progressive degradation 
of Th cells, thus increasing the risk of clinical TB. HIV infected individuals usually manifest 
extrapulmonary forms of tuberculosis. Besides, immunosuppressive treatments, malignancies 
such as leukemia, organ solid or bone marrow transplantation, severe aplastic anemia or 
malignant infantile osteoporosis can also cause increased risk for TB development [78]. Biological 
treatments, such as anti-TNF-α drugs, can also be causative of a Mtb reactivation, such so, that all 
patients need to be tested and treated for Mtb infection prior treatment [225,226].  
The importance of the host-genetic background was dramatically illustrated during the 
Lübeck accident in Germany, where 251 newborns were administered a BCG vaccine 
contaminated with Mtb. From those infected infants, 72 died, 135 had a spontaneous recovery 
and 44 had no clinical symptoms [78,227]. Non immune-related inherited conditions affecting the 
lungs have been described to confer TB susceptibility such as primary ciliary dyskinesia [78,228], 
pulmonary alveolar proteinosis [78,229] or cystic fibrosis [78,230]. Besides, during the last years, 
pediatric extrapulmonary TB has been linked to PIDs including CGD [78,80], T-cell deficiencies 




deficiencies causing anhidrotic dysplasia with immunodeficiency [78,231], X-linked recessive 
CD40L deficiency [78,232] and autosomal recessive TYK2 deficiency [78,125].  
Classical clinical spectrum of MSMD mostly include non-tubercular mycobacteria, but can 
also confer increased susceptibility to TB infection. Two systematic studies had been performed 
in order to unravel MSMD defects in Mtb infected individuals, the first showing a 4% (2 out of 50) 
of TB patients with IL-12Rβ1 deficiency in an area of high consanguinity [82]. The second, 
performing genetic MSMD studies of children and adults with severe Mtb infection in an area of 
low consanguinity, revealed no defects [233]. Despite the lack of more systematic studies, 
different etiologies of MSMD, were found in patients with severe TB, especially IL-12Rβ1  
deficiency [78,95,234], followed by IFN-γR1 [93,95], STAT1 [94,95], and IL-12p40 deficiency 
[89,95]. There are currently 26 patients reported with severe TB due to inborn errors of IFN-γ, 13 
of whom are IL-12Rβ1-deficient, including six who did not suffer from any other mycobacterial 
disease (BCG, EM) [78,95,154,234]. It has been estimated that around a 45% of the patients with 




Leishmaniasis is a tropical, sub-tropical and Mediterranean basin vector-borne disease 
caused by distinct species of parasites from the genus Leishmania [236,237]. It’s the second cause 
of death and the fourth cause of disease by tropical infections in the world. Infections are endemic 
in more than 98 countries (including Spain), and it is considered one of the most important 
neglected diseases. Due to the suboptimal casuistic studies in endemic areas, there is not an exact 
number of infected patients, but there is an estimated annual incidence of 0.9 to 1.6 million cases 
of leishmaniasis worldwide [236]. Leishmania species are obligated intra-macrophagic protozoan 
parasites in their mammalian cell hosts, living extracellularly in their vector, the female sand-fly 
[236,238,239]. (Figure 9) 
 
Figure 9. Map of countries with endemic visceral leishmaniasis. Countries with endemic visceral 
leishmaniasis are displayed in red and countries with past reported cases of visceral leishmaniasis are 
displayed in pink. Map from (http://apps.who.int/neglected_diseases/ntddata/leishmaniasis/ 
leishmaniasis.html), accessed on 2018/03/22.  
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There are two major genus of sand flies that are vectors of this pathogen: Phlebotomus in 
the Old World and Lutzomyia in the New World [236,237]. Sand flies are smaller than mosquitoes, 
silent and bite from dusk to dawn. They do not have a strong power in their fly, since they cannot 
fly against a wind current, and do not fly at high heights. For this reason, they often byte in the 
non-protected skin of the legs, arms and face. In the Mediterranean region they are active in the 
warm summer months and tend to bite the same host more than one time, increasing the chance 
of transmission. One of the most successful forms of leishmaniasis prevention is the control of 
sand fly’s population with insecticides, bed nets… [236,238].  
Leishmania parasites vary their shape/form during the different stages of their life cycle 
(Figure 10), represented by the promastigote morphology in the sand-fly and the amastigote form 
in the mammalian host. The same modules compose both forms of the parasite: the flagellum, 
the basal body, the mitochondrial kinetoplast unit (a mass of concatenated mitochondrial DNA 
and a Golgi) and the flagellar pocket neck unit. During the amastigote phase, the parasite is smaller 
and more spherical; the flagellum is short and immotile, and is thought to have sensory functions. 
On the other hand, the promastigote has an elongated ovoid cell form, and the flagellum is long 
and motile, providing propulsive force. On entrance, the promastigote is engulfed by the 
macrophage and transitions to a amastigote phase, then divides by binary fusion until 
macrophage’s lysis, and is then prepared to infect other cells; after the bite of another sand-fly, 
the amastigote is ingested with the blood and transforms into the promastigote form in the 
intestine of the sand-fly [239]. 
 
Figure 10 Schematic of promastigote and amastigote morphologies and the Leishmania life cycle 
with different cell types highlighted. A) Promastigote and amastigote morphologies aligned along 




understanding of the Leishmania life cycle. A sand fly takes a blood meal from an infected 
mammalian host and ingests a macrophage containing Leishmania amastigotes. Once in the sand 
fly amastigotes differentiate into promastigotes. After several phases in the sand-fly, metacyclic 
promastigotes are ready to infect mammalian hosts, where promastigotes will be phagocyted and 
differentiate to amastigotes. A circular arrow indicates proliferative stages. From Sunter et al, Open 
Biology, 2017 [239]. 
 
Leishmanial infection leads to a broad range of clinical manifestations of the infection, 
from subclinical signs to lethal infection. The major forms of leishmaniasis are i) cutaneous 
leishmaniasis, ii) diffuse cutaneous leishmaniasis, iii) muco-cutaneous leishmaniasis and iv) 
visceral leishmaniasis (VL). Although boundaries are not clearly set, there are different species of 
Leishmania considered dermotropic or viscerotropic. Also, there is differentiation between New 
World and Old World species. The New World’s are considered to be more aggressive. Although 
there are many zones in which Leishmania is endemic, over 90% of the cases of cutaneous 
leishmaniasis occur in Afghanistan, Iran, Saudi Arabia, Syria, Alegria, Tunisia, Brazil and Peru and 
90% of visceral leishmaniasis occur in Bangladesh, India, Nepal, Ethiopia, Kenya, Sudan and the 
northeast of Brazil [236].   
The main species causing leishmaniasis in the Mediterranean basin is Leishmania 
infantum, known to be causative agent of both cutaneous and visceral disease. In Spain it is 
transmitted both by Phlebotomus perniciosus, present in almost all the peninsula, and 
Phlebotomus ariasi, especially present in the Mediterranean basin and the North-East area of 
Spain (Figure 11) [240,241]. Three patterns of infection have been described in the area: i) 
sporadic infections due to endemicity, being the dog the reservoir [240,241]; ii) epidemic flares, 
with the recent example of the leishmaniasis outbreak recently occurred in Madrid Community 
with the hare as reservoir [240–242] and iii) infection of immunocompromised individuals 
[241,243]. People living in rural and peri-urban areas are the most prone to develop disease 
[240,241,244]. The rising of temperatures due to climate change has facilitated vector arrival to 
northern or higher zones that used to be vector-free, thus increasing the probability to contract 
the infection [244].  
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Figure 11. Distribution of Leishmania spp. in the Mediterranean region. Autochthonous human 
leishmaniasis in the Mediterranean area. Countries where human leishmaniasis was diagnosed by 
serological tests and/or Leishmania isolation and/or PCR method are depicted in yellow. Diagrams 
show Leishmania species identified and/or isolated in human cases. Adapted from Moriconi et al, 
PLoS Negl Trop Dis, 2017[245]. 
Microbiological confirmation of Leishmania infection is of outmost importance, especially 
in visceral leishmaniasis. Detection of the parasite is performed by direct observation or by PCR 
methods. Direct observation of the amastigotes can be performed in slit skin smears for cutaneous 
leishmaniasis or in medullar or splenic aspirates for VL. Direct observation has a moderate 
sensitivity. PCR targets conserved sequences in the Leishmania kinetoplasts or the ribosomal RNA 
gene; it can be performed in different tissue samples or blood, and is especially useful in cases of 
low parasite load, such as in patients with HIV co-infection. Besides, anti-leishmanial antibody 
detection or leishmanin skin test may be useful but does not distinguish between active or past 
infection [236,238]. Culture isolation of parasites is also performed but has a low efficacy and is 
expensive and time consuming [236].  
VL is also known as Kala-Azar, and is the result of the dissemination through the 
reticuloendothelial system of infected macrophages. Its clinical signs include fevers, weight loss, 
anorexia, weakness, pallor, cough, diarrhea, epistaxis, hepatosplenomegaly, lymphadenopathy 
and growth retardation in children. Patients can develop normocytic anemia, thrombocytopenia, 
neutropenia, transaminitis, hypoalbuminemia and hypergammaglobulinemia. Within the 
immunocompetent hosts, visceral leishmaniasis occurs especially during infancy, from 1 to 4 
years. Once started, and without treatment, visceral leishmaniasis lead to death from infection, 
severe anemia or hemorrhage within two years [238,246,247].  
Treatment for visceral leishmaniasis, as well as other forms of leishmaniasis, has high 
toxicity, high costs, lack of efficacy in some circumstances and lack of access and/or emerging drug 
resistance. Amphotericin B deoxycholate is very effective against visceral leishmaniasis, leading to 
more than 90% rate of curation. However, it is difficult to tolerate as it can lead to fevers, rigors, 
nephrotoxicity, hypokalemia and anemia. In high-income countries, first line treatment for VL is 
liposomal amphotericin B, which has a shorter regimen, decreased toxicity and more than 95% 
cure rate. However, it is very expensive, making it unaffordable for the zones with higher burden 
of disease. Miltefosine is the unique oral treatment with efficacy against all types of leishmaniasis; 
it also has a 95% cure rate in VL. The adverse events are vomiting, nausea, motion sickness, 
headache, diarrhea and creatinine elevation, but is an alternative to amphotericin B 
[238,246,247].  
 
3.3.1.Immunity to visceral leishmaniasis 
Leishmania infection is asymptomatic in most individuals; however, it can give rise to 
cutaneous or visceral disease. The outcome of a Leishmania infection depends on three major 
factors: the parasite itself, the vector and the host immune response and genetic background. 
During the last decade, efforts have been made to unravel immunologic responses that confer 
resistance or susceptibility to clinical leishmaniasis; however, it is still a neglected disease and 
more research must be performed to better understand, treat and prevent Leishmania infection. 




models, but they have a different natural history of infection: even susceptible mice develop a 
self-limited visceral disease, in contrast to life-threatening disease in dogs and humans 
[248].Different strains of mice have different degrees of susceptibility to Leishmania infection, 
with B6 as a commonly used resistant strain and BALB/c used as a susceptible one, indicating the 
importance of the genetic background on the clinical outcome of Leishmania infection [249].  
After a blood-meal the sand-fly release the promastigotes into the dermis, where the 
complement system kills most of the parasites by lysis. Leishmania parasites can be phagocyted 
by macrophages, neutrophils and dendritic cells. Upon macrophage phagocytizing, the parasites 
transform into amastigotes. Immune response following phagocytosis is genetic background-
dependent. In resistant mice, infected dendritic cells produce the Th-1 polarizing cytokine IL-12, 
enhancing IFN-γ production by T and NK cells thus activating macrophages to produce nitric 
oxygen (NO) and ROI which will lead to parasite destruction. In susceptible strains, IL-4 is produced 
thus driving Th-2 like responses that in combination with IL-10 and tumor growth factor (TGF)-β 
production by Treg cells, deactivate infected macrophages, inhibiting NO and ROS production 
[249–251].  
The role of neutrophils in Leishmania pathogenesis also depends on the genetic 
background: in susceptible mice, they are considered as Trojan horses delivering parasites after 
apoptosis to macrophages and promoting Th2 immunity, while in resistant mice they induce TNF-
α production by macrophages [250,251]. Some Leishmania strains can inhibit oxidative burst and 
avoid the targeting to the lysosome in monocytes [250]. Macrophage responses after infection 
are also different in susceptible and resistant mice strains. While in susceptible mice, infection 
activates FasL-dependent apoptosis of resident macrophages, in resistant mice it induces a cellular 
stress with ROI production and activation of stress activated protein kinases [251]. Leishmania 
spp. have developed tools to inhibit immunologic responses: although macrophages are the last 
step on the destruction of the parasite, they have altered IL-12 production after Leishmania 
infection [250,251]. One of the mechanisms is the inhibition of JAK1/JAK2/STAT1 signaling in the 
infected macrophage [250]. 
Normal human serum has an important anti-leishmanial activity, killing most 
promastigotes at the time of infection, it has been shown that when cultured with human serum, 
85—90% promastigotes are lysed in less than three minutes [252]. However, complement-
dependent lysis on entrance is not sufficient for the clearance of the parasite in most individuals. 
Patients with VL present with altered responses during infection. While healthy infected 
individuals can respond to stimulation with leishmanial agent, PBMCs from patients with active 
infection do not produce IFN-γ. However, response to leishmanial agent is restored after the 
infection is cleared [248,253].  Differently to what is observed in murine studies, the dichotomy 
between Th1 association with resistance and Th2 with susceptibility is blurrier in humans.  Indeed, 
elevated levels of IFN-γ have been found in the spleen and bone marrow during infection 
accompanied with increased IL-10 production [248,253]. Other mechanisms of susceptibility in 
humans include helminth infections that can alter the Th1/Th2 balance. Besides, TNF-α production 
has a role in granuloma formation and maintenance to contain Leishmania parasites[253].  
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3.3.2.Leishmania in the immunocompromised host 
Leishmaniasis is thought to occur both in immunocompetent and immunocompromised 
hosts; however, immunocompromised hosts are more vulnerable to leishmaniasis and tend to 
have a more severe disease. Acquired forms of immunosuppression such as HIV infection, 
malignancy, immunosuppressive treatment (including biologic drugs specially anti-TNF-α 
antibodies [254,255]) and malnutrition are the most common forms of susceptibility to 
Leishmania infection; to date, infection resulting from a PID is rare [243]. Nonetheless, patients 
with PID causing leishmaniasis have been described: one patient with Ataxia-Telangiectasia [256], 
one patient with CVID and Evan’s syndrome, 3 patients with hypogammaglobulinemia [257] and 
2 patients with CGD [258]. Recently, five cases of Leishmania infections in patients with mutations 
in MSMD-causing genes have been described, both alone [134,259] or in combination with other 
infections [82,89,260]. Patients had mutations in IL12RB1 [82,134,259,260] and IL12B [134]. 
Despite the few cases of PID-related leishmaniasis reported, more entities of single-gene 





4. Anti-TNF-α biologic treatments 
4.1.TNF-α 
The effects of TNF-α stimulation are a double edge sword, with beneficial consequences 
when tightly regulated and potential destruction when dysregulated. TNF-α was first described by 
its anti-tumor properties, however it is a major player in immune system regulation, 
organogenesis and development, especially in lymphoid organ architecture and in defense against 
pathogens, including destruction of infected cells and granuloma formation, tissue regeneration 
and resolution of inflammation with functions in cell survival, proliferation, differentiation and 
apoptosis.[261–263]. On the other hand, it can also promote (1) tumorigenesis by the expression 
of invasion and metastasis related genes and inhibition of apoptosis and (2) autoimmunity and 
chronic inflammation, atherogenesis, hyper-nociception and tissue destruction [262,263]. TNF-α 
is a member of the TNF superfamily (TNFSF), members of this family have multiple receptors that 
differentiate into two groups depending on the presence or absence of death domains (DD) in 
their structure. The first group, with presence of DD, lead to the activation of the caspase cascade 
upon TNF-α ligation and, usually, apoptosis; on the other hand, the second group signals through 
adaptor proteins and their activation leads to activation of transcription factors associated with 
cell survival. For this reason, the activity of these proteins is strictly bonded to the balance 
between pro- and antiapoptotic signals on the cell [261,262,264]. 
Since its first description in 1975 [265], TNF-α is one of the most studied cytokines [261] 
and its signaling and function have been extensively reviewed [261,262,264,266]. TNF-α is a 
homo-trimeric protein, first expressed as a transmembrane molecule, then cleaved by the TNF-α 
converting enzyme, ADAM17 metalloprotease, into a soluble extracellular protein; both forms are 
bioactive. It can be produced by macrophages, T, B, natural killer (NK), mast endothelial cells, 
fibroblasts and neurons [261–263,267,268]. The trimeric glycoproteins TNF Receptor (TNFR) 1 and 
TNFR2 are its two receptors [267]. TNFR1 is virtually constitutively expressed in all cells but 
erythrocytes, and preferentially binds soluble TNF-α; TNFR1 contains a DD and its activation is 
majorly related to inflammation and tissue degradation. TNFR2 does not contain DD and gets 
activated by, preferentially, the transmembrane form of TNF-α; its expression is tightly regulated 
and is present mostly in immune and endothelial cells. It is associated with homeostasis, by 
regulating cell survival and tissue regeneration [261–264,268]. Regulation of TNF-α and its 
receptors expression is clue for the development of fine-tuned cell type-specific responses 
[261,263].  
TNF-α ligation to TNFR2 promotes cell survival while TNFR1 activation can lead to both 
cell death or survival [261]. Signaling upon TNF-α ligation to TNFR1 and TNFR2 leads to NF-κB 
activation with different consequences. The regulation of TNFR1/TNFR2 expression and signaling 
is not completely understood: since immune cells commonly co-express TNFR1 and TNFR2, it is 
difficult to predict the cell fate after TNF-α stimulation. After stimulation, both receptors recruit 
adaptor molecules and occurring phosphorylation/ubiquitination processes determine the 
outcome of TNF-α ligation [261,262,264]. The ligation of transmembrane TNF-α can lead to 
reverse-signaling, giving rise to its immunomodulatory response. Immune complexes formed after 
anti-TNF-α biologic drug therapy can mimic this regulatory mechanism [267]. 
After TNF-α binding to TNFR1 both cell survival or death can occur. Differently to what is 
observed after FAS – FAS-ligand interaction, TNF-α binding to TNFR1 leads to a complex apoptotic 
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cascade with many components. It is thought that RIPK1, a protein downstream TNFR1 activation, 
is a central molecular switch that, depending on its ubiquitylation state, mediates TNFR1 signaling 
to cell survival or apoptosis. When RIPK1 is polyubiquitylated, TNF-α ligation to TNFR1 leads to 
NF-κB activation and nuclear translocation, where it will promote the transcription of genes 
involved in cell survival [261,262,264]. On the contrary, if it is not polyubiquitylated, there is no 
NK-κB activation and the balance falls into the apoptotic signals and cell death via caspase 8 
activation. Besides, TNFR1 activation can also lead to necrosis, a pro-inflammatory form of cell 
death when RIPK1 is not ubiquitylated and the caspases are inactivated (Figure 12) [261,263].  Of 
note, pathways leading to TNF-α production by different cells are highly redundant, including 
different pattern recognition receptors and signaling pathways, thus showing the importance of 
this cytokine [269]. 
 
Figure 12. Different bioactivities downstream of TNF receptors. TNF receptor 1 (TNFR1) signaling 
is activated by both soluble and transmembrane TNF-α. TNFR1 bears a death domain that recruits the 
adaptor protein TNFR1-associated death domain protein (TRADD). Ligation of TNFR1 by soluble TNF-α or 
transmembrane TNF-α leads to different outcomes: i) inflammation, tissue degeneration, cell survival and 
proliferation, and orchestrates the immune defense against pathogens; ii) apoptosis; iii) necroptosis and 
inflammation. TNFR2 is proposed to be fully activated primarily by transmembrane TNF-α, in the context of 
cell-to-cell interactions. TNFR2 recruits TNFR-associated factor 2 (TRAF2) via its TRAF domain and mediates 
primarily homeostatic bioactivities including tissue regeneration, cell proliferation and cell survival. This 
pathway can also initiate inflammatory effects and host defense against pathogens. Adapted from Kalliolas 





The use of anti-TNF-α drugs in IBD represented the first FDA-approved indication for an 
anti-TNF-α biological treatment in 1998 [270]. The success of this therapy led to an increase in the 
research and commercialization of biologic drugs. Nowadays anti-TNF-α biologics are within the 
first sales positions drugs in the world [271,272]. Global spent on anti-TNF-α drugs is beyond $US 
25 billion per year. This enormous quantity of money derives from the particularly high cost of 
anti-TNF-α treatment per patient/year, which ranges from $US 25,000 to 30,000. Because of this 
price, not all people eligible for anti-TNF-α therapy can be treated. Hopefully, this situation will be 
rescued in the near future with the appearance of biosimilars. Biosimilars are to biologic 
treatments what generic drugs are to classical small molecules. ‘Remsima’ is the first biosimilar 
for Infliximab that was approved for its use in Europe [271].  
Currently, there are 5 FDA-approved anti-TNF-α biologic drugs: Infliximab (Remicade, 
1998), Adalimumab (Humira, 2003), Golimumab (Simponi, 2009), Etanercept (Enbrel, 2000) and 
Certolizumab pegol (Cimzia, 2009) [271–274]. The first approved indication for all drugs was 
Rheumatic Arthritis, except for adalimumab (approved for Crohn’s Disease). The approved 
indications include rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis, 
IBD (ulcerative colitis (UC) and Crohn disease (CD)) and hidradenitis suppurativa [263,272]. 
Besides, it is used in several off-label indications such as Behcet’s disease and uveitis [272]. Anti-
TNF-α drugs may be used both in adults and in pediatric patients, especially after failure of classic 
therapy [272]. This treatment is contraindicated in patients with uncontrolled infections. While 
vaccination against pneumococcus, influenza and human papillomavirus is recommended, live 
vaccines should be avoided until 3 months after discontinuation of therapy [273,275]. 
Infliximab is a chimeric antibody with a 25% of murine-derived amino-acids, consisting in a murine 
Fab region and a human constant fraction. Adalimumab was the first totally humanized antibody 
approved by the FDA. It is a recombinant human immunoglobulin (Ig)G1 antibody produced using 
phage-display technology.  Golimumab is a human IgG1κ mAb, created in engineered mice 
immunized with human TNF-α; it has increased stability, affinity and neutralization capacity and 
it was not until 2013 that golimumab was approved for IBD treatment. Certolizumab pegol is a 
humanized anti-TNF-α, consisting on murine-
derived amino-acids inserted into a human Fab 
region linked to pegol to increase half-life of the 
drug and improve solubility. Etanercept is a soluble 
recombinant TNFR2 protein, fused to IgG1 constant 
fraction, thus preventing the union of TNF-α to the 
receptor; it is the unique anti-TNF-α approved drug 
not used for IBD treatment (Figure 13) [268,272–
274].  
Anti-TNF-α drugs comprise different 
mechanisms of action. The most obvious 
mechanism is the neutralization of soluble TNF-α in 
blood, and also the binding to transmembrane TNF-
α (inhibiting the interaction with its receptor). The 
binding of transmembrane TNF-α to anti-TNF-α drugs 
Figure 13. Approved anti-TNF-α biologic 
drugs. Fc: constant fraction; TNFR2: TNF 
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with IgG1 constant region (thus excluding certolizumab pegol) leads to 3 different mechanisms of 
inhibition: (1) antibody-dependent cellular cytotoxicity, (2) complement dependent cytotoxicity, 
which occurs by the classical pathway and (3) reverse signaling, meaning the capacity to induce 
intracellular signals in the cell that express transmembrane TNF-α, leading to regulation of 
cytokine production and caspase-dependent FAS-independent apoptosis (this last mechanism is 
currently on debate) [268,272–274]. 
As expected, anti-TNF-α biologics are not free of adverse events. Infliximab, because of 
the need of intravenous administration and its chimeric nature, has a 10% frequency of acute and 
delayed infusion reactions including anaphylaxis, which have been described with the 5 drugs. 
Infections are a serious adverse effect of TNF-α inhibitors, being TB the major problem. It has been 
proved that exposure to more than one immunomodulatory or immunosuppressive treatment 
dramatically increases the risk of severe infection. There is no agreement in the statement that 
anti-TNF-α treatment can lead to malignancy, especially regarding immune-cell related cancer. 
Although an increased risk has been observed in some studies, it was related to the use of 
concomitant azathioprine treatment, which already caused similar effects in monotherapy. 
Patient monitoring is of outmost importance. Infections should be closely monitored by urinalysis, 
complete blood count, acute-phase reactants, creatinine and electrolytes measurement. Besides, 
liver enzyme levels should be also checked regularly as well as the apparition of cancer; 
dermatologic careful follow-up is highly recommended, since both melanoma and non-melanoma 
skin cancer has been observed [261,270,272,273,275]. 
 
4.3. Acquired susceptibility to mycobacteria and leishmaniasis after anti-TNF-a 
treatment 
The knowledge on the importance of TNF-α role in mycobacterial, specially Mtb, and 
Leishmania infections , has dramatically increased with the anti-TNF-α use [213,269,276,277]. 
Patients exposed to anti-TNF-α showed higher frequency of TB, histoplasmosis, cryptococcosis, 
coccidomycosis, listeriosis, aspergillosis [213,225,277,278] and leishmaniasis [255,279]. The 
increased susceptibility to TB is one of the most relevant adverse effect of anti-TNF-α antibodies. 
It has been described that these treatments increase at least 5 times the risk of TB infection after 
drug exposure [213]. The risk of TB is mainly due to reactivation of latent tuberculosis infection, 
leading to disseminated forms; TNF-α is thought to be important for the containment of the 
dormant mycobacteria [225,226,269,276]. As opposed to the common pulmonary tuberculosis in 
adults, the forms seen after anti-TNF-α are specially severe, usually extrapulmonary [269,276]. 
Besides, the withdrawal of anti-TNF-α treatment in patients with latent tuberculosis infection can 
lead to a state of increased inflammation due to the immune reconstitution syndrome. For this 
reason, prior to anti-TNF-α treatment it is mandatory to perform a TB screening and, if needed, 
antibiotic therapy to avoid TB reactivation [225,269,276–278,280]. 
Low levels of TNF-α are associated with fatal TB progression. It plays a non-redundant role 
in preventing primary progression and control of the reactivation of latent TB [213,269].  Of note, 
virulent strains have mechanisms to inhibit TNF-α production while non-pathogenic mycobacteria 
lead to increased TNF-α production [269]. After mycobacterial encounter, macrophages and 
dendritic cells are the major source of TNF-α, especially when co-stimulated with IFN-γ [269]. 




intermediates as well as killing peptides [276]. Normal levels of TNF-α release by mononuclear 
cells lead to recruitment of T cells to the site of infection, activation cytotoxic T cells, promotion 
of monocyte maturation [276] and apoptosis in infected macrophages [269]  
TNF-α production is highly modulated by cytokines, enzymes and lipid mediators to avoid 
unwanted responses. Dysregulation of TNF-α production in the context of a mycobacterial 
infection leads to increased disease. TNF-α has a major role in granuloma formation and 
maintenance [213,269,276,277]; for example, animal models have shown that low levels of TNF-
α lead to disorganized granulomas, with impaired activation of macrophages and presence of 
increased numbers of bacilli; on the other hand, increased levels of TNF-α, although with well-
defined granulomas, can lead to the hyperactivation of infected macrophages, necrosis and 
extracellular replication after the release of the bacilli causing hyperinflammation and tissue 
destruction in the host [269]. Of note, the effect on the granuloma structure in humans is not 
totally understood yet. Thus, the balance between TNF-α production and other 
immunomodulatory molecules as IL-10 is of outmost importance to prevent excessive harm.  
Of interest, this increased infectious risk is observed with monoclonal antibodies and not 
with soluble molecules anti-TNF-α [213,277]. Differences observed between types of biologic 
drugs against TNF-α can be explained by two major reasons. Frist, because monoclonal antibodies 
as infliximab and adalimumab can form immune complexes with the complement system and 
provoke the lysis of the cell [277] and second, because of the differential inhibition of TNFR1 – 
TNFR2. Second, TNFR1 has a major role in the outcome of mycobacterial infection, infliximab and 
adalimumab monoclonal antibodies block both TNFR1 and TNFR2, while etanercept totally inhibits 
TNFR2 signaling but only blocks partially TNFR1 [276]. While whole blood treated with infliximab 
showed reduced CD69 early activation marker expression, reduced IFN-γ production and a 
tendency towards an increased intracellular viability of the mycobacteria inside the macrophage; 
treatment with etanercept did not cause any of these effects [277].  
Although there are not known PID causing specifically a deficiency in TNF-α, it plays a key 
role in the IL-12/IFN-γ axis by synergistically acting with IFN-γ and macrophage activation for intra-
macrophagic pathogen destruction (Figure 14). Infections observed in adult patients treated with 
anti-TNF-α mAbs resemble those observed in patients with MSMD [26].  
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Figure 14. Impact of anti-TNF-α blocking on the IL-12/IFN-γ axis. Simplified representation of the 
IL-12/IFN-γ axis and the impact of blocking the synergistic effect of TNF-α. Drugs used for TNF-α 
inhibition are displayed in red.  
 
4.4.Anti-TNF-α drugs in inflammatory bowel disease 
IBD is an advancing problem in westernized countries and is characterized by chronic 
inflammation of the intestine and/or the colon. UC and CD are the main representatives of IBD. 
The prevalence of IBD in Europe is 505 and 322 per 100,000 for UC and CD, respectively [281]. IBD 
has serious implications for the patient, with high morbidity and a decrease in quality of life 
[275].UC is characterized by a relapsing inflammation of the colonic mucosa and is normally 
diagnosed after the presence of bloody diarrhea. Disease severity can range from mild 
inflammation to severe fulminant disease, dependent on the affected colonic extent. When the 
disease is not controlled by drugs, surgery (including proctocolectomy) can be needed; besides, at 
the long term, UC is related with increased risk of colorectal cancer [282]. CD is a more complex 
relapsing disease affecting the gastrointestinal tract but including also extraintestinal 
manifestations such as osteoporosis or pyoderma gangrenosum. Besides, it is associated with 
other immune disorders such as psoriasis or multiple sclerosis. CD usually presents with abdominal 
pain, fever, bowel obstruction, diarrhea that can be bloody and/or contain mucus. If not 
controlled, CD can become an invalidating disease; a big fraction of CD patients will need surgery 
and, almost half of them, more than once [275,283]. Anti-TNF-α mAb have revolutionized IBD 
treatment [275,281,284–286], by decreasing the rate of hospitalization due to complications or 
need for surgery [275].  
Microbiota and immune system relationship is tightly regulated. The intestinal mucosa is 
covered by commensal bacteria; consequently, the interaction between the patrolling immune 
system and the environmental stimuli needs to be strictly regulated to prevent intestinal 
inflammation [275]. IBD is caused by a destructive loop between a non-controlled immune 
response against normal intestinal flora and epithelial barrier disruption after TNF-α over-
production [261,264,275]. UC has been associated with the disruption of the barrier function 
while CD with a dysfunction on the microbe sensing [275]. Overexpression  of TNF-α is related to 
hyper-inflammation and tissue damage [267], concretely in the disruption of the epithelial barrier 
by both the rearrangement of adhesion proteins and the induction of intestinal cell apoptosis after 
an increased iNOS expression [264,268]. After this disruption, luminal antigens can penetrate and, 
then, promote inflammation [264]. TNF-α presence in serum directly correlates with disease 
severity in IBD patients, giving conceptual rationale for anti-TNF-α treatment.  
Anti-TNF-α drugs are normally used after failure of conventional treatments. Conventional 
treatments include budesonide, 5-aminosalycilic acid, topical or oral glucocorticoids, antibiotics, 
immunomodulatory molecules such as azathioprine, mercaptopurine or methotrexate (only for 
CD patients). Among biological therapies, infliximab and adalimumab are the most common used 
anti-TNF-α mAbs; however, certolizumab pegol and golimumab have also been recently approved 
for their use in IBD therapy. Placebo-controlled trials have proven that infliximab, adalimumab 
and certolizumab pegol are efficacious in the treatment of moderate-to-severe CD, promoting 
mucosal healing and the sparing or stop of glucocorticoid treatment. Randomized trials for UC 




therapy [273,275]. The effect of these drugs in IBD pathogenesis has been proven by different 
clinical trials, showing clinical response, reduction of acute inflammatory molecules and mucosal 
healing [268].  
The mechanism of action of anti-TNF-α drugs in IBD is complex. It includes apoptosis of 
lamina propria T cells and the induction of M-2 type wound-healing macrophages. Lamina propria 
T cell apoptosis occurs as fast as 24h after administration of infliximab, adalimumab or 
certolizumab (not yet studied in golimumab) and continued after 4 weeks of treatment, thus 
stopping or reducing inflammation. CD206+ M-2 type macrophage generation is dependent on the 
Fc binding activity of monocytes; for that reason, only full antibodies can exert this action. The 
appearance of CD206+ macrophages is related with good outcome in infliximab treated patients. 
The production of these macrophages is increased when biological drugs are used in combination 
with azathioprine. Besides, it has been shown that anti-TNF-α treatment modifies transcription 
factor and gene expression profiles in intestinal cells, as they respond differently to other stimuli 
that would trigger the inflammatory response [274].  
Anti-TNF-α therapies in IBD start with an induction phase followed by a stable phase. 
Infliximab is typically administered intravenously at a dose of 5 mg per kilogram of body weight; 
induction phase consists of three doses at weeks 0, 2 and 6, followed by a subsequent treatment 
every 6 to 8 weeks., Adalimumab, certolizumab pegol and golimumab are administered 
subcutaneously, and the administration can be performed in-house by the trained patient. For 
adalimumab, the first dose is administered at 160 mg, the second at 80 mg and then at 40 mg 
every two weeks [272,274,275,287]; for Certolizumab pegol the recommended dose is of 400 mg, 
first at weeks 0, 2 and 4, and then after every 4 weeks [272,275,288]. Golimumab is administered 
at a dose of 200 mg the first time, then 100 mg at week 2, followed by 100 mg administration 
every four weeks [272,275,289].  
Although anti-TNF-α treatments have greatly improved the prognosis of IBD patients, 
there are still patients that do not respond to treatment. Approximately from 10 to 40% of CD 
patients and a 50% of UC patients do not have clinical responses to anti-TNF-α treatments. If 
persistent inflammation is observed, dose or frequency of administration of anti-TNF-α can be 
increased or the anti-TNF-α drug can be changed [272,273,275]. Treatment with infliximab and 
azathioprine has increased clinical responses, compared with the two treatments alone. Also the 
occurrence of anti-infliximab antibodies is reduced [275]. Levels of anti-TNF-α and presence of 
anti-drug antibodies should be monitored to prevent relapses of the disease, as persistently 
detectable drug levels correlate with favorable responses. Therapeutic dosage for adalimumab is 
>4 µg/ml and for infliximab >3 mg/ml. Undetectable drug levels may correspond with the 
apparition of anti-drug antibodies, as their presence detection calls for medical actions regarding 
treatment [290].  
 
4.5.Anti-TNF-α drugs during pregnancy 
There is increasing interest in the use of anti-TNF-α drugs during pregnancy in women with 
IBD. Indeed, IBD debut occurs frequently in women during childbearing age (78% of UC and 51% 
of CD patients debuted between 20 and 29 years, with a female predominance) [281,286]. 
Nevertheless, pregnancy is not associated with IBD improvement, as opposed to other 
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inflammatory diseases such as rheumatoid arthritis [291–295]. Active IBD can lead to increased 
pre-term deliveries and spontaneous abortion (up to 31% in active UC patients), and increased 
probability of low birth weight [291–294,296]. These risks have resulted in an increased frequency 
of elected childless woman within the IBD group [286]. To increase safety in IBD pregnant woman, 
sustained remission of IBD is mandatory, often only achievable with anti-TNF-α treatment. 
Anti-TNF-α mAb cross placenta mostly from week 28 of gestation to delivery [297]; they 
are included in category B (no apparent risk) of FDA-classification for pregnancy risk. However, 
drug level’s safety in newborns and the full consequences of such exposure in newborn's immune 
system development are unclear. Several recent studies in extensive cohorts (PIANO (n=426), OTIS 
registry (n=74) and CRIB study (n=31)) of infants exposed to anti-TNF-α drugs during, at least, the 
second and third trimester of pregnancy, showed that both anti-TNF-α adalimumab and infliximab 
were detectable in infants from treated mothers for 12 months after birth, while certolizumab 
was barely detectable. Infants showed no apparent major clinical consequences [298–301]. 
Nevertheless, a fatal case of disseminated BCG disease after vaccination was reported in an infant 
whose mother had been treated with high doses of infliximab during pregnancy [302]. It is 
recommended to delay immunization with live vaccines until 12 months or after confirmation of 
negative drug levels [300,303].  
TNF-α plays a pivotal role in fetal development. Both in regulation of necroptosis and fate-
programming during the embryonic state [304–307] and, afterwards, in B cell development. TNF-
α knock out mice present abnormal B cell structures; they lack splenic B cell follicles, organized 
follicular dendritic cell networks and germinal centers. These alterations lead to a decreased 
humoral response and increased infection risk [308,309]. Nonetheless, mice exposed to anti-TNF-
α mAb during gestation did not show any abnormal B cell structures. However, B cell development 
occurs 3 weeks after birth in mice. Instead, in humans, B cell development occurs during the third 
trimester of pregnancy and through 8 weeks after delivery [310–312]. A study on the impact of 
the exposure to golimumab during pregnancy in macaques revealed no effect in B or T cell 
frequency, nor in humoral responses, or in lymphoid organ formation, but maturation status of 





5. The immune system in the neonate 
Upon labor, the fetus must transition from the semi-allogenic but sterile uterus of the 
mother, to a world full of antigens. Most of these antigens will be harmless but some will be 
harmful and dangerous, and the development of different strategies to overcome these different 
challenges is of dramatic importance. Just after birth, especially after vaginal delivery, the mucosa 
of the infant is colonized by commensal microbiota. Thus, the avoidance of excessive responses 
after this massive first contact with microorganisms is critical, as well as to reduce the risk of 
alloimmune reactions during late pregnancy; to do so, the immune system has developed 
different strategies to manage this situation. The neonate’s immune system plays a principal role 
in this special and delicate moment. Study of the neonate’s immune system is still on 
development, and current knowledge has been thoroughly reviewed [314–318]; concretely, 
Kollmann et al have recently elegantly reviewed immune defense against infections in newborns 
[314] 
Neonatal infection is responsible for approximately 700.000 newborns’ deaths per year. 
Transition from the last stages of pregnancy, labor and the first encounters of the newborn with 
the real-world, claims for rapid changes and adaptation of the immune system: from cell 
autonomous and innate immunity to the adaptive immune system. Although the neonate’s 
immune system can fight pathogen infections, as a result of the need of tolerance, there is an 
increased risk for severe infections [314]. For this reason, immunization through maternal IgG 
during late pregnancy is critical. IgG transfer can confer around three months of broad protection 
for a variety of infectious diseases including measles, mumps, rubella and varicella. Altered IgG 
transfer, observed in very low weigh and preterm infants, results in an increased risk of lethal 
neonatal infection. Newborns have an increased risk of intracellular pathogens infections 
requiring Th1 responses, especially Listeria monocytogenes, Salmonella spp. and Mycobacterium 
infections [314–316]. 
External factors, such as maternal condition during pregnancy and microbiota acquisition, 
will shape the development of the neonate’s immune system. Maternal conditions include 
infections during the last trimester of pregnancy, highlighting parasitic infections, maternal 
nutritional imbalance and inflammatory conditions such as autoimmune or inflammatory disease. 
Microbiota acquisition during delivery and lactation will shape long-term immunological 
responses, being essential for optimal immune development. Full gut colonization lasts 12 to 18 
months, and a symbiosis relation is established between the microbiota and the host. This 
colonization has been related with tolerance acquisition and innate training to mount effective 
immune responses upon pathogen encounter. Pharmacological treatments, such as antibiotics, 
can cause dysbiosis during early age, which is associated with increased risk of immune-mediated 
diseases or allergy in the newborn [314–317].  
The immune system of the newborn has different regulatory mechanisms to promote 
tolerance.  Hypoxia during labor can cause tissue damage enhancing inflammation, so the strong 
immune bias towards resolution of inflammation and healing is very important. In fact, vaginal or 
cesarean delivery can affect leukocyte populations and plasma concentration of cytokines [319]. 
Upon TLR-mediated activation, APCs promote Treg cell differentiation; besides, non-inherited 
maternal antigens challenge also results in CD4+ T-cell differentiation into Treg cells. Along with 
Treg cells, myeloid-derived suppressor cells and erythroid suppressor cells are present in cord 
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blood and regulate CD4+, CD8+ and NK cell activity. Besides, high adenosine levels in blood after 
inflammatory events and hypoxic states contribute to the generation of an increased presence of 
cyclic adenosine monophosphate. The presence of these purines promotes a tolerogenic state of 
the immune system through the impairment of MyD88 pathway activation, thus reducing TLR-
mediated Th1 polarizing cytokine induction and neutrophil activation. Besides, altered TLR 
activation in neonates partially responds to a different micro-RNA profile, including increased 
levels of the inhibitory micro RNA146a [314–317].  
Besides the above-mentioned inflammatory responses’ regulation, the neonate has other 
compensatory non-inflammatory weapons to protect against germ insult. Newborn’s skin and 
mucosa produce high amounts of antimicrobial proteins and peptides. What is more, at birth the 
skin of the neonate is covered with the vernix, consisting of a waxy-coating full of microbicidal 
peptides to compensate the reduced toughness of the skin. Innate regulation of the immune 
system comprises 1) decreased complement system function; 2) decreased neutrophil quantity 
and functions, including respiratory burst; 3) mononuclear presenting cells (monocytes, 
macrophages and dendritic cells) have decreased IL-1β, TNF-α and IL-12p70 production, along 
with normal IL-23 and IL-6 production; 4) decreased IFN-γ response in certain conditions; 5) IRF3 
has decreased DNA binding capacity; 6) monocytes produce increased levels of IL-10 and cyclic 
adenosine monophosphate; 7) conventional DC number is decreased and cells are more immature 
and produced less inflammatory cytokines and 8) NK cells express higher levels of the inhibitory 
receptor NKG2A and lower levels of the activating receptors NKG2C, LIR-1 and KIR [314–318]. 
In the neonate, CD4+ T-helper cells are biased towards Th2-like immunity, with a more 
anti-inflammatory profile. There is low IFN-γ production, in concordance with decreased IL-12p70 
production by mononuclear antigen presenting cells. However, in response to some insults such 
as BCG vaccination, the newborn can develop adult-like Th1 responses and the Th2 bias can be 
reverted after this BCG training. This bias is related with epigenetic modifications, as regulatory 
regions of the Th2 locus are hypomethylated and IFN-γ and other Th1 associated molecules 
promoter sites are hypermethylated. Besides, Th17 cell levels are low because of reduced 
transcription of RORC transcription factor. There is also impaired T cell signaling by the T cell 
receptor resulting in decreased transcription of CD40L, IL-2 and IFN-γ genes. B cells are mostly 
naïve with a poor repertoire and diminished B-cell receptor activity, resulting in decreased antigen 
response. For this reason, not all vaccines are successful when given at birth, as observed with 
oral polio, measles and rubella vaccination [314–317].  
Neonatal B-cells have been less studied. B cell development and maturation is a complex 
and regulated process. In peripheral blood we can encounter different B cell subsets that include 
naïve, transitional, marginal zone like B-cells (expressing IgM, IgD and CD27 in their membrane 
[320,321]), mature B cells and plasmablasts [320,322]. B cells have been thought as mere 
“antibody-factories” during years; nowadays it is known that they have different functions 
including cytokine production and regulation of T cell responses. Activation status of B cells has 
been studied and is tightly modulated. CD22 is a B cell-restricted molecule that down-regulates 
the signal between CD19 and the BCR [323–325], the lack of this regulatory molecule results in an 
increase in B10 cells in mice [326]. Some few published studies on B cells in the neonate have 
associated B cells with the Th2 bias: asthmatic mothers of infants with early-allergy had an 
increase in transitional B cells in the late-pregnancy period, suggesting that these cells could have 




cells of newborn mice also contribute to the decrease in IL-12p70 production [328]. On the other 
hand, it is known that infusion of stem cells from cord blood rather than adult bone marrow 
enables transplantation in patients with increased donor-recipient HLA-mismatch [329], and one 
of the possible mechanisms explaining this augmented allogenic tolerance is the B cell-mediated 
regulation trough B regulatory cells (Breg). [330] The frequency of Breg cells in the neonate can 
predict the severity of acute bronchiolitis disease after respiratory syncytial virus, thus showing 
how neonatal Breg cells can modulate microbial pathogenesis [331].  
 
5.1.Breg cells 
Avoidance of unwanted immune responses through peripheral tolerance involves several 
regulatory/suppressor molecules and cell types. Breg cells are a rare B cell subpopulation with this 
regulatory/suppressor function. Although B cells [332] and, more concretely, IL-10 production by 
B cells [333] have been shown to be important in inflammation in mice, it was not until 2010 by 
the hand of Blair et al that the first description of the phenotype and function of a human Breg 
cell subset was published [334]. Since then, several markers have been described for the detection 
and sorting of these cells, although there is not yet a consensus. Breg cells represent fewer than 
a 10% of total B-cells in circulation; their regulatory activity is mostly but not uniquely performed 
through IL-10 production; nevertheless, less than 20% of cells from the different described subsets 
are IL-10 producers after stimulation [335,336]. 
 
Figure 15. Induction of Bregs. IL-10–producing Bregs that express regulatory genes are generated 
as a consequence of immune activation. The signals that induce the differentiation of Bregs 
include inflammatory stimuli (via TLRs), costimulatory signals (CD40, CD80, CD86), microbiota, 
and cytokines (IFN-α/β, IL-1β, IL-6, IL-21, and BAFF). Adapted from Mauri 2017[335] 
There are two theories regarding Breg development: the first states that B cells are a 
specific lineage with a specific transcription factor that controls the suppressive nature of the cells; 
the second suggests that B cells can take on a regulatory phenotype after certain stimuli to 
suppress inflammation. Inflammation is a potent trigger of Breg cell development and 
differentiation, Breg cells need combination of different molecules to get activated, including 
TLRs, CD40, the B cell receptor, CD80, CD86 and cytokines (Figure 15) [335,336]..  
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With that, there are 8 different described types of Breg cells in humans [335–338]: 
1. Immature B-cells, phenotypically described as CD24hiCD38hi. These cells perform 
their action on CD4 and CD8 T-cells, plasmacitoid DCs and invariant NKT cells by 
IL-10 secretion, PD-L1, CD80, CD86 and CD1d ligation [334,339–342]. 
2. B10 cells, described as CD24hiCD27hi, produce IL-10 and regulate monocytes and 
effector CD4 T cells [343]. 
3. Granzyme B+ (GZMB) cells, described as CD38+CD1d+IgM+CD147+ exert their 
regulatory function on CD4 T-cells by IL10, indoleamine 2,3-dioxygenase (IDO) and 
GZMB [344]. 
4. Br1 cells are defined as CD25hiCD71hiCD73low B cells and they produce IL-10 and 
allergen-specific IgG4, thus suppressing allergen-specific CD4 cells, thus 
maintaining allergen tolerance [345].  
5. Plasmablasts, defined as CD27intCD38hi; some of them can produce IL-10 but their 
target cell type is not known yet [346]. 
6. B-cells expressing CD39 and CD73 that regulate CD4 and CD8 T cells by adenosine 
formation, thus reducing inflammation by ATP [347]. 
7. Induced Breg cells, without known phenotypic markers produce TGF-ß and IDO to 
suppress CD4 T cells. These cells are developed after T-cell CTLA-4 interaction 
[348].  
8. Cells expressing TIM1 inhibit CD8 and CD4 T cells by producing IL-10 [349]. 
Main functions of Breg cells include inhibition of Th1 cells activation, Th17 differentiation 
and promotion and maintenance of the Treg cell population [335–337]. The major suppressive 
mechanism for Breg cell function is IL-10 secretion. IL-10 is a suppressor cytokine that can inhibit 
chemokine and pro-inflammatory cytokine production, thus inhibiting the effector mechanisms of 
the immune system; Breg cells are known IL-10 producers and IL-10 blockade partially inhibits 
their regulatory function. Although IL-10 is a key player in Breg inhibition of inflammation, other 
mechanisms have been described, including TGF-β (specially for the differentiation of tolerogenic 
DCs) and IDO production, cell to cell contact by CD80/86 interaction with T-cells, PD-L1 inhibition 
of T follicular helper cells and CD73-dependent adenosine production [334,336,338,339,343,350–
352] .  
The most studied subset of Breg cells is defined by CD24hi and CD38hi expression in B-cells 
[334,339,353]. Phenotypically, these cells also express IgM, IgD, CD5, CD10 and CD1d [334], 
resembling transitional B cells [354]. Breg-cells are mainly defined by its regulatory function: Mauri 
et al. demonstrated that the CD19+CD24hiCD38hi subset is enriched in IL-10 production and can 
inhibit IFN-γ production [334,355] and block Th1 and Th17 differentiation while maintaining Treg 
cell population [339]. Their implication in human immune-related diseases has mostly been 
studied in autoimmune and allergic diseases [356–365], persistent infections such as HIV [340], 
HBV [366] and Mtb [367], cancer [368–371], transplantation [355,372–375] and, as demonstrated 
recently, pregnancy [327,356,376–380]. 
Viruses, bacteria, helminths [381] and parasites [382] can induce B cells with regulatory 
functions. Rapidly after infection, Salmonella and Listeria induce the apparition of IL-10 producing 
cells in a TLR/MyD88 dependent fashion in mice. Some helminth-derived molecules can directly 




allergens, studies in humans have also shown this bystander regulatory functions after helminthic 
infections. The lack of helminth infections in westernized countries has been proposed as one of 
the reasons that can explain the increased incidence of allergy and autoimmunity. Breg role in 
viral infection has been more studied because of their role in HIV infection and in chronic HBV 
infection [381]. Immature Breg cells inhibit IFN-γ production by CD8+ T-cells after HBV virus 
infection [335,366]. Besides, CD24hiCD38hi IL-10 producing cell frequency directly correlates with 
HIV virus load [383]; what is more, after in vitro Breg depletion, CD8+ T-cell effector function was 
restored and HIV infected CD4+ cells were cleared in vitro [340].  
Breg cells are considered to promote a stable tolerant immune profile in the local 
microenvironment. Recently, Guzman-Genuino et al, reviewed how the previous knowledge of 
the role of Breg cells in autoimmunity and transplantation (promoting tolerance) and cancer 
(promoting tumor growth) could help in the understanding of the role of Breg cells in the 
establishment and maintenance of pregnancy, where a semi-allogenic mass of cells grows inside 
the women [379]. Immunological changes are needed to avoid allogenic reactions that could lead 
to miscarriage. Body conditions to allow conception and implantation, as well as changes needed 
to allow embryonic and fetal growth, are regulated by pregnancy hormones. Therefore, it is logic 
to think about human gonadotropic hormone, estrogen and progesterone as regulators or 
promoters of these changes.  
Similar to what happens in the neonate, after conception, the mother needs to modify its 
immune system in order to tolerate the semi-allogenic embryo. Maternal-fetal tolerance is 
achieved through different mechanisms that include an increase of Treg cells, IL-10 and TGF-β 
expression [384], increase of the inhibitory molecule PD-L1 in the trophoblastic tissue, reduction 
of APCs and of mononuclear phagocytes and, as reported recently, an increase of Breg-cells 
[380,385,386]. Pregnancy hormones modify immune responses after conception, including Breg 
cells. It is known that estrogen can modify decidual immune cells by turning DCs and NK cells into 
tolerogenic cells; besides it can regulate T cell activities including the expansion of Treg cells [379]. 
It also has a role in B cells, as it is known to increase, in mice, CD1dhighCD5+ IL-10 producing Breg 
cell subset and PD-L1 expression in B cells, thus protecting mice from experimental autoimmune 
encephalomyelitis [379,380,387,388]. Progesterone promotes Th2-like immune responses with a 
reduction in pro-inflammatory cytokines and increased IL-10 production that is associated with a 
B cell expansion. Human gonadotropic hormone from pregnant women sera increase IL-10 
production by B-cells (Figure 16) [376,380].  
First associations of Breg cells with pregnancy success were performed in mice. In 
pregnant mice, the increase in CD5+CD1d+ Breg cells is necessary to avoid immunological abortion. 
In fact, the transfer of Breg cells to abort-prone mice promotes fetal-maternal tolerance by leading 
to a Treg cell increase and by maintaining DCs in an immature state [377]. In humans, it was 
observed that women treated with rituximab, a B cell depleting antibody, during pregnancy 
presented a higher rate of first-trimester pregnancy loss[389], thus suggesting a principal role of 
B-cells in pregnancy. Later, CD24hiCD38hi [334] and CD24hiCD27+ [343] have been recently used for 
the study of Bregs in pregnant women [378,380]. CD24hiCD27hi cells increase in the first trimester 
of pregnancy but, as observed with mice Breg cells, this increase does not occur in patients with 
spontaneous abortion. What is more, almost 95% of CD24hiCD27 hi B cells express the receptor for 
human gonadotropic hormone [376]. These data highlight the importance of B-cells, specifically 
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Breg, in the mother’s achievement of immune tolerance during the first steps of pregnancy. The 
importance of this subset of cells in the fetus and the newborn is still yet to be determined.  
 
Figure 16. Schematic representation depicting the influence of female sex hormones in the 
activation and subsequent function of regulatory B cells (Bregs). (A) Estradiol (E2), acting through 
estradiol receptor alpha (ERα), induces the proliferation as well as the production of IL-10 by 
regulatory B cells (Breg). In addition, E2 mediates the control of T cells’ activation by B cells 
throughout a mechanism involving PDL1/PD1 pathway. (B) Human chorionic gonadotropin (hCG) 
was proposed to induce proliferation of regulatory B cells. Besides, this hormone induces the 
production of IL-10 by B cells that in turn inhibit the production of TNF-α by T cells. (C) Progesterone 
(P4) induces the production of the potent anti-inflammatory and Breg hallmark cytokine IL-10 by B 



















This thesis is framed in the concept that the IL-12/IFN-γ axis is fundamental for the 
control of intracellular infections. A dysfunction in this axis, inherited or acquired, can be 
observed in specific clinical situations not yet explored, concretely: 
We hypothesize that patients with extrapulmonary Mycobacterium tuberculosis 
infection or visceral leishmaniasis have a primary dysfunction of the IL-12/IFN-γ axis and that 
the study of these patients will lead to detection of new cases of MSMD, in which specific 
treatment approaches could be applied and that exposure to anti-TNF-α antibodies during 
whole pregnancy in children born to mothers with inflammatory bowel disease affects the 
normal development of the neonatal immune system, conferring a secondary 
immunodeficiency, which includes a dysfunction of the IL-12/IFN-γ axis.  
  








The general objective of this project is to better understand the state of IL-12/IFN-γ axis defects 
both by inborn errors of immunity and secondary to anti-TNF-α exposure during pregnancy.  
 
The specific objectives are:  
Objective 1. To elucidate if patients with intra-macrophagic infections (visceral leishmaniasis or 
severe/tuberculosis) have defects on the IL-12/IFN-γ axis.  
 
Objective 2. To define the effect of whole-pregnancy exposure to anti-TNF-α antibodies used in 
inflammatory bowel disease in the exposed infant immune system. 
Objective 2.1. To determine if IL-12/IFN-γ axis is affected in the exposed infants 
Objective 2.2. To characterize different lymphoid populations in the exposed infants 
 
Objective 3. To establish lymphoid populations normality values in cord blood, including Breg 














Chapter 1. Study of IL-12/IFN-γ axis in patients with severe/extrapulmonary 
tuberculosis and visceral leishmaniasis 
We have studied the IL-12/IFN-γ axis in patients with severe TB or VL. For the recruitment 
of patients, we established different collaborations with autonomic, state and international 
centers, including Hospital Sant Joan de Déu and Hospital Vall d’Hebron in Barcelona, Hospital 
Joan XXIII in Tarragona, Hospital General in Granollers, Hospital La Fe in Valencia, Hospital 
Gregorio Marañón and 12 de Octubre in Madrid, Hospital Son Espases in Mallorca and Instituto 
Nacional del Niño in Lima in Perú. Thanks to this collaboration, we have been able to recruit 25 
patients with TB and 23 with VL. However, one of the patients was removed from the TB cohort 
because, although first diagnosed as suffering from TB, he was misdiagnosed and indeed suffered 
from complicated BCGosis. We have also included in the study 41 healthy controls, of whom 23 
were related to the patients (R-HC, mostly parents) and 18 were non-related to the patients (NR-
HC).  
Epidemiologically, patients with TB presented a broader ethnic variation while most of VL 
where from Caucasian origin. Of interest, VL patients were younger at age of infection (1.58 years 
old, 0.25 to 8 years old in VL patients and 3 years old, 0.47 to 16 years old in TB patients, median, 
range). However, these differences disappeared when comparing the age at test (7.42 years old, 
0.42 to 12.54 years old in VL patients, 7.28 years old, 0.62 to 12.54 years old in TB patients, 
median, range). Only two families declared consanguinity. In TB patients, location of the infection 
was majorly disseminated (33% of total), with (36.4% of disseminated infections) or without 
(63.6% of disseminated infections) meningitis, adenopathic (21% of total) or meningitis (17% of 
total). All patients showed normal lymphocytic subsets, proliferation response to mitogens and 
oxidative burst responses.  
Gold-standard technique for the study of the integrity of IL-12/IFN-γ axis, used for MSMD 
diagnosis, is the detection of secreted cytokines after a whole blood culture in presence of BCG, 
with or without hrIL-12p70 or hr-IFN-γ in order to evaluate anti-mycobacterial response ex vivo 
[119,173] (see section 2.2.2). This technique is especially useful for the detection of complete 
defects of the IL-12/IFN-γ axis. However, there is a big variability in the observed responses both 
in healthy controls and patients [81,89,119] that hinders the identification of partial defects. 
Besides of the culture, we have studied IFN-γR1, IFN-γR2 presence in monocytes, IL-12Rβ1 
presence in activated lymphocytes and STAT1 phosphorylation in response to IFN-γ in monocytes, 
without observing any alterations. 
High variability observed in cytokine production was observed in both NR- and R-HC. 
However, after the performance of co-stimulation ratio (Co-SR, cytokine production with 
‘BCG+Co-stimulus’/BCG alone), there was a reduction of the coefficient of variation in NR-HC that 
was not observed in R-HC. Also, the pattern of produced cytokines was different between the two 
groups. R-HC, when compared to NR-HC, had a decreased production of IFN-γ and increased 
production of IL-6, IL-10 and TNF-α after BCG stimulation. Besides, there was a reduced Co-SR of 
IL-6 and TNF-α after hr-IL-12p70 co-stimulation and a reduced Co-SR of TNF-α and IL-12p70 after 
hr-IFN-γ co-stimulation.  
Concordantly with the cytometric studies results we did not find any complete defects of 
the IL-12/INF-g axis in patients with extrapulmonary TB or VL infections. However, we observed 
different cytokine production patterns. Patients with TB showed an increased IL-10 and TNF-α 
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secretion and a diminished IL-1RA secretion after BCG stimulation when compared with NR-HC 
(this difference was not observed in R-HC). Of note, response to IFN-γ in terms of IL-12p70, IL-1β 
and TNF-α production was diminished. VL patients presented diminished IFN-γ production after 
BCG stimulation compared to all the other groups studied, which was rescued to normal levels 
after IL-12p70 co-stimulation. Altogether, these data showed that studied TB patients had an 
impaired response to IFN-γ while studied VL patients had an impaired production of IFN-γ. 
Detailed methods, results and figures are shown in “Altered IFN-γ circuit in 
extrapulmonary tuberculosis and visceral leishmaniasis patients and related controls” manuscript.  
The case of the patient that was removed from the TB cohort was of special interest. She 
was a Peruvian 6 years old girl diagnosed with a recurrent, severe and disseminated TB. Her case 
was remitted to us for the study of the integrity of the IL-12/IFN-γ axis. We observed no expression 
of IL-12Rβ1 in the membrane of activated lymphocytes. Further studies confirmed this 
functionally, as there was no STAT4 phosphorylation in response to IL-12p70 in activated 
lymphocytes and the production of IFN-γ after BCG stimulation was low and non-rescued after IL-
12p70 co-stimulation. Genetic studies confirmed a mutation in IL12RB1 gene (p. (Arg211*; 
c.631C>T). Thus, being the first Peruvian patient with a genetic confirmation of MSMD disease. 
To receive the appropriate treatment, consisting in hr-IFN-γ, she was transferred to the National 
Institute of Health in the United States of America. Once there, further microbiological studies 
revealed that the patient had been initially misdiagnosed and that BCG-derived Mycobacterium 
bovis infection was the infectious agent. Anti-mycobacterial treatment was then optimized and 
supplemented with hr-IFN-γ. The patient is now stable and without active infection. This case 
demonstrates the importance of PID suspicion amongst clinicians. BCGosis is a much rarer 
infectious event compared with TB; however, its presence is virtually always associated with 
immunodeficiency states, inherited or acquired.  
Detailed methods, results and figures are shown in “Severe BCGosis misdiagnosed as 
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Background: Genetic defects in IL-12/IFN-γ axis confer susceptibility to intracellular pathogens 
in otherwise healthy children, especially but not restricted to non-tuberculous mycobacteria. The 
main aim of this work is to understand the status of the IL-12/IFN-γ axis in patients with/severe 
extrapulmonary tuberculosis (TB) or visceral leishmaniasis (VL) and unravel if this susceptibility 
is due to complete defects in the pathway.   
Methods: A retrospective and prospective cohort study of the IL-12/IFN-γ axis of 23 patients with 
VL and 24 patients with TB compared to controls (n=41, 18 non-related controls and 23 related 
controls). After discarding other PIDs, whole blood culture in the presence of BCG with or without 
IL-12p70 or IFN-γ co-stimulation was performed to analyze cytokine secretion.  
Results: Related and non-related controls presented differential cytokine production patterns. 
Although we did not detect any complete defect, patients with VL or severe TB showed an altered 
IL-12/IFN-γ axis with reduced IFN-γ production and response, respectively.  
Conclusions: TB and VL infections in our media are not warning signs for complete defects of the 
IL-12/IFN-γ axis. However, the altered cytokine production after mycobacterial challenge reveals 




Genetic theory of infectious tries to explain why not all individuals respond the same way to 
infections. It states that susceptibility to severe primary infections in the pediatric age can be 
explained by single-gene mutations in immune-related genes. This concept has been stated and 
nicely reviewed by Casanova and Abel1–4. Primary immune deficiencies (PID) are the paradigm of 
single-gene mutations conferring susceptibility to infectious disease. During many years, PIDs 
were thought to be extremely rare and to confer susceptibility to a wide range of pathogens. 
However, in the last years, “atypical” PIDs have shown how single-gene errors can lead to 
susceptibility to one or a narrow range of pathogens, and that there can be only one infection during 
lifetime which, by the way, can be lethal1–4.  
Mendelian Susceptibility to Mycobacterial Disease (MSMD) is one of the better known “atypical” 
PID. It is caused by inborn errors impairing the final killing of intra-macrophagic pathogens. 
Immunity to these pathogens, whose major representative are mycobacteria, relies on the IFN-γ 
circuit5,6. Briefly, after mycobacteria (or other intra-macrophagic pathogens) are engulfed by 
dendritic cells or macrophages, these cells produce IL-12p70, thus activating T helper (Th) cells 
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and enhancing IFN-γ production. IFN-γ makes macrophages produce more IL-12p70; creating a 
positive loop; besides, it activates oxidative burst leading to the killing of intra-macrophagic 
pathogens7–11. Currently, at least ten MSMD-causing genes (IFNGR1, IFNGR2, STAT1, IRF8, 
CYBB, IL12B, IL12RB1, IKBKG, ISG156 and TYK212) have been described, giving place to 19 
different genetic etiologies. 
MSMD has not yet defined its clinical boundaries, but is characterized by infections by non-
pathogenic mycobacteria (including BCG and environmental mycobacteria) alone or in 
combination with Salmonella or Candida. Infection by other intra-macrophagic pathogens has also 
been observed6; including severe forms of Mycobacterium tuberculosis (Mtb) infections and 
visceral leishmaniasis (VL) (alone13,14 or in combination with other infections6). Leishmania 
infantum is endemic in Spain, especially in the Mediterranean basin; giving rise to VL in 
childhood15–18.  
Before the suspect of MSMD in patients with severe disease caused by Mtb or VL, other forms of 
PID need to be discarded, such as chronic granulomatous disease19,20, T-cell deficiencies, NF-κB 
deficiencies, CD40L deficiency and AR TYK2 deficiency21. Different etiologies of MSMD, 
especially IL-12Rβ1 deficiency22, followed by IFN-γR1, STAT1, and IL-12p40 deficiency, were 
found in patients with severe tuberculosis (TB). There are currently 26 reported patients with severe 
TB due to inborn errors of IFN-γ, 13 of whom are IL-12Rβ1-deficient, including six who did not 
suffer from any other mycobacterial disease21–23. Recently, five cases of Leishmania infections in 
patients with mutations in MSMD-causing genes have been described, both alone13,14 or in 
combination with other infection24–26; patients had mutations in IL12RB113,14,24,26 and IL12B13. 
The main aim of this work was to reveal whether patients with extrapulmonary Mtb or visceral 
Leishmania spp. infections had defects in the common disease-causing described genes in MSMD 
or have defects in mycobacterial response. We have observed no complete defects in the studied 
patients but a distinct cytokine secretion pattern in related healthy controls, extrapulmonary TB and 
VL patients showing a decreased response after mycobacterial challenge, rising the need to perform 





Materials and methods: 
Study design 
This is a transversal study. We recruited patients both retrospective and prospectively. Inclusion 
criteria consisted of pediatric patients with extrapulmonary Mycobacterium tuberculosis complex 
infection, all of them were pyrazinamide sensitive to exclude Mycobacterium bovis infection, or 
VL confirmed by direct observation or positive PCR. Patients with other PID, concomitant 
treatment with immunosuppressive drugs or other conditions predisposing to infections were 
excluded. All samples were obtained at least 1 month after infection’s resolution.   
For ethical reasons, controls were not paired by age. However, a cohort of anonymous non-related 
healthy controls (NR-HC) was recruited along with related (mostly parents) healthy controls (R-
HC) cohort.  
This study was carried out in accordance with the recommendations of Ley General de Sanidad 
(25/4/1986) Art. 10., with written informed consent from parents of pediatric patients and from 
healthy controls. The protocol was approved by the ethics committee of the Hospital Sant Joan de 
Déu (Number of the Comité Ético de Investigaciones Clínicas: PIC-50-12).  
 
Whole blood culture and cytokine detection 
Venous blood was collected into heparinized tubes, and diluted 1:2 in complete medium (RPMI 
(Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS; 
Sigma-Aldrich, St. Louis, MO, USA), 1 μg/ml penicillin and 1 μg/ml streptomycin (Invitrogen, 
Grand Island, NY, USA) and incubated at 37ºC in a 5% CO2 humidified incubator for 18h and 48h. 
Activation conditions: medium alone, live BCG (Mycobacterium bovis BCG, Pasteur sub-strain, 
kindly provided by Dr. Julià González at the Microbiology Department at Hospital Clínic de 
Barcelona) at a multiplicity of infection of 20 BCG per leukocyte, BCG plus human recombinant 
IL-12p70 (hrIL-12p70, 20ng/ml, Milteny Biotec, Germany), BCG plus hr-IFN-γ (5,000 IU/mL) as 
described elsewhere20,27.  
IFN-γ detection was performed by enzyme-linked immunosorbent assay (eBiosciences, San Diego, 
CA, USA) at 48h culture point and IFN-γ, IL-10, IL-12p70, IL-6, IL-1RA, IL-1β and TNF-α 
secretion determination was assessed by Luminex (Millipore, Billerica, MA, USA) at 18h culture 
point following the manufacturer’s instructions.  
Besides the production of cytokines to mycobacteria itself, an important part of the mycobacterial 
response is the cross-talk from T cells and macrophages by responding to cytokines. Here, we have 
evaluated BCG co-stimulation with hrIL-12p70 or IFN-γ by studying the capacity of the system to 
respond to two key cytokines (IL-12p70 and IFN-γ) co-stimulation, as a co-stimulation ratio (Co-
SR; i. e. IFN-γ costimulation ratio = ‘IFN-γ production after BCG + IL-12p70 stimulation’ ⁄’IFN-
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γ production after BCG stimulation’). Methods for cytometric determination of IFNGR1, IFNGR2, 
IL-12Rβ1 and STAT1 phosphorylation by flow cytometry are explained in supplementary methods.  
 
Statistical analysis 
Data distribution and shape were studied with coefficient of variation calculation (standard 
deviation/mean) and asymmetry tests. Asymmetry tests revealed that data did not follow a normal 
distribution (data not shown). Accordingly, non-parametric tests were performed. First, Krustal-
Wallis test was performed to study if differences observed between groups were statistically 
significant. If statistically-significant differences were found, U from Mann-Whitney test was 
performed to study the differences between the groups by pairs. Statistical significance was set for 
p values lower than 0.05.  
To assess correlation between variables, Spearman test was performed. If p<0.05 variables were 
considered to be associated. Besides, correlation coefficient determined the strength of the 
association. When correlation coefficients were lower than 0.5 association was considered weak 
association, if between 0.5 and 0.8 moderate association and higher than 0.8 strong association. 
In favor of the understanding and legibility of the paper, median and standard deviation values are 
showed in Supplementary Table 1 and 2 instead of inserted in the text. Statistical analysis was 
performed with SPSS v22 (IBM corporation, Armonk, NY, USA) and graphical representation was 




We included 24 patients with extrapulmonary TB infection, 23 patients with VL and 41 healthy 
controls (18 non-related and 23 related to the patients, usually parents). There was a bias to female 
patients in VL (65,2% female vs. 34.8% male). Patients with TB infection presented with a variety 
of ethnicities while VL patients were mostly Caucasian (Table 1). Of note, only 2 families reported 
consanguinity. Patients with VL were younger at principal infection than TB patients (1.58 years 
old (yo); range 0.25 to 8 yo in VL vs. 3 yo; range 0.47 to 16 yo in TB; p:0.002). However, this 
difference disappeared when comparing the age when the test was performed (7.42 yo; range 0.42 
to 12.54 yo for VL vs. 7.28 yo; range 0.62 to 18 yo in TB; p: 0.496). Table 1. TB infections were 
mostly disseminated (33%), with (12%) or without meningitis (21%), adenopathic (21%) or 




Immunophenotype, proliferation in response to mitogens and oxidative burst response studies 
discarded more common PID associated with the infections (data not shown). Besides, patients 
showed no alterations after cytometric study of IFN-γ receptors 1-2 expression in the membrane of 
monocytes and IL-12Rβ1 expression in the membrane of PHA-activated lymphocytes and STAT1 
phosphorylation in response to IFN-γ (data not shown).  Thus, discarding common causes of 
complete defects giving rise to susceptibility to mycobacterial disease.  
Mycobacterial responses present a big interindividual variability in healthy controls 
To assess mycobacterial response, we measured cytokine secretion in the supernatants of a whole 
blood culture with live BCG. We have measured IFN-γ, IL-12p70, IL-1β, IL-1RA, IL-6, IL10 and 
TNF-α after 18h and IFN-γ after 48h culture. In almost all cytokines assayed, coefficient of 
variation (CV) of cytokine production after BCG stimulation was >100, thus showing a high 
variability both in R-HC and NR-HC Variability of Co-SR was reduced significantly in NR-HC 
compared to cytokine production after BCG stimulation (p=0.014). This did not happen in R-HC, 
in fact, we observed increased CV in R-HC compared to NR-HC, although it did not reach statistical 
significance (p=0.086). (Figure 2, Supplementary table 1). 
R-HC showed an altered cytokine secretion pattern 
Comparison between NR- and R-HC revealed differences in cytokine production. R-HC produced 
less IFN-γ (p=0.013) and more IL-10 (p=0.002) after 18h post-stimulation than NR-HC while 
presenting with increased IL-6 (p=0.028), and TNF-α (p=0.044) and a trend towards an increased 
IL-1β production (p=0.07). After IL-12p70 co-stimulation, R-HC presented a reduced Co-SR in 
IL-6 (0.003) and TNF-α (0.01), and a trend towards a diminished Co-SR in IL-1β (p=0.068). On 
the other hand, after IFN-γ co-stimulation, they presented a reduced Co-SR in TNF-α (p=0.028).  
Also, we observed a trend towards a diminished Co-SR in IL-12p70 (p=0.066) and IL-1β 
(p=0.076). Altogether, this data shows an altered response after mycobacterial challenge in R-HC 
(Figure 3, Supplementary Table 2).  
TB and VL patients have altered cytokine producing patterns compared with NR-HC.  
BCG stimulation in TB patients led to increased production of IL-10 (p=0.01) and TNF-α (0.019) 
and a trend towards increased IL-6 (p=0.077) after BCG stimulation when compared with NR-HC. 
Besides, we observed a diminished IL-1RA production compared to both R-HC (p=0.03) and NR-
HC (p=0.014). As observed in R-HC, TB patients presented a decreased IL-12p70 Co-SR after 
IFN-γ co-stimulation (p=0.008). These patients also presented a decreased IL-1β and TNF-α Co-
SR both to IL-12p70 (IL-1β, p=0.016; TNF-α, p=0.006) and to IFN-γ (IL-1β, p=0.016; TNF-α, 
p=0.021). We can then state that TB patients presented a decreased response to IFN-γ.  
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IFN-γ decreased production after BCG stimulation was a distinctive feature in VL patients. IFN-γ 
production was reduced in VL patients in comparison with all the other groups studied both at 18h 
(TB, p<0.001; R-HC, p<0.001; NR-HC, p<0.001) and 48h (TB, p=0.001; R-HC, p<0.008; NR-HC, 
p<0.001) post-culture. IL-10 production was also reduced in comparison to NR-HC (p=0.022). VL 
patients presented differences with R-HC: a diminished IL-1β (p=0.0.49) and IL-6 (p=0.047). IFN-
γ Co-SR after IL-12p70 addition was superior in VL patients than in the other groups studied (MTB, 
p=0.003; R-HC, p=0.015; NR-HC, p=0.005). Besides, there was a trend towards a decreased IL-1β 
Co-SR ratio after IFN-γ co-stimulation (p=0.064).  
The ratio between inflammatory and anti-inflammatory cytokines conditions the final response. As 
we have observed differential changes in IL-10 and IFN-γ production, we wanted to compare the 
ratio between these cytokines; of note, IFN-γ/IL-10 ratio after BCG stimulation was lower in all 
studied groups when compared with NR-HC, and was especially low in VL patients (Figure 4). 
Neither age at infection nor age are strongly associated with cytokine secretion. 
As the range of age at which both the test is performed (0.42 to 18 yo) and the age of primary 
infection (0.25 to 16 yo) was large we wanted to test if there was any association of the different 
cytokine production with age. After correlation test was performed, we found no association 
between the age of the test and cytokine production or fold-change after co-stimulation in VL 
patients. In TB patients, however, we observed a weak association between age at infection and IL-
1RA production (r: 0.454, p=0.026). Besides, after IL-12 co-stimulation we observed a weak 




Development of severe intra-macrophagic infections in otherwise healthy children without any 
acquired predisposition implies the suspicion of inborn errors of immunity. Since disease-causing 
mutations have been found in MSMD-related genes in patients with severe extrapulmonary TB26,28 
and VL we considered that the study of the function of the IL-12/IFN-γ axis in these patients needed 
to be studied. To our knowledge, this is the first time that the function of the IL-12/IFN-γ axis has 
been systematically studied in patients with severe/extrapulmonary TB and VL. After functional 
evaluation of the pathway with described methods20, we did not find any classical complete defect 
on the IFN-γ circuit. Nonetheless, both groups showed altered cytokine secretion patterns: a defect 
in IFN-γ production in VL patients and of IFN-γ response in TB patients.   
The gold-standard technique for MSMD diagnosis consists in cytokine secretion determination 




stimulation20,27. However, cytokine secretion detection techniques have intrinsic associated 
variability; cytokine production is strongly influenced by concurrent or past infections29, time of 
blood drawn30,31, stress32,33, seasonality34 or the point in the menstrual cycle in women35. High 
variability in healthy controls have been already observed25,36,27 but has not been quantified. 
Quantification of the CV revealed a high variability in healthy controls, especially on R-HC. There 
are two main types of functional impairment of the IL-12/IFN-γ axis, IFN-γ production defects and 
IFN-γ response defects. We speculate that the increased variability in response to IFN-γ and IL-
12p70 observed in R-HC may respond to the differential affectation of the pathway observed in the 
two groups of patients, carried by their parents.  
Patients with VL had a defective response after mycobacterial challenge. Although we have not 
detected any complete defect, VL patients had a defect in IFN-γ production in response to BCG, 
rescued after IL-12p70 co-stimulation. Since IFN-γ production is required for parasite killing in the 
macrophage, an altered production may result in defective killing37–39. Of note, during active 
infection, PBMC’s of infected individuals have an altered IFN-γ production that is restored upon 
clearance of the infection40,41. Since in all patients the study was performed, at least, one month 
after resolution of the infection, the inhibitory capacity of Leishmania parasites should not interfere 
with the test. Innate immune training theory states that at birth innate immunity is immature and 
acquires Th-1-like characteristics after antigenic exposition due to epigenetic changes42–45. On the 
other hand, BCG vaccination is shown to have Th-1 driving capacities, and it has been shown to 
confer cross-protection to other pathogens by increasing IFN-γ and TNF-α production after specific 
epigenetic changes46–48. The low IFN-γ production after mycobacterial challenge might respond to 
both inborn errors of immunity or, also, to epigenetic changes derived from the exposure to 
Leishmania at young ages, alone or in combination. 
Severe/extrapulmonary TB patients present with altered cytokine production after BCG stimulation 
and reduced response to IFN-γ. IL-1β, along with TNF-α, contributes to granuloma formation and 
maintenance and restriction of intracellular growth in macrophages49–54. TNF-α is necessary for the 
control of both non-virulent, as BCG, and virulent species as Mtb of mycobacteria, IL-1β is only 
necessary for the control of virulent mycobacteria49. Decreased IL-1RA (reflect of IL-1β 
production) might reflect defects on granuloma formation, thus promoting dissemination of the 
disease to other organs that may not be rescued with an increased production of TNF-α. Impaired 
response to IFN-γ may be somehow explained by the increase of IL-6 production after 
mycobacterial challenge, as IL-6 has been shown to inhibit IFN-γ responses in mycobacterial 
infection55. Of note, a similar pattern of cytokine production and response has also been observed 
in the R-HC group.  
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There are two other studies screening for MSMD-related defects in Mycobacterium tuberculosis 
infections, one searching for mutations in IL12RB1 (2/50 deficient patients) in endemic and highly 
consanguineous regions26 and the other searching for common mutations in 114 adults with severe 
tuberculosis and for common or new mutations in 10 children with extrapulmonary mutations in 
IL12RB1, IFNGR1, IFNGR2 and STAT1 genes without encountering any mutations in a region with 
low consanguinity rates28. With these and our results, we hypothesize that severe/extrapulmonary 
TB in patients without consanguinity is not a warning sign for known MSMD-related complete 
defects. However, studies searching for hypo-morphic or somatic mutations as well as epigenetic 
defects are needed to better characterize and treat these patients. 
Although this study has several strengths, it also has some limitations: 1) the variability observed 
in healthy controls difficult the interpretation of patient’s results, 2) the size of the cohort and 3) 
the impossibility to compare the results to healthy controls paired by age. However, we have 
observed coherent and robust results showing statistically significant differences between the 
studied groups. Altogether, these data suggest that severe/extrapulmonary TB and VL patients have 
a familial altered mycobacterial response. More research needs to be performed to discover new 
mechanisms conferring this susceptibility. The use of high throughput technologies may facilitate 
the study of epigenetic changes, somatic mutations or complex mechanisms of susceptibility. 
Besides, it is necessary to develop tools to diminish this variability in order to maximize the 
diagnostic value of this technique.   
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Figure 1. Mycobacterium tuberculosis infection localization in TB patients. (n=24) 
Figure 2. Coefficient of variation after mycobacterial challenge. Coefficient of variation (CV) 
is calculated as “standard deviation/mean”. CV for different conditions is represented as a heat 
map; blue indicates the minimum values, red the maximum, and yellow median values. NR-HC, 
n=18; R-HC, n=23. NR-HC: non-related healthy control; R-HC: related healthy control; CV: 
coefficient of variation 
Figure 3. Differential cytokine secretion after mycobacterial challenge. Cytokine production 
after BCG stimulation, and co-stimulation ratio is represented as a heat map. Co-stimulation ratio 
(Co-SR) is calculated as “BCG + co-stimulation (IFN-γ or IL-12p70) condition /BCG condition”. 
Blue indicates the minimum values, red the maximum, and yellow median value for cytokine 
secretion after BCG stimulation and next to one for co-stimulation ratio. NR-HC, n=18; R-HC, 
n=23; VL patients, n=23; MTB patients, n=24. NR-HC: non-related healthy control; R-HC: related 
healthy control; VL: visceral leishmaniasis; TB: tuberculosis.  
Figure 4. IFN-γ/IL-10 ratio. Ratio of IFN-γ/IL-10 after 18h of culture with BCG. NR-HC, n=18; 
R-HC, n=23; VL patients, n=23; MTB patients, n=24. NR-HC: non-related healthy control; R-HC: 







Table 1. Cohort characterization 
  TB n=24 VL n=23 
Gender Female 54.2% (13) 65.2% (15) 
 Male 45.8% (11) 34.8% (8) 
Ethnicity Caucasian 29.2% (7) 95.7% (22) 
 North-African 16.7% (4) 3.3% (1) 
 Sud-African 8.3% (2)  
 Arabic 20.8% (5)  
 Latin-American 16.7% (4)  
 Asiatic 8.3% (2)  
Age at infection1 Median 3  1.58 
Years old Range 0.47 to 16 0.25 to 8 
Age at test2 Median 7.28 7.42 
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Flow cytometry tests 
Cytometric determination of IFN-γR1 and IFN-γR2 presence and STAT1 phosphorylation in 
response to IFN-γ were performed in whole blood. For IFN-γR1 (GIR-94, BD Bioscience, San 
Jose, CA, USA) and IFN-γR2 (polyclonal, R&D, Minneapolis, MN, USA). 50ul of whole blood 
were blocked with goat serum, then stained with specific antibodies, lysed (BD lysing solution, BD 
Bioscience) and washed twice with phosphate buffer saline (PBS, Roche, Spain, EU). For STAT1 
phosphorylation detection (clone 4a, BD Bioscience), 50 µl of whole blood were stimulated with 
5·103 IU/ml of IFN-γ (Imukin, Boehringer Ingelheim, Spain) for 15 minutes prior to intracellular 
staining following BD PhosFlow protocol.  
IL-12Rβ1 presence and was performed in density gradient isolated peripheral blood mononuclear 
cells. Cells were stimulated 72h with phytohemagglutinin (5ug/ml, Sigma-Aldrich, St. Louis, MO, 
USA) previously to IL-12Rβ1 (clone 2.4E6, BD Bioscience) detection.  
Cells were acquired with a Canto II cytometer in the next two hours after staining. Data was 





Supplementary table 1. Coefficient of variation of the different parameters. 
 
NR-HC R-HC TB VL 
 
BCG stimulation CV 
IFN-γ (48h) 110.25 127.48 151.86 325.04 
IFN-γ (18h) 129.81 136.32 126.96 169.87 
IL-10 109.10 111.09 72.80 90.82 
IL-12p70 156.48 102.05 165.37 200.59 
IL-1RA 89.68 86.74 107.10 107.90 
IL-1β 138.59 133.54 461.24 110.68 
IL-6 111.39 69.65 85.73 91.79 
TNF-α 141.55 152.19 285.46 141.98 
 
IL-12p70 co-stimulation CV 
IFN-γ (48h) 93.59 179.66 93.76 136.23 
IFN-γ (18h) 114.40 116.47 123.96 161.51 
IL-10 31.55 71.95 42.40 55.95 
IL-1RA 26.01 29.25 22.90 32.17 
IL-1β 33.08 74.55 198.81 56.91 
IL-6 44.34 157.93 33.45 96.51 
TNF-α 53.56 78.77 77.86 62.22 
 
IFN-γ co-stimulation CV 
IL-10 86.84 135.47 73.62 78.30 
IL-12p70 164.54 279.87 305.34 168.85 
IL-1RA 39.49 39.11 47.25 58.44 
IL-1β 57.55 74.23 405.89 108.46 
IL-6 91.38 183.75 180.35 118.03 
TNF-α 120.38 129.48 129.24 125.93 
CV: Coefficient of variation; NR-HC: non-related healthy controls, R-HC: related healthy controls; 
TB: Mycobacterium tuberculosis patients; VL: visceral leishmaniasis patients.  
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Supplementary table 2. Median, standard deviation and statistical significance values for the 
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Abstract   
We report the first Peruvian patient with IL-12Rβ1 deficiency. The patient developed a severe recurrent 
systemic mycobacterial disease, initially misdiagnosed as tuberculosis. The identification of the IL-12Rβ1 
deficiency led to microbiological reevaluation of the patient, confirming BCG vaccine-related infection. 
Treatment was then adjusted, eventually with good response. Identification of the underlying primary 
immunodeficiency led to specific and successful treatment.  
 
Key words:  BCGosis; IFN-γ; IL-12Rβ1deficiency; Mendelian susceptibility to mycobacterial diseases 
(MSMD); Mycobacterium tuberculosis. 
 
Introduction  
Mendelian susceptibility to mycobacterial disease (MSMD, OMIM 209950) syndrome is a rare primary 
immunodeficiency (PID) caused by monogenic inborn errors of interferon (IFN)-γ and IL-12 mediated 
immunity, with at least ten causal genes known to date1,2. MSMD was classically defined as conferring 
susceptibility to poorly pathogenic mycobacteria, including attenuated Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) vaccine and environmental mycobacteria, being IL-12Rβ1 deficiency the most 
common genetic etiology. Recently, it has been shown that patients with MSMD can also develop severe 
disease from Mycobacterium tuberculosis (Mtb)2. Differentiating BCG from Mtb infection, both included in 
Mtb complex (MTC), is difficult 3 but important since these conditions are treated differently1. We report and 
discuss here the first Peruvian patient diagnosed with IL-12Rβ1 deficiency, suffering from a severe recurrent 
BCGosis initially misdiagnosed as multidrug-resistant Mtb infection.  
 
Methods 
Mycobacterial identification within MTC was performed directly on DNA extracted from an acid-fast 
bacillus smear positive stool sample by a polymerase chain reaction (PCR) assay targeting the mycobacterial 
secA1 gene4. For species identification a second PCR was performed3: Touchdown PCR amplification with 
a first step of 98°C (30s), 20 cycles of 98°C (10s), annealing starting at 65°C (20s; decreasing 0.6°C/cycle), 
and extension at 72°C (30s) followed by a second step of 20 cycles of 98°C (10s), 53°C (20s), 72°C (30s). 
PCR products were sequenced on ABI3130 Genetic Analyzer (Applied Biosystems, Waltham, MA) and their 
identity was confirmed by comparison with NCBI GenBank database, using BLAST. 
IFN-γ production was evaluated in heparinized-venous blood after stimulation with live BCG (Pasteur sub-
strain) at a multiplicity of infection of 20 BCG/leukocyte and BCG plus human recombinant IL-12p70 (hrIL-
12p70, 20ng/ml, Milteny Biotec, Germany) during 48h as previously described 5,6. IFN-γ detection in the 
culture’s supernatant was performed with enzyme linked immunosorbent assay (eBiosciences, San Diego, 
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CA, USA) following the manufacturer’s instructions. Cytometric determination of IL-12Rβ1 presence and 
STAT4 phosphorylation in response to hrIL-12p70 (STAT4p) was performed in peripheral blood 
mononuclear cells as described elsewhere 6. IL12RB1 exons and flanking regions were amplified by PCR in 
genomic DNA and sequenced with 3730xl DNA Analyzer apparatus (Applied Biosystems).  
This study was carried out in accordance with the recommendations of Spanish Ley General de Sanidad 
(25/4/1986), and parental written informed consent was obtained. The protocol was approved by the local 
ethics committee (PIC-50-12).  
 
Results 
The patient was a 6-year-old Peruvian (Cuzco region) girl from non-consanguineous parents, with no relevant 
family history. She had received routine Peruvian vaccinations, including BCG at birth. At 10 months of age, 
she was diagnosed with axillary Mtb lymphadenitis, ipsilateral to the site of BCG vaccination (fine needle 
aspiration with positive bacilloscopy and positive culture to MTC), with negative tuberculin skin test. Anti-
tuberculosis treatment was started (see Figure 1 for a detailed chronogram of clinical evolution and 
treatment). Three months later, an enlargement of the lymphadenitis was observed needing surgical excision. 
At that time, a culture-based phenotypic drug susceptibility testing (DST) from the initial sample yielded 
resistance to pyrazinamide. She was switched to a directly observed treatment with an empiric regimen7 and 
clinical signs of infection resolved. Four months after finishing the treatment, she presented an early relapse, 
with an ipsilateral pectoral abscess (positive bacilloscopy and MTC culture). The strain was tested for drug 
resistance by Genotype® MTBDR PLUS (rifampicin and isoniazid) and resistance to rifampicin was 
identified. After 10 months on a new regimen, the patient was admitted with fevers and weight loss because 
of a disseminated mycobacterial infection, including a massive thoracic wall abscess that was debrided, with 
positive bacilloscopies in urine and feces. Simultaneously, mucocutaneous candidiasis (vaginal, oral and 
esophageal) was observed. She had an initial good response to a new empiric treatment for multi-drug 
resistant tuberculosis, but was then readmitted with intestinal semi-occlusion due to mesenteric adenopathies’ 
growth, persistent cough, weight loss, a psoas abscess, and Pott's disease (T12 and L1 vertebrae), with acid-
fast bacilli present in feces and gastric aspirates. Abdominal computed tomography showed signs of ileitis 
and portal hypertension. Extended resistance to Etoposide was confirmed by DST causing a switch to an 
empiric therapy for extensively drug-resistant tuberculosis regimen. A primary immunodeficiency (PID) was 
then suspected, and she was transferred to a reference center in Peru, for an immunologic diagnostic workup.  
Lymphocyte populations, lymphocyte proliferation to mitogen stimulation and phagocyte oxidative response 
were within the normal limits for patient’s age, ruling out T-cell deficiencies and chronic granulomatous 
disease (data not shown). Both IL-12Rβ1 expression and STAT4 phosphorylation in response to hrIL-12p70 
were absent (see Figure 2a). After 48h culture with BCG, IFN-γ levels were low (30.46pg/ml) without 
recovering after hrIL-12p70 addition (43pg/ml); these results were consistent with IL-12Rβ1 deficiency 
(Figure 2b). A homozygous mutation p. (Arg211*; c.631C>T) was found in IL12RB1 gene, creating a 
premature stop codon in exon 7 (Figure 2c). This mutation was found in heterozygosis in her parents; her 5-
year-old brother was found to have the same homozygous mutation but no symptoms despite BCG 




America) for hr-IFN-γ treatment and further evaluation. Simultaneously, she had developed a severe protein-
losing enteropathy with lymphopenia and hypogammaglobulinemia.  
Microbiological studies performed from stool samples identified MTC4, speciated as M. bovis3, assumed to 
be from the vaccine strain due to its initial location next to the BCG administration site, timing of the initial 
disease in infancy and the early demonstration of pyrazinamide resistance. Identification of M. bovis BCG 
was later confirmed on grown isolate by the US Centers for Disease Control and Prevention. hr-IFN-γ was 
initiated at a dose of 25mcg/m2 subcutaneously three times weekly, and titrated up to approximately 
150mcg/m2 subcutaneously three times weekly over several months, without complete clinical improvement. 
Antimicrobial regimen was switched, and in five months, stool cultures cleared, lymphocyte count 
normalized and albumin improved, consistent with the improvement of her protein-losing enteropathy. The 
patient was discharged on anti-mycobacterial therapy but hr-IFN-γ was interrupted. She has remained 
clinically stable, except for a diarrhea from Cryptosporidium and a Candida parapsilosis central line 




We describe a patient with a mutation in IL12RB1 gene causing MSMD whose infection was misdiagnosed 
as tuberculosis being indeed a BCG-derived infection. This mutation has already been reported in a Turkish 
patient with salmonellosis, mycobacterial (not BCG-related) and fungal infections8. Warning signs for IL-
12Rβ1 deficiency include adverse events after BCG vaccination, invasive BCG infection, invasive or 
recurrent salmonellosis, or a combination of severe mycobacterial infection and candidiasis, although other 
intra-macrophagic infections can occur1. There is an unexplained variation in infection susceptibility1, since 
not all mutation-carriers develop infections despite abnormal functional studies, as for the sibling of our index 
case. This unexplained variation in infectious susceptibility in IL-12Rβ1 deficiency is currently a new line of 
research for the identification of modifying factors.   
 
PID suspicion in the context of a mycobacterial infection is of outmost importance. Disseminated M. bovis 
BCG infection (BCGosis) is very uncommon (estimated at 1∶10,000–1∶1,000,000)9 and almost only occurs 
in patients with AIDS, severe combined immunodeficiency, chronic granulomatous disease and MSMD. The 
confirmation of an MSMD-causing mutation has therapeutic implications: exogenous hr-IFN-γ can improve 
the outcome of patients with deficient production of, or partial response to IFN-γ; it is useless in complete 
IFN-γ response defects1. In IL-12Rβ1 deficiency, treatment is aimed at extensive and prolonged 
antimycobacterial treatments followed by secondary prophylaxis, and exogenous hr-IFN-γ is typically 
recommended1,8,10, with doses ranging from 50 mcg/m2 up to 200 mcg/m2 subcutaneously three times weekly 
over several months1,8,10. 
 
Inborn errors of IFN- should be considered in patients with severe mycobacterial infections worldwide. As 
MDR-TB is an emerging problem in Peru7, the patient’s lack of clinical response was first ascribed to drug-
resistant Mtb, thus delaying the suspicion of other less virulent mycobacteria in the context of an underlying 
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immunodeficiency. A similar case of disseminated tuberculosis from Colombia, finally diagnosed with IL-
12Rβ1 deficiency has recently been published10. Both cases developed severe gut inflammation, causing 
protein-losing enteropathy, hypoalbuminemia, and antimicrobial malabsorption, needing IV administration. 
Both M. bovis BCG and Mtb must be considered in the differential, as different therapeutic approaches will 
be needed. 
 
M. bovis is closely related to Mtb within the MTC3 and the BCG vaccine is derived from a virulent strain of 
M. bovis9. BCG is difficult to differentiate from other strains such as M. bovis and other members of the MTC 
by conventional methods as mycobacterial culture. All BCG vaccine strains are intrinsically resistant to 
pyrazinamide, which is uncommon in naïve patients with M.tb3, and the study of specific regions by PCR is 
needed3; unfortunately, these studies are not widely available. Besides, IFN- release diagnostic assays, 
which are specific for virulent MTC species such as Mtb and M. bovis, avoiding cross-reactivity with M. 
bovis BCG11, are less reliable in patients with inborn errors of IFN-γ mediated immunity, such as MSMD.  
 
Conclusions 
This case highlights the need to consider PID (especially defects in the IFN- circuit) in patients with severe 
mycobacterial infection, and/or major adverse events after BCG vaccination1 and how BCGosis can mimic 
disseminated tuberculosis and delay appropriate diagnostic and therapeutic management. The consideration 
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Figure 1. Chronogram of clinical evolution and treatment. Isoniazid (H); rifampicin (R); pyrazinamide 
(Z); ethambutol (E); amikacin (Am); levofloxacin (Lfx); ethionamide (Eto); moxifloxacin (Mfx); 
capreomycin (Cm); cycloserine (Cs); paraamino salicylic acid (PAS); ciprofloxacin (Cfx); linezolid (Lnz); 
Imipenem/Cilastatin (Ipm/Cln); amoxicillin/clavulanate (Amx/Clv); thioridazine (Tio); multidrug resistant 
tuberculosis (MDR-TB); extensively multidrug resistant tuberculosis (XDR-TB). 
Figure 2. Immunological and genetic studies. A) IFN-γ production after no stimulation, BCG stimulation, 
BCG + hrIL-12p70 stimulation, ratio between BCG+hrIL-12p70/BCG stimulations. B) Cytometric 
determination of IL-12Rβ1 and STAT4 phosphorylation after hrIL-12p70 stimulation in PHA-stimulated 
lymphocytes. Solid line represents stimulated condition and dashed line represents basal condition) 
















Chapter 2. Study of the impact of whole-pregnancy exposure to anti-TNF-α on 
the development of the exposed infant’s immune system.  
For the study of the effect of the exposure to anti-TNF-α during pregnancy 7 patients (out 
of the 8 patients fulfilling inclusion criteria) enrolled the study. From these, 2 stopped analytical 
follow up after birth, 4 completed the study until 12 months and 1 until 18 months. The size of 
the cohort was limited by the fact that, at the time of project conception, the IBD Unit of Hospital 
Clinic de Barcelona was the only place in Spain where anti-TNF-α was maintained during whole-
pregnancy in patients with IBD.  
During the follow up of the anti-TNF-α drug levels during the first 12 months in exposed infants’, 
clearance of the drug corresponded with the expected immunoglobulin’s half-life and the drug 
was detectable until 6 months after birth. We did not observe changes in the main lymphocytic 
and leukocytic populations. However, at birth, T and B subpopulations showed a more immature 
phenotype in exposed infants compared to non-exposed infants. After one year, T and B 
population were within reference range defined per age. This initial immaturity had no 
consequences in immunoglobulin production or vaccine responses (against tetanus, diphtheria 
and pneumococcus). We also observed a diminished frequency of Treg cells, that inversely 
correlated with the through level of anti-TNF-α in the mother during the third trimester of 
pregnancy (r: -0.9; p: 0.03). Treg cell frequency also inversely correlated with T cell proliferation 
after the challenge with a weak T cell stimulus (r: -0.68; p:0.01), increased in exposed infants (p: 
0.01).  On the other hand, CD24hiCD38hi Breg cells were increased (p: 0.0007).   
We evaluated anti-mycobacterial response by studying surface activation markers and IL-
12/IFN-γ axis by cytokine secretion in whole blood cultures in the presence (non-washed 
condition) and absence (washed condition) of autologous sera. Exposure to anti-TNF-α during 
pregnancy reduced the response after mycobacterial challenge. We observed a diminished 
stimulation ratios (SR) in the early activation marker CD69 (p: 0.004) expression and in HLA-DR (p: 
0.003), which were partially rescued after drug removal. Without stimulation, washed samples 
from exposed infants produced higher amounts of IL-17 compared with the non-washed condition 
(p: 0.03) and with non-exposed infants (p: 0.02). On the other hand, after BCG stimulation, IL-17 
production in exposed infants was reduced. Also, at birth, TNF-α induction was reduced in the 
exposed-infant (p: 0.0002), being only partially recovered after drug removal (p: 0.005) although 
still being reduced (p: 0.02) in comparison to non-exposed infants. Despite not reaching statistical 
significance, IL-1β SR was reduced and IL-6 and IL-1RA SR were increased. Along with the decrease 
of anti-TNF-α drug presence (3 to 12 months after birth), IFN-γ, IL-12p70, IL-1β, and TNF-α 
production increased while IL-6 production was stable.  
Detailed methods, results and figures are shown in “Esteve et al, Immunological Changes 
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2.1.Manuscript “Immunological Changes in Blood of Newborns Exposed to Anti-TNF-


































































































































































Chapter 3. Study of Breg cells and IL-12/IFN-γ axis in healthy neonates 
Since TNF-α is a key factor for B cell development, we decided to perform a sub-study 
evaluating Breg cells in healthy neonates, which, by the time of the study, had not been described. 
Also, it would provide us with normality values for the evaluation of the impact of anti- TNF-α 
drugs. Breg cells (defined as CD19+CD24hiCD38hi) are tolerance promoters in the adult immune 
system. They are capable of inhibiting IFN-γ and IL-17 production by T cells and have a significant 
role in different situations, including pregnancy. We hypothesized that Breg might have a role in 
the achievement of intrauterine tolerance expanded to the first moments after birth.  
We studied CD19+CD24hiCD38hi in cord blood on healthy neonates (hUCB) and in 
peripheral blood of healthy adults (hAPB). Frequency of Breg cell was increased in hUCB in 
comparison with hAPB (34.39% vs. 2.49%; p: 0.0002), especially in the circulating marginal zone B 
cells, where the difference was bigger (60.8% vs. 4.94%). hUCB Breg cells were capable of 
producing IL-10 and to inhibit IFN-γ production after co-culture with T cells (1.63 T cells alone, 
0.95 Tcell:Breg, stimulation ratio, SR; p: 0.004) and IL-4 (1.66 T cells alone vs. 0.86 Tcell:Breg SR; 
p: 0.02), which was not observed when co-cultured with noBreg (CD19+CD24lowCD38low) cells. 
hUCB Breg cells presented a IgMhiIgDhiCD5+CD10+CD27- phenotype, similar to that of adult Breg 
cells but with some differences. There was an increment of the quantity of IgM per cell and a 
decreased expression of CD27, CD22 and CD73 markers. Our work has characterized the 
frequency, phenotype and function of hUCB Breg.  
Detailed methods, results and figures are shown in “Esteve et al, Characterization of the 
Highly Prevalent Regulatory CD24(hi)CD38(hi) B-Cell Population in Human Cord Blood. Front 
Immunol. 2017” manuscript. 
Besides Breg cell characterization, we also studied the state of the IL-12/IFN-γ axis in 
healthy neonates. Overall response to mycobacterial challenge was reduced in neonates: hUCB 
cells produced significantly less IFN-γ (p: 0.001) and IL-6 (p: 0.005) upon BCG stimulation, as well 
as displayed lower frequency (p: 0.014) and levels (p: 0.051) of CD69. Besides, IFN-γ production 
after BCG stimulation inversely correlated with Breg cell frequency (spearman correlation test, R2: 
0.618, p: 0.043). After the study of the general anti-mycobacterial response we studied the 
integrity of the system in terms of response to hr-IL-12p70 and hr-IFN-γ co-stimulation. We 
observed a decreased Co-SR after hrIL-12p70 co-stimulation in TNF-α production (p: 0.022), 
however, we observed a tendency towards an increased IFN-γ Co-SR (p: 0.073). We have not 
observed any significant differences in cytokine production in Co-SR after hr-IFN-γ addition but an 
increased CO-SR in HLA-DR positive cells frequency (p: 0.026).  
Detailed methods, results and figures are shown in “Breg cells in umbilical cord blood: two 
sides of the same coin” manuscript. 
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3.2.Manuscript: “Breg cells in umbilical cord blood: two sides of the same coin” 
Title page 
Breg cells in umbilical cord blood: two sides of the same coin 
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Immunological responses in neonates are specifically shaped for managing the transition between 
the allogenic sterile uterus to the real world full of antigens. We have compared antimycobacterial 
responses in neonate’s cord blood compared to adult’s peripheral blood, observing a diminished 
response to Bacille Calmette-Guerin challenge, with a decreased CD69 expression stimulation ratio 
(SR) and a decreased IL-6 and IFN-γ production SR with a normal response to IFN-γ and IL-12p70. 
B regulatory (Breg) cells are known to be increased in cord blood, as part of the tolerogenic 
mechanisms to maintain pregnancy, here we show for the first time that IFN-γ SR production after 
mycobacterial challenge inversely correlated with Breg cell frequency. This association may have 
implications for the indication of cord blood transplantation in conditions with constitutively 
increased IFN-γ production such as in IFNGR1 deficiency, and in understanding increased 




Umbilical cord blood (UCB) has been considered a safer source of hematopoietic 
progenitors for stem cell transplantation. Its superior immune plasticity of UCB grafts allows a less 
stringent HLA matching, increasing the probabilities to find a compatible donor. Still, infection is 
a major problem in cord blood stem cell recipients, especially during the first 100 days post-
transplantation, including bacterial and fungal infections1–3. This has been ascribed to the lower 
number of infused cells, the more immature immune system and to the observed transitory 
neutropenia1,4; however, the mechanisms of increased susceptibility to infections have still not been 
fully studied.  
UCB recipients can present with severe disseminated forms of Mycobacterium tuberculosis 
infection5 that resemble those observed in patients with Mendelian Susceptibility to Mycobacterial 
Disease (MSMD)6. MSMD is a primary immunodeficiency with a clinical spectrum including 
severe disease after poorly pathogenic mycobacteria, including attenuated Mycobacterium bovis 
bacillus Calmette-Guérin (BCG) vaccine and environmental mycobacteria, severe disseminated 
Mycobacterium tuberculosis, infection by Salmonella species and fungal infections6,7. It is caused 
by inborn errors of the IFN-γ circuit that impair IFN-γ production or response to IFN-γ6,7. Thus, the 
correct production and/or response to IFN-γ after the exposure to mycobacteria are crucial in the 
ability to control the infection.   
The neonate’s immune system must effectively manage the transition from the sterile uterus 
to the real world full of antigens. Just after birth, especially after vaginal delivery, the mucosa of 
the infant is colonized by commensal microbiota. To avoid excessive responses to this colonization, 
the immune system of the neonate is modulated: for example, antigen presenting cells from the 
newborn selectively impair production of T helper-cell 1-related cytokines such as IFN-γ8,9. This 
regulation is partially explained by impaired IL-12 production caused by a defect in nucleosome 
remodeling and the repression of IL-12p35 at the chromatin level. Besides, B regulatory (Breg) 
cells, which have the capacity to suppress IFN-γ production by T cells, are increased in UCB10,11 
and have been shown to be pivotal in the establishment of pregnancy12,13.   
The main aim of this study was to evaluate anti-mycobacterial responses in UCB compared 
to adult peripheral blood (APB). We have observed diminished responses to mycobacterial 
challenge with a diminished IFN-γ production. Interestingly, this observation inversely correlated 
with Breg cell frequency. This allows us to hypothesize that the benefit of Breg in tolerance may 
have as a counterpoint that there is a reduced IFN-γ production in response to mycobacteria. 
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Results and discussion 
Overall response to mycobacterial challenge was reduced in neonates. Cytokine production 
and cytokine markers expression were measured in neonate’s UCB and APB cultured with live 
BCG with or without exogenous rhIL-12p70 or hr-IFN-γ during 48h. Compared to adults, neonates 
showed no statistically significant changes in IL-10, IL-12p70, IL-1RA, IL-1β and TNF-α 
stimulation ratio. Instead, they showed a diminished IFN-γ (p: 0.001) and IL-6 (p: 0.005) 
stimulation ratio. Stimulated lymphocytes displayed also lower frequency (p:0.014) and levels (p: 
0.051) of CD69 (Figure 1A, Table 1). Different from what we observed, it has been published that 
IL-6 production in UCB can be higher than in APB in basal conditions and after TLR 
stimulation8,14; these differences may be explained by the strong Th-1 polarizing capacity of BCG15. 
Currently, there is still a lack of consensus for the phenotypic definition of Breg cells16–20. 
However, CD19+CD24hiCD38hi-defined Breg cells have been studied by us and others in neonate’s 
cord blood, demonstrating the capacity to suppress IFN-γ production by T cells10,11. Given that 
neonatal Breg cells are increased in UCB and block IFN-γ production by T cells10,11 we 
hypothesized that Breg cells are, in part, responsible of the decreased IFN-γ production after BCG 
stimulation observed in neonates. After performing linear regression tests, we observed statistical 
association between frequency of Breg cells and IFN-γ stimulation ratio after BCG stimulation 
(spearman correlation test, R2: 0.618, p: 0.043, Figure 2), thus suggesting that Breg cells may be, 
at least in part, responsible of the diminished antimycobacterial response observed in UCB.  
The IL-12/IFN-γ axis is responsible for anti-mycobacterial responses and is impaired in 
susceptible patients with inborn errors in this axis, also known as Mendelian Susceptibility to 
Mycobacterial Disease7,21,22. We tested the integrity of the axis by analyzing the effect of the co-
stimulation with hrIL-12p70 and hr-IFN-γ. We observed a decreased co-stimulation ratio (Co-SR) 
in TNF-α production after hr-IL-12p70 co-stimulation (p: 0.022). However, we observed a 
tendency towards an increased IFN-γ Co-SR (p: 0.073), showing that the axis can be, at least, 
partially rescued by the addition of hr-IL-12p70. We did not observe any significant differences in 
cytokine production in Co-SR after hr-IFN-γ addition, but an increased Co-SR in HLA-DR positive 
cells frequency (p: 0.026; Figure 1B). Altogether these data show that responses to 
proinflammatory cytokines were preserved in neonates’ cord blood.  
High IFN-γ levels are associated with graft versus host disease (GvHD) development23,24.  
Consistently with the lower rates of GvHD observed in cord-blood transplanted patients25, Breg 
cells are increased in UCB10,11 and are found to be reduced in cord blood transplanted patients that 
developed GvHD10. On the other hand, UCB transplantation is also associated with increased 
morbi-mortality due to infections25. IFN-γ plays a major role in immunity to infections, especially 
in tuberculosis5: thus, after showing for the first time a correlation between Breg cell frequency 
with a diminished IFN-γ production after BCG stimulation, we hypothesize that Breg cells might 
play a double edge sword role in cord blood transplantation.  
This work presents some limitations, including a big variability in the response to 
mycobacteria with respect to cytokine production, which has already been described26–28 and 
observed by our group (unpublished results), along with the size of the studied cohort. However, 
we have observed coherent, consistent and robust results showing statistically significant 
differences between the two groups studied.  
 
Concluding remarks 
In summary, we have observed that neonate’s immune system has a diminished response 
to mycobacterial challenge, concretely diminished IFN-γ production, which is partially determined 




might have implications in clinical practice, especially in UCB stem cell transplantation. For 
example, in IFN-γR1 deficiency, where basal levels of IFN-γ in blood are increased7,29 and bone 
marrow transplantation has been difficult to perform with success30, UCB transplantation might 
help to reduce IFN-γ levels in blood, and improve engraftment.  
 
Materials and methods 
This study was carried out in accordance with the recommendations of Ley General de 
Sanidad (25/4/1986) Art. 10, with written informed consent from parents. The protocol was 
approved by the ethics committee of the Hospital Sant Joan de Déu (Comité Ético de 
Investigaciones Clínicas number PIC-50-12). All healthy controls and parents of the included 
infants in the study signed the informed consent, complying with current legislation. Eight 
umbilical cord blood samples from uneventful pregnancies from healthy mothers were included; 
on the delivery day, 20mL of heparinized blood was extracted from umbilical cord blood. 20ml of 
venous blood from 6 adult healthy controls was extracted into heparinized blood-collection tubes.  
We evaluated the function of the IL-12/IFN-γ axis based on a whole blood culture 27,28: 
heparinized blood was diluted 1:2 in complete medium (RPMI (Gibco, Grand Island, NY, USA) 
supplemented with 10% heat-inactivated fetal calf serum (FCS; Sigma-Aldrich, St. Louis, MO, 
USA), 1 μg/ml penicillin, and 1 μg/ml streptomycin (Invitrogen, Grand Island, NY, USA) and 
incubated at 37ºC in a 5% CO2 humidified incubator for 48h. Activation conditions: medium alone, 
live BCG (Pasteur sub-strain) at a multiplicity of infection of 20 BCG per leukocyte, BCG plus 
human recombinant IL-12p70 (hrIL-12p70, 20ng/ml, Milteny Biotec, Germany), BCG plus hr-
IFN-γ (5,000 IU/mL; Imukin, Boehringer Ingelheim, Germany) as described elsewhere27. Cytokine 
production determination was assessed by Luminex (Millipore, Billerica, MA, USA) at 48h culture 
point following the manufacturer’s instructions. Breg cells (CD19-SJ25C1, CD25-ML5, CD38-
HIT211) and activation marker expression (CD69-FN50, CD71-M-A712 and HLA-DR G46-631) 
were evaluated by flow cytometry. All antibodies are from BD Bioscience, San Jose, CA, USA.   
Data did not follow normal distribution; thus Mann-Whitney test was performed. Statistical 
association studies were performed with linear regression studies and spearman correlation test. 
Statistical analysis and graphical representation of the data were performed with SPSS 22 (IBM, 
Armonk, NY, USA) and Microsoft Excel (2016). In favor of the understanding and legibility of the 
paper, detailed results (median, standard deviation and p values) for cytokine production and 
activation marker expression are shown in Table 1. 
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Figure 1. Cytokine and activation markers stimulation ratio. Cytokine (A) and activation 
markers (B) stimulation ratio is represented as a heatmap where blue indicates the minimum 
values, red the maximum, and yellow next to 1 for each parameter. SR: stimulation ratio, Co-SR: 
costimulation ratio. UCB: umbilical cord blood, APB: adult peripheral blood. APB, n=6, UCB, 
n=7. 
 
Figure 2. Correlation between Breg frequency and IFN-γ SR. SR: stimulation ratio. R2 
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The center of this thesis is the analysis of the IL-12/IFN-γ axis in health and disease 
(primary and secondary immunodeficiencies). We wanted to explore the function of this 
pathway in two different settings: first in the context of children with severe intracellular 
infectious diseases, concretely VL and severe/extrapulmonary TB. These infections during 
childhood have sporadically been associated with inborn errors of the IL-12/IFN-γ axis, but this 
axis has never been systematically evaluated in big cohorts. Second, in infants prenatally 
exposed to anti-TNF-α monoclonal antibodies, since the death of one exposed child due to BCG 
vaccination [302] suggested that exposure to this drug during pregnancy impaired the infant’s  
immune system, conferring a secondary immunodeficiency, being the IL-12/IFN-γ axis most 
probably involved.  
For the study of the impact of anti-TNF-α drugs on the immune system of exposed 
infants, we had to first establish normality values for the different immune populations as well 
as for the analysis of IL-12/IFN-γ axis. On the light of recent studies highlighting the role of Breg 
cells in different conditions of health and disease, including in pregnancy, and the role of TNF-α 
in B cell development, we included in this evaluation, the assessment (quantitatively and 
qualitatively) of CD38hiCD24hi B cell-subset (Bregs) since there were no previous published 




3. Strengths and limitations of our studies 
1.1.Cohort size 
Samples used for the present thesis represent both strength and a limitation. Fortunately, 
in our area, severe/extrapulmonary TB and VL diseases in pediatric population are not common. 
Thus, we tried to collaborate with as much hospitals as possible. Despite this multicentric 
approach the size of the cohort remains small. We included 23 pediatric patients with VL, 24 
pediatric patients with severe/extrapulmonary TB and 41 controls in which we performed an 
immunophenotype, oxidative burst test, proliferative assays and testing of the IL-12/IFN-γ axis. 
The performance of these tests on fresh whole blood was a big effort of coordination between 
clinicians and the laboratory. Two previous studies have been reported searching for mutations 
in MSMD-causing genes in TB patients [82,233] but this is, to our knowledge, the first systematic 
and thorough evaluation of  the state of the IL-12/IFN-γ axis function searching for inborn defects 
of immunity in both sets of patients. 
Our work on the normality in cord blood has also been marked by the low number of 
samples: cord blood samples were not easily achievable and, besides, for functional studies high 
numbers of cells were needed. With no doubt, the cohort of infants born to mothers with IBD for 
the study of the effects of the exposure to anti-TNF-α drugs during whole-pregnancy represented 
the higher challenge. As stated in the results section, the IBD unit in Hospital Clinic de Barcelona 
was unique in our area that maintained the treatment during whole pregnancy in severe cases of 
IBD at the time of the study. Between January 2014 and January 2016, we were able to recruit 7 
patients fulfilling inclusion criteria of the 8 eligible patients in Catalonia. Although results need to 
be interpreted on the light of this limitation, we could obtain robust and statistically significant 
results. Due to the high value of the studied cohorts, we strongly believe that the results obtained 
are of special interest.  
1.2.Control groups 
The choice of control groups is of outmost importance for further interpretation of results. 
This project has been performed in pediatric cohorts, increasing the difficulty to recruit an optimal 
control group. Unfortunately, recruitment of age-paired pediatric healthy controls was not 
possible due to ethical limitations. We have therefore compared the cohort of children with VL or 
severe/extrapulmonary TB with healthy adults. Age-paired comparison would have been of 
especial interest in patients below 2 years old, where Th1-like immunity has been shown to be 
physiologically diminished [314–318]. It is of special interest that, from our knowledge, 
description of IL-12/IFN-γ axis in the context of a mycobacterial challenge during infancy and 
childhood have never been assayed. We might also speculate that variability in young children 
could be lower than in adults due to decreased immunological experience conditioning the 
immune response.  
For the study of anti-TNF-α exposed infants, the control group for the birth time-point 
consisted of infants born to healthy mothers. The perfect control group would have been a group 
of infants born to mothers with moderate-to-severe IBD without immunomodulatory treatment 
(or treatment without transplacental pass-through). However, virtually all pregnant women with 
moderate-to-severe IBD were treated with anti-TNF-α or another immunomodulatory drug. 




maternal condition. However, this does not hamper the traslationability of our study in IBD-
pregnant women, the original clinical scope, as they can mostly be reassured based on our results.  
The availability of cord blood samples after the recruitment of a control group of infants 
born to healthy mothers was a unique opportunity. On one hand, it allowed us to generate our 
normality values and, on the other hand, to study Breg cells in this special state of immunity. The 
study of Breg cells in human neonates was of great novelty as, at the time of the start of this study, 
there were no previous reports. Unfortunately, another group working on cord blood stem 
transplantation published for the first time the presence of CD38hiCD24hi B cells with regulatory 
functions in human cord blood, just 9 months before (Sarvaria et al [330]). Their study was more 
focused on the description of the functional properties of neonatal cord blood and their 
implication in cord blood transplantation. We then pursued this work by relating Breg cells and 
IFN-γ production after mycobacterial challenge: we have showed an association between infant’s 
reduced IFN-γ production after microbial challenge and increased Breg cell frequency.  
1.3.Variability in cytokine production 
Whole blood culture stimulation with live BCG is (although no-perfect) one of the best 
simulations of what happens in “real-life” after an intra-macrophagic infection in humans, being 
the gold-standard technique for MSMD diagnosis [81,89,119,173]. The classical read-out of this 
technique is the detection of the different secreted cytokines after stimulation. Cytokine 
production is strongly influenced by a broad variety of factors including different concurrent or 
past infections [390], time of blood drawn [391,392], stress [393,394], seasonality [395] or the 
time-point in the menstrual cycle in women [396]. High variability, already seen in adult healthy 
controls, is characteristic of this technique [81,89,119]. This intrinsic variability does not influence 
the detection of complete defects, as we have shown in the cytokine production pattern of the 
IL-12Rβ1 deficient patient we diagnosed. In any case we hypothesize that this variability could 
hamper the detection of partial defects, a problem that would need to be solved. 
Reduction of variability in this technique in healthy controls could improve its diagnostic 
power. One method would be the use of Co-SR, in which we study the capacity of the system to 
respond to IFN-γ or IL-12p70. We observed that variability is reduced, but only in non-related 
controls but is maintained in related ones. This suggests that the use of Co-SR of non-related 
controls may be useful for diagnostic procedures as well as for the study of this pathway in the 
research context. Complex data analysis performed with the aid of bioinformatic tools could be 
an option to better differentiate between normal responses, partial functional defects and 




4. Study of the IL-12/IFN-γ axis in extrapulmonary severe Mycobacterium 
tuberculosis and visceral leishmaniasis  
Severe/extrapulmonary TB and VL are two severe diseases with global impact. The 
development of severe disease by these pathogens is increased in low-income countries, where 
pediatric patients have more possibilities to have acquired predisposition because of malnutrition 
or HIV infections. Patients included in this study did not have any of these acquired predisposition 
factors, nor were treated with immunosuppressive or immunomodulatory drugs. The reason why 
these children developed the severe infectious disease, while other community members did not, 
is an important question to improve prevention and treatment strategies. To evaluate the genetic 
theory of infectious diseases (severe infections in childhood respond to monogenic inborn errors 
of immunity), we studied first well-described PIDs (SCID by performing a general 
immunophenotype and a proliferation assay and CGD by performing an oxidative burst assay). 
None of the studied patients presented a phenotype compatible with these diseases. After 
discarding them, we evaluated MSMD. 
Although VL and severe/extrapulmonary TB are not within the classical warning signs for 
MSMD, patients with Leishmania spp. or Mtb infections have been described to have inborn errors 
in described MSMD-causing genes [78,95,134,234,259]. Therefore, we hypothesized that 
pediatric patients that had suffered from severe/extrapulmonary TB or VL lacking other factors of 
predisposition/susceptibility could have congenital susceptibility to these diseases, and that this 
susceptibility could be explained by inborn errors of the IL-12/IFN-γ axis. To rapidly detect 
complete defects of the pathway we performed cytometric analysis of the IFN-γR1, IFN-γR2 and 
IL-12Rβ1 receptors presence as well as functional assays to determine STAT1 phosphorylation in 
response to IFN-γ. We did not found alterations in cytometric determinations in the studied 
patients, thus lowering the possibilities to detect an MSMD-causing defect.  
The gold standard technique to detect defects in the IL-12/IFN-γ axis consists in the 
measure of cytokine secretion after whole blood stimulation with BCG [119,173]. We did not find 
any pattern of cytokine production that could be associated with a complete defect in the integrity 
of the IL-12/IFN-γ axis. There are two other studies screening for MSMD-related defects in Mtb 
infections, one searching for mutations in IL12RB1 (2/50 deficient patients) in endemic and highly 
consanguineous regions [82] and the other searching for i) common mutations in IL12RB1, 
IFNGR1, IFNGR2 and STAT1 in 114 adults with severe tuberculosis and ii) common or new 
mutations in children with extrapulmonary TB in an area of low consanguinity rates, not 
encountering any mutations [233]. In our studied cohort consanguinity was also a rare event. With 
that, we suggest that complete forms of MSMD may not to be suspected at first in patients with 
severe/extrapulmonary TB or VL in our area. Nevertheless, we found suggestive and clear 
differences in cytokine production profiles between healthy controls and patients, pointing out 
that still, the axis is partially impaired, which needs further studies.  
Both related and non-related controls presented high variability after BCG-stimulation, 
shown by coefficients of variation higher than 100. MSMD defects are divided in two main 
categories: ones causing defective production to IFN-γ and others causing defective response to 
IFN-γ. Defective production of IFN-γ is usually caused by IL-12 response or production defects. For 
this reason, the combination of cytokine production levels after BCG stimulation with the 




information on the integrity of the pathway. We performed Co-SR ratios with the intention of 
reduce the variability in healthy controls. This was true for NR-HC but not for related controls, 
where variability did not decrease. We speculate that the increased variability of Co-SR in 
response to IFN-γ and IL-12p70 observed in R-HC may be ascribed to the different defects of the 
pathway observed in patients, since they both carry the same genetic background. 
Studied patients with VL or severe/extrapulmonary TB had differentially altered cytokine 
secretion patterns. While VL patients had decreased IFN-γ production after mycobacterial 
challenge, rescued with IL-12p70 co-stimulation, extrapulmonary TB patients had an impaired 
response to IFN-γ. Production and response to IFN-γ is required for parasite/mycobacteria killing 
in the macrophage [213–215,249–251]. Of note, during active VL infection, PBMC’s of infected 
individuals have an altered IFN-γ production that is restored upon clearance of the infection 
[248,253]. Since in all patients the study was performed at least one month after resolution of the 
infection, the inhibitory capacity of Leishmania parasites should not have interfered with the test. 
Besides, epigenetic changes responsible for the transition to a more Th-1 like immunity [397–400] 
occur in an accelerated way after BCG immunization [318,401,402]. With that, we speculate that 
the exposure to Leishmania at young ages may interfere with these epigenetic changes or, 
alternatively, that susceptible patients have inborn errors in genes implicated on IFN-γ 
production. 
Besides of the defective IFN-γ response, extrapulmonary TB patients showed an altered 
cytokine production pattern after BCG stimulation. This group produced decreased amounts of 
IL-1RA and increased levels of TNF-α and IL-10. TNF-α and IL-1ß are both contributors of the 
granuloma formation and maintenance as well as restriction of intracellular growth in 
macrophages [213,269,276,277,403,404]. TNF-α is necessary for the control of both non-virulent 
(i. e. BCG), and virulent species (i. e. Mtb) of mycobacteria; on the other hand IL-1β is only 
necessary for the control of virulent mycobacteria [403]. Decreased IL-1RA (a reflect of IL-1β 
production) might reflect defects on granuloma formation, thus promoting dissemination of the 
disease to other organs that may not be rescued with an increased production of TNF-α. Although 
we did not find any complete defect, this altered cytokine production and response to IFN-γ 
suggest the need of more studies searching for hypomorphic or somatic mutations as well as 
epigenetic defects to better characterize and treat these patients. 
Altogether, these data strongly suggest that severe/extrapulmonary TB and VL patients 
have a familial altered anti-mycobacterial response, that involves the IL-12/IFN-γ axis, still 
undefined. The use of high throughput technologies may facilitate the study of epigenetic 
changes, somatic mutations or complex mechanisms of susceptibility. Decreased frequency of 
MSMD in our media could be explained by the low rates of consanguinity, reducing the chances 
of recessive diseases. Besides, detection of MSMD may be also decreased since BCG infection 
after vaccination is the main sign of MSMD, and BCG vaccination is no longer used in our country.  
The warning signs of MSMD in our media are still to be defined, and also training of physicians on 
the need to evaluate immunity in children with severe infections.  
Differentiation from a BCG-vaccination related disease from Mtb infection have major 
implications in diagnosis procedure and treatment. The described patient with disseminated 
vaccine-related BCGosis was misdiagnosed as resistant extrapulmonary. Since MDR-TB is an 




resistant Mtb. BCG and Mtb differentiation is not easy because Mycobacterium bovis (the virulent 
strain from where BCG derives [405]) is closely related to Mtb within the Mycobacterium 
tuberculosis complex [406]. Mycobacterial culture from patient’s sterile liquids or tissues (the gold 
standard diagnostic technique), does not differentiate between these two microbes. Resistance 
studies may help, since all BCG vaccine strains are intrinsically resistant to pyrazinamide, which is 
uncommon in naïve patients with Mtb [406]. Only PCR studies and IFN-γ release assays specific 
for virulent strains of the Mycobacterium tuberculosis complex are capable of clearly differentiate 
between Mycobacterium bovis  and Mtb, but they are not widely available[406,407].  
Besides the primary microbiologic misdiagnosis, immunologic and genetic diagnosis of the 
underlying immune defect (IL-12Rβ1 deficiency in our case), allowed for a specific management 
and improved survival: in our case, the patient was transferred to the National Institute of Health 
(United States of America) for specific treatment with extensive and prolonged antimycobacterial 
drugs followed by secondary prophylaxis, in combination with exogenous hr-IFN-γ [95,154,408]. 
After hr-IFN-γ treatment was started, the patient started to respond and get cured of her 
infectious disease. This case highlights the need to consider PID (especially defects in the IL-
12/IFN- axis) in patients with severe mycobacterial infection, and/or major adverse events after 
BCG vaccination [95] and how BCGosis can mimic disseminated TB and delay appropriate 
diagnostic and therapeutic management. The consideration of these concepts in the healthcare 






5. MSMD diagnosis: from research to clinical practice 
Set up and performance of specific functional techniques for MSMD diagnosis is not 
trivial. Besides of the technical limitations, interpretation of the results can also be challenging; 
therefore, presence of qualified staff is required. Especially in low-income countries, the needed 
infrastructures and equipment’s could be also limiting, as there is a need to work in sterile 
conditions with high cost equipment and consumables, specifically in relation to flow cytometry 
or some cytokine detection techniques. MSMD diagnosis is usually only possible in specialized 
immunology laboratories. Functional techniques for MSMD diagnosis were set up to study 
patients with severe/extrapulmonary TB and VL in our laboratory, deriving in the implementation 
of MSMD diagnosis in the clinical practice in the Immunology Service of the Hospital Clinic de 
Barcelona from the Functional Unit of Clinical Immunology Sant Joan de Déu-Clínic, leading to the 
publication of a manuscript reviewing current laboratory tests for MSMD diagnosis [173]. 
In fact, currently there is a broad array of available tests for MSMD diagnosis, each one 
with different strengths and limitations [173]. However, considering price, working hours and 
complexity in the interpretation of results, we propose a step-by-step algorithm (Figure 17) for 
MSMD diagnosis in the routine practice after clinical suspicion: 1) discard other more frequent 
intra-macrophagic-susceptibility-conferring PIDs, 2) performance of cytometric determination of 
the presence of IL-12Rβ1, IFN-γR1, IFN-γR2 and, when possible, of STAT1 phosphorylation in 
response to IFN-γ, 3) genetic evaluation depending if in step 2 there is a clear candidate (targeted 
Sanger sequencing) or not (NGS with a panel or WES) and 4) functional confirmation of the genetic 
result, which normally needs to be performed in the context of a research laboratory. 
Nevertheless, only genetics with a functional confirmation of the identified mutation will lead to 
a real diagnosis. Thus, functional studies will always be necessary.   
 
Figure 17. Step-by-step diagnosis algorithm for MSMD diagnosis. SCID: severe combined 
immunodeficiency, CID: combined immunodeficiency, CGD: chronic granulomatous. GC: genetic 
confirmation, NGS: next generation sequencing, WES: whole exome sequencing; WGS: whole 
genome sequencing; GC: genetic confirmation.  
More than thirty years have passed since the first genetic diagnosis of MSMD [71,72] and 




for awareness regarding MSMD, so that physicians taking care of children or adults, can suspect 
these disorders. The knowledge of the specific warning signs is of outmost importance. Patients, 
especially children, with BCGitis or BCGosis or EM infections, alone or in combination with other 
intracellular infections, should be suspected of having a PID, especially MSMD. Global frequency 
of MSMD has been estimated to be around 1/50,000, although it had been previously thought to 
be more infrequent.  
Second, there is a need to facilitate the diagnosis of MSMD once suspected. Indeed, the 
detection of the genetic defect is necessary to offer the patient the best treatment option and 
genetic counseling, and, therefore, decrease mortality, as the final genetic diagnostic will 
condition the treatment of the infectious disease in patients with MSMD [81,89,93,95,409]. For 
this reason, we are now setting up a panel with all the known disease-causing genes that would 
serve to both better study the cohorts described here and as a diagnostic tool in the clinical 
practice for patients with clinical and/or functional suspicion.  Unfortunately, although during the 
last years big efforts have been made to discover new MSMD-causing mutations, there is still a 
great proportion of MSMD patients (almost 50%) without a definitive genetic diagnostic. Further 





6. Prenatal exposure to anti-TNF-α drugs impacts on the immune system 
maturation in exposed infants 
Anti-TNF-α treatment is a new opportunity to female patients with IBD to have a non-
complicated pregnancy. Still, a big group of families decide not to have children when the woman 
suffers from IBD because of the fear of reactivation of the disease or the effect that the disease 
itself or the treatments might have on the infant. TNF-α treatment is, sometimes, the only way to 
control the disease in patients with moderate-to-severe IBD. For this reason, the assessment of 
the effects of the exposure to this drug during whole pregnancy on the infant is an imperative for 
the management of these patients. Although other studies concerning safety and general effects 
on the immune response of exposed infants exist, we aimed at thoroughly studying the effect of 
anti-TNF-α exposure in the developing immune system, especially focused in the study of 
mycobacterial response.   
The transfer of anti-TNF-α to the fetus during third trimester of pregnancy leads to drug 
exposure in the exposed neonate until approximately 6 months. In accordance with published 
data [298,300], we could detect TNF-α inhibitors in the blood of the exposed infants until 6 
months of age. The observed level on the infant was related to the though level of the mother 
and the time-to-delivery of the last injection. It has been shown that exposed-infants had 
increased levels compared with their mothers [300]. Our results were slightly different to those 
published: for adalimumab exposure reported child/mother mean ratio was 1.21 while ours was 
0.99; on the other hand, for infliximab reported ratio was 1.97 and ours was 3.25. Experimental 
design differences may explain the differences observed. First, we measured mother’s trough 
level during pregnancy instead of birth’s levels. Besides, all patients included in this study received 
the last dose of treatment the last week before delivery while in the previous study [300] there 
was a huge range of time from the last dose to delivery, from 0 to 25 weeks.  
Although due to sample size limitations we could not make comparisons between 
adalimumab and infliximab exposed infants, it seemed that the effects of infliximab on the 
immune system of the exposed infant were stronger than in adalimumab exposed ones. This 
possible different affectation could be explained by the larger inter-dose interval of infliximab 
than adalimumab (4-8 folds), being the dose higher in infliximab patients. Our recommendation 
would be to try to separate as much as possible from birth the administration of the last dose of 
anti-TNF-α in the mother, to reduce the drug level in the newborn. There are also studies 
recommending ADA and IFX discontinuation after week 20 of pregnancy in order to try to reduce 
drug levels in the newborn [410–412]; however, in some circumstances the risk of a disease 
reactivation prevent the adoption of these strategies. 
 Neutropenia can be an associated complication of anti-TNF-α exposure during 
pregnancy. Neutropenia in infliximab-exposed infants after approximately 15 days after birth had 
been previously reported: 3 patients presented with severe and 1 with moderate neutropenia 
that improved after 3 months [413]. In our studied cohort, at birth none of the included infants 
had severe neutropenia, although 2 infants presented with levels below the reference range for 
the age. On the other hand, we observed one case of severe and two cases of moderate 
neutropenia in 3-months old exposed infants. Reported exposed infants had also infectious skin 
lesions that occurred during the neutropenic period [413] while none of the included infants 




infusion pattern. In the 4 cases described, the infusion of the last infliximab dose was, at least, 8 
weeks’ pre-partum. Instead, patients included in our study received the last dose of either 
infliximab or adalimumab from 3 to 7 days pre-partum. After these observations, we conclude 
that neutrophil count should be routinely performed in infants exposed to anti-TNF-α drugs 
during pregnancy, especially in the event of an infection.  
Exposure to anti-TNF-α drugs affects immune system maturation. For the first time, we 
evaluated the maturation status of B and T cell compartments. In concordance to what had been 
previously observed in anti-TNF-α exposed non-human primates [313], there was no impairment 
of total numbers of B and T cells in all exposed infants but in one that had B-cell lymphopenia at 
birth after adalimumab and azathioprine exposure (azathioprine  exposure during pregnancy can 
lead to B cell lymphopenia at birth [414]). Although maturation is impaired at birth, after 12 
months values of B and T cell subpopulations were within the normality values for age, and 
patients produced normal amounts of immunoglobulins with normal responses to vaccines. 
Except for one infant with recurrent non-severe infections from 6 to 12 months, no clearly 
increased susceptibility to infections was observed in exposed infants, possibly ascribed to the 
transferred immunoglobulins from the mother in late-pregnancy.  
Immune dysregulation should be considered and monitored in anti-TNF-α exposed 
infants. 4 of out the 7 studied children presented atopy in the first year (2 of them without family 
history), and all ADA-exposed infants had increased eosinophil counts in cord blood. We have 
observed a diminished frequency of Treg cells in all exposed infants compared to healthy controls. 
Interestingly, there are some publications showing an increase in Treg cells in responder adult 
patients after anti-TNF-α treatment [415–417]. However, cells that increase in adult are not 
natural (CD62L+) but induced (CD62L-) Treg cells [416]. As induced Treg cells are differentiated 
upon an antigenic insult [418], in the umbilical cord blood the majority of Treg cells would be 
expected to be natural Treg (also suggested by the fact that they express high levels of 
CD62L)[419]. The decreased Treg cell frequency correlated with increased T-cell response to weak 
stimulus, thus suggesting higher reactivity of T cells. However, we cannot rule out the possibility 
that this may be influenced by the mother’s disease [420]. On the other hand, there was an 
increased immature Breg frequency. Regulatory populations in TNF-α inhibitors exposed infants 
need to be further studied in larger cohorts to confirm these results. Besides, clinical evolution of 
exposed infants should be specifically followed-up, with special attention to allergic, 
inflammatory, and autoimmune events.   
We have shown that drug exposure decreases the response to mycobacterial challenge at 
birth, which is not totally rescued after drug cleaning and increased with age. Comparison 
between the effect of anti-TNF-α inhibitors exposure in the immunity of adults with inflammatory 
disease with respect to the exposure of infants during late pregnancy and early infancy, is difficult 
because both cases are special situations of immunity [318,421–425]. In adults, it has been 
observed that there is a decreased production of IL-12 (but not of IL-6) after anti-TNF-α therapy 
[426] as well as a decrease in IFN-γ-producing CD8+ T-cells and in the Th1/Th17 subset with an 
increase in IFN-γ-producing NK cells [427]. Our results obtained after BCG stimulation do not 
totally correspond with those published: we observed no significant differences in IL-12p70 
production in comparison with non-exposed infants and an increased production of IL-6. Also, 




after whole-blood washing. On the other hand, the reduced CD69 expression has been reported 
previously in exposed patients’ T cells [277]. 
Based on empirical experience, including the death of an infliximab exposed infant after 
BCG vaccination [302] and theoretical knowledge [428], the use of all live vaccines was delayed 
from 6 to 12 months of age in infants exposed to adalimumab or infliximab during the late second 
and third trimester of pregnancy [298,303]. With this work, we provide objective data to ponder 
this statement: at birth, exposed infants showed more immature B- and T-cell-subsets. However, 
we observed a normal T-cell proliferation to mitogens, as well as T- and B-cell numbers and 
maturation, immunoglobulin production and inactivated vaccine responses, accomplishing the 
criteria for attenuated vaccination in patients with cellular immunodeficiency [429]. Also, none of 
the 4 infants who received rotavirus-inactivated vaccine presented adverse events. After these 
results, we speculate that vaccine policy in those infants could be revised, highlighting the 
avoidance of BCG vaccination in anti-TNF-α exposed neonates.  
The advent of new biosimilars will broaden the use of biological treatments in developing 
countries, some of which have endemic TB or vaccination programs including BCG immunization 
soon after birth. Until more investigations are performed, BCG vaccination must be absolutely 
avoided in exposed infants until recovery of antimycobacterial function is verified or at least until 
12 months of age. In vitro functional studies would be relevant for this purpose. This study is the 
first thorough evaluation of the impact of prenatal anti-TNF-α on the immune system 
development of exposed-infants. Although we observed specific changes, infants were not 
clinically compromised. Our results aim at generating consciousness of the need to further study 
and follow-up on exposed-infants. Pediatricians should be informed of the mother’s mAb 
treatment during pregnancy, because of the impact on vaccine recommendations, especially with 









7. Breg cells can play a major role in neonate immunity  
The immune system has developed mechanisms to accommodate the especially 
important period before, during and after birth: there is a breaking transition from the allogenic 
but sterile uterus to the ‘outside-maternal’ world, where the newborn will be massively colonized 
by commensal microbiota and exposed to a myriad of different non-hazardous antigens, while 
will also be attacked by pathogens. When we try to define reference values in newborns, we 
detected a surprisingly increased frequency of CD24hiCD38hi B cells in cord blood; this B-
subpopulation showed regulatory capacities with a phenotype similar to that of adult 
CD24hiCD38hi cells. Of note, Breg cell frequency was associated with IFN-γ production after whole 
blood BCG-stimulation. Neonatal response to BCG was, therefore, reduced, showing lower levels 
of IFN-γ and IL-6 as well as diminished CD69 response upon stimulation. However, responses to 
IL-12 and IFN-γ co-stimulation were preserved.  
Increased frequency of CD24hiCD38hi B cells in neonates could be due to the immaturity 
of the system, being these cells ‘only’ transitional B-cells. We made functional studies to check if, 
neonatal CD24hiCD38hi B cells had regulatory functions. We observed a capacity to produce IL-10 
upon stimulation and a suppressive activity on IFN-γ and IL-4 production by T cells after co-culture 
that did not occur after CD24intCD38int co-culture. Besides, they have a similar phenotype 
compared with adult CD24hiCD38hi Breg cells, with an increased IgM and a decreased CD27 
expression. Since CD27 is a memory marker, the decrease can be explained by their very young 
age [334]. Our results are in consonance with the studies performed with adult CD24hiCD38hi Breg 
cells, named ‘immature Breg cells’ with proven regulatory functions [334,335,339].  
Interestingly, without any stimulation, both Breg and noBreg cells produced more IL-10 
than their adult counterparts, in consonance to what was observed in the other study on neonatal 
Breg cells [330]. After IL-10 blockade experiments, the authors concluded that although IL-10 is in 
part responsible of their suppressive functions, it is not the only mechanism involved. However, 
differently to our observation, they observed inhibition of the production of inflammatory 
cytokines by both CD24hiCD38hi and CD24intCD38int [330]. We speculate that discrepancy in the 
results could be explained by differences in the experimental design. While we co-cultured either 
Breg or noBreg cells with CD3+CD25- T cells for 72h in the presence of plate-bound CD3 and a re-
stimulation step with PMA and Ionomycin before intracellular cytokine staining; Sarvaria et al co-
cultured CD4+ cells with either Breg or NoBreg cells, stimulated them with anti-CD3/CD28 for 96h, 
and then analyzed the concentration of inflammatory cytokines in the supernatant [330]. 
Although we were both analyzing CD4+ cytokine production; in our setting, cells were in contact 
with other types of T-cells (as CD8+ cells), while in the other study there were only CD4+ cells. With 
that, we can speculate that Breg cells affect differentially to different subsets of T cells.  
It is known that Breg cells can carry out part of their functions via IL-10-independent 
mechanisms. Immune regulation by cord blood B cells seems to be partially mediated by i) IL-10 
production and ii) cell-to-cell direct contact (mediated by CD80/CD86), but independently of TGF-
β, as has also been observed in adults [330,335]. Other mechanisms for Breg cell inhibitory 
functions have been proposed, including the production of adenosine by CD73. After studying this 
mechanism in neonatal CD24hiCD38hi Breg cells we conclude that adenosine production by CD73 
seems not to be a mechanism of action for these cells, as CD73 expression is decreased in neonatal 
Breg cells. On the other hand, we speculate that the increased quantity of IgM per cell in neonatal 




for their inhibitory function. Naturally occurring IgM Anti-Leukocyte Autoantibodies (IgM-ALA) are 
antibodies with suppressor capacity that can inhibit T cell activation and chemotaxis [430,431]. 
IgM-ALA antibodies are present at birth [431], and they inhibit proinflammatory cells from 
producing IFN-γ and IL-17 in response to alloantigens in mice [430]. More research should be done 
to evaluate whether if this is a true regulatory mechanism of neonatal Breg function. 
Neonatal marginal zone-like B cells presented the greatest difference in proportion of 
Breg-cells when compared with adults. Circulating marginal zone B cells are representative of 
splenic marginal zone B cells; these cells are characterized for having a pre-diversified Ig repertoire 
and initiating T-cell independent responses through TLRs as activation signals. Their responses are 
mainly directed against encapsulated bacteria, including commensal microbiota [321,432,433] 
and play a role in normal pregnancy development [434]. As TLRs activate Bregs [334,343], the 
greater proportion of marginal zone-like B cells observed might indicate increased regulatory 
responses after encapsulated bacterial stimulation, thus explaining lower responses to 
encapsulated bacteria in infants [318]. Besides, we observed lower levels of CD22; this surface 
molecule modulates the BCR signal and prevents the hyperactivation of B cells upon stimulation 
[323–325]. Besides, in CD22 knock-out mice, increased circulating IgM was detected and more 
Breg-cells were observed in the spleen [326,435]. These B cells had the capacity to inhibit the IgG 
response to estrange and self-antigens [326]. Overall, it suggested a lower activation threshold of 
these neonatal Breg cells. This could be of importance in the rapid abrogation of unwanted 
responses to commensal bacteria. We might hypothesize that, during the first contacts with the 
extra-uterine environment and the adoption of microbiota, the increased proportion of Breg-cells 
among marginal zone B cells could be one of the mechanisms by which the neonatal immune 
system protects itself from an exacerbated response to the new range of antigens encountered. 
Breg increased levels in umbilical cord blood have been related to lower rates of graft 
versus host disease in cord-blood transplanted patients [330,436]. Besides, patients developing 
GvHD present a decreased frequency of Breg cells [330]. On the other hand, cord-blood 
transplantation has also been associated with an increased morbi-mortality due to infections 
[436]. We hypothesized that, as CD5+ murine B-cells contribute to the reduced production of IL-
12 by APCs [437], increased hUCB Breg contributes to the limited Th1 response observed in 
neonates inhibiting IFN-γ production. We evaluated the state of the IL-12/IFN-γ axis in neonates 
using the gold standard technique used to detect inborn errors of this pathway [119,173] and 
observed decreased response to mycobacterial challenge consisting in decreased IFN-γ and IL-6 
secretion as well as diminished expression of CD69 early activation marker. BCG infection has 
been proven as one of the stimulus capable of inducing IL-12p70 by neonatal lymphocytes [398], 
concordantly, there were no significant differences in IL-12p70.  
We propose that neonates maintain the IL-12/IFN-γ axis integrity after observing normal 
responses to IL-12p70 and IFN-γ co-stimulation; what is more, IFN-γ production ratio after IL-
12p70 co-stimulation showed a tendency to be higher, as well as increased HLA-DR+ T-cell 
frequency after IFN-γ co-stimulation. BCG vaccination has been shown to confer protection to 
other non-related diseases as well as to reduce total infant mortality due to infections. This 
protection has been proposed to be due to epigenetic modifications in innate cells, what is known 
as innate training. After these results, we hypothesize that although IFN-γ production is low after 
the first 48h post-infection, the effect of the secreted IFN-γ together with IL-12p70 might lead to 




Breg cell frequency is inversely associated with IFN-γ secretion after whole blood BCG 
stimulation. It is known that after BCG challenge in neonates, the major providers of IFN-γ are NK 
cells instead of T cells [438]; therefore, we hypothesize that Breg cells could be, at least in part, 
responsible of this decreased T cell response. Since high IFN-γ levels are associated with graft 
versus host disease development [439,440], we consider that this association altogether with the 
increased Breg cell frequency in neonates, deserves further investigation and may have 
implications in clinical practice, especially in stem cell transplantation from cord blood. For 
example, in IFN-γR1 deficiency, where basal levels of IFN-γ in blood are increased [95,174], stem 
cell transplantation has been difficult to perform with success [142]. We propose that UCB 
transplantation in those patients could help to reduce IFN-γ levels in blood, thus helping the 
engraftment. 
In summary, we have observed that neonate’s immune system has a diminished response 
to mycobacterial challenge with a diminished IFN-γ production, possibly partially determined by 
Breg cell frequency.  More research on neonatal Breg cell subset is required in order to decipher 
their regulatory mechanisms and their role in special pregnancy conditions such as chronic 






8. Implications and prospects 
The work presented here is the result of a translational project; therefore, it has direct 
implications for clinical practice. The consecution of the different objectives has raised more 
questions than were answered.  
None of the studied patients with severe/extrapulmonary TB or VL had a complete MSMD 
defect. However, the two groups of patients had altered function of the IL-12/IFN-γ axis, known 
to be essential for immunity against both Leishmania and mycobacterial infections. We strongly 
believe that the increased susceptibility of these patients to develop these severe diseases might 
be hereditary (at least in part), because their parents showed also an altered IL-12/IFN-γ axis 
function. Although it will be mandatory to study the presence of mutations in the known MDMS-
causing genes, currently approximately half of the patients with clinical signs of MSMD have not 
a defined genetic diagnosis. For this reason, we believe that WES or WGS will expand the 
understanding of the basis of the infectious susceptibility of these patients. Besides, since only 
partial defects of the IFN-γ/IL-12 axis were identified, we hypothesize that other genetic factors 
could be occurring in susceptible patients, such as epigenetic variations or somatic mutations 
affecting both IFN-γ/IL-12 axis and the macrophage function.  
Due to intrinsic variability in cytokine secretion, which is the basis for the gold standard 
technique for MSMD diagnosis, this approach hampers the diagnosis of partials defects. We 
believe that this assay has still options for improvement: we propose the performance of 
multiparametric assays in order to integrate the different read-outs of the technique to decrease 
variability and/or to find other forms of analyzing results in order to better differentiate between 
a normal and a pathogenic response. This type of studies can only be performed with the use of 
advanced bioinformatic technology; for this reason, collaboration with bioinformatic experts is 
critical.  
Because of the methods established, we have developed a clinical pipeline for the 
management of patients with suspicion of MSMD in our area. We are currently a reference 
laboratory for the study of suspected MSMD defects. I would like to highlight the diagnosis of the 
IL-12Rβ1 deficiency of a Peruvian patient, despite it is probably not the most relevant scientific 
contribution of this thesis. In fact, our diagnosis allowed the transfer of the patient to the National 
Institute of Health in the United States of America, where she was properly treated and 
microbiologically diagnosed. As a biologist, it is uncommon to observe direct clinical 
consequences of an experimental research.  
The results obtained with the study of the impact of whole-pregnancy anti-TNF-α 
treatment on the immune system of infants born to IBD patients arose interest in other medical 
areas where anti-TNF-α treatment is used, such as rheumatology (in fact, most of studies on the 
effect of anti-TNF-α have been performed in rheumatic patients); like in IBD, a great proportion 
of patients with rheumatic disease are women in childbearing age. To our knowledge, our study 
was first of its kind, by thoroughly studying the immune system of the exposed baby. For this 
reason, and in collaboration with the group for the study of the effect of biologic drugs 
administered during pregnancy, there is on ongoing project to study the influence of different 
treatments with TNF-α blockers in pregnant patients with inflammatory rheumatic diseases.  
The decreased response to mycobacterial challenge of exposed infants has implications 




exposure to anti-TNF-α during pregnancy was first suspected after the death of an exposed infant 
after BCG vaccination [302]; however mechanisms leading to this susceptibility were not further 
studied. After the results obtained, we energetically stress that BCG vaccination must not be 
administered to anti-TNF-exposed infants, as well as other attenuated vaccines for intra-
macrophagic pathogens (oral typhoid vaccine) [441–443]. Therefore, a global study of the capacity 
of exposed neonates to respond to pathogens (especially of intracellular lifestyle) is still to be 
performed.  
The study of regulatory subsets, especially Treg cells, in exposed infants is a new area to 
be developed: we observed a significant reduction on Treg cell frequency in exposed infants that 
did not recover after 12 months of follow-up. We aim at following this population at one more 
time-point around 3 years-old, as well as better studying in the new project all the different Treg 
subpopulations in exposed infants (including their functionality). Due to this altered Treg cell 
subset and the fact that 4 out of 7 patients presented atopy, the follow-up of clinical signs of 
allergy, inflammation or autoimmunity in this cohort is of special interest. Besides, to study the 
effect to anti-TNF-α exposure on the microbiota seems also to be potentially relevant: it is known 
that the composition of the microbiota is of outmost importance for the development of the 
immune system. Besides, different maternal conditions determine the composition of the 
microbiota in the infant. Therefore, we speculate that exposed infants might show differences in 
the microbiota that can lead to different maturation of the immune system.  
The study of the safety of anti-TNF-α drugs can change the course of some pregnancy-
related diseases. Amongst them, obstetric antiphospholipid syndrome (a known cause for 
reduced fertility in women) where anti-phospholipid-related thrombosis in the placenta partially 
explains the increased frequency of miscarriage in affected women, has been recently linked to 
inflammation, especially related to TNF-α production [444,445]. The use of anti-TNF-α drugs to 
overcome infertility has been successfully used before [446], and their use in patients with 
antiphospholipid syndrome is being now proposed [444,445]. The study of the effect of TNF-α on 
the exposed infant is an imperative especially when using this drug for fertility problems. We 
believe that our work increases the safety of TNF-α drugs during pregnancy and improves the 
knowledge of the management of the exposed infant. Nevertheless, similar studies in different 
conditions and with bigger cohorts are obviously needed.   
On a more basic-research area, together with Sarvaria et al [330] we were the first to 
describe the population of Breg cells in neonates, thus opening the door for new research and 
possible treatments. We propose three lines of research on neonatal Breg cells: 
1. To study of new mechanisms of action, such as the possible presence of IgM Anti-
Leukocyte Antibodies in Breg, that could explain the increased levels of IgM per cell 
in neonatal Breg cells. 
2. To define the role of Breg in different conditions, such as neonatal infection, 
autoimmunity, inflammation as well as the effect of maternal conditions on the Breg 
cell population or the evolution of this subset during the first years of life. 
3. To characterize the role of Breg cells in cord blood transplantation, as beneficial actors 













1. In our area, we did not detect an underlying primary immunodeficiency in pediatric 
patients with visceral leishmaniasis or severe/extrapulmonary tuberculosis, including 
T cell defects, chronic granulomatous disease and complete defects of IL-12/IFN-γ axis 
or MSMD.  
2. Nevertheless, IL-12/IFN-γ axis was partially impaired in pediatric patients with visceral 
leishmaniasis and severe/extrapulmonary tuberculosis, suggesting an intrinsic 
susceptibility to intra-macrophagic infections. Definition of the concrete mechanism 
of susceptibility needs new approaches including next generation sequencing and 
epigenetic studies.  
3. The early diagnosis of an MSMD, based on the development of specific warning signs 
and a diagnostic methodology of MSMD, is of outmost importance, since 
immunological and genetical confirmation of an MSMD will condition patient’s 
management.  
4. Prenatal exposure to anti-TNF-α drugs for the treatment of inflammatory bowel 
disease in the pregnant woman can be considered safe, with no significant clinical 
events.  
5. Nevertheless, changes in the infant’s immune system development are observed; 
especially regarding the IL-12/IFN-γ axis, which is partially defective, possibly 
increasing their susceptibility to mycobacteria. Therefore, BCG vaccination must be 
avoided at birth.  
6. Infants exposed to TNF-α inhibitors during pregnancy born to mothers with 
inflammatory bowel disease should be followed-up on the long term for the advent 
of allergic, autoimmune or inflammatory events. 
7. B regulatory cell subset is expanded in healthy neonates’ cord blood, with a confirmed 
regulatory function. This observation might have a pivotal role in explaining the 
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2. Resumen de la tesis 
2.1.Introducción: 
2.1.1.Inmunodeficiencias  
El sistema inmunitario es un sistema altamente complejo y controlado con capacidad 
para discernir entre lo propio y lo extraño, entre lo peligroso y lo inocuo para poder responder 
de manera efectiva. Su función principal es la defensa ante patógenos, pero también tiene un 
papel importante en otros procesos como el cáncer, el establecimiento y mantenimiento del 
embarazo y la regeneración tisular entre otros. Defectos en la función del sistema inmunitario, 
ya sean congénitos o adquiridos, pueden ser causantes de inmunodeficiencia [1,2]. Las 
inmunodeficiencias primarias (IDP) son enfermedades consideradas raras causadas por defectos 
congénitos del sistema inmunitario. Las IDP “clásicas” son aquellas en que la mutación en un 
gen genera susceptibilidad a un amplio rango de patógenos, con un inicio temprano y mal 
pronóstico, como en la inmunodeficiencia combinada severa. Por otro lado, la descripción de 
IDP que confieren susceptibilidad a un rango de patógenos más estrecho, que pueden aparecer 
desde edades tempranas hasta la edad adulta y que tienen un pronóstico variable generó el 
concepto de “IDP atípicas” [3]; uno de los ejemplos más estudiados es la susceptibilidad 
mendeliana a las micobacterias (Mendelian Susceptibility to Mycobacterial Disease, MSMD; 
OMIM 209950) [4,5]. 
Las inmunodeficiencias secundarias son defectos adquiridos del sistema inmunitario 
que pueden ser reversibles o no. Pese a que el síndrome de inmunodeficiencia adquirida 
causado por el virus de la inmunodeficiencia humana es la causa de inmunodeficiencia 
secundaria más conocida y estudiada, la malnutrición es la causa más común [6]. Por otro lado, 
se ha postulado que los pacientes tratados con fármacos biológicos dirigidos a moléculas del 
sistema inmunitario pueden presentar estados similares a esos pacientes con 
inmunodeficiencias primarias [7]. Las infecciones que se observan en los pacientes tratados con 
anticuerpos monoclonales (AcMos) anti-TNF-α recuerdan a aquellas observadas en pacientes 
afectos de MSMD [7], como son las infecciones atípicas, diseminadas y miliares por 
micobacterias [8]. 
 
2.1.2.MSMD como paradigma de la teoría genética de las infecciones 
El estudio del “por qué” y “cómo” de las enfermedades infecciosas está en el centro de 
numerosas investigaciones. Existen 4 teorías principales que tratan de explicarlo, centrándose o 
bien en el ambiente (teoría microbiológica y teoría ecológica) o en el huésped (teoría 
inmunológica y teoría genética). Estas teorías se han desarrollado en paralelo con el avance del 
conocimiento y son complementarias. La teoría microbiológica de las infecciones estableció que 
los gérmenes eran necesarios y suficientes para el desarrollo de enfermedad. La variabilidad 
observada en las enfermedades infecciosas hizo cuestionar esta teoría. Por su parte, la teoría 
ecológica propuso que los microorganismos son necesarios para que se desarrolle la 
enfermedad, pero que es el entorno (estado nutricional, coinfecciones, …) lo que va a 
determinar que se desarrolle o no la enfermedad. Más adelante, tras la observación de las 
respuestas a microorganismos atenuados apareció la teoría inmunológica de las infecciones, que 




menos virulentos o en menor número. Esta teoría explicaba la variabilidad tras reactivaciones o 
reinfecciones, pero no en las infecciones primarias. Por último, la teoría genética de las 
infecciones propone que el background genético del individuo determina la respuesta a los 
microorganismos, concretamente postula que “las infecciones primarias que amenazan la vida 
en la infancia responden a defectos heredados en un único gen mientras que las reactivaciones 
e infecciones secundarias en adultos jóvenes son consecuencia de defectos en locus principales 
y en adultos mayores son debidas a causas poligénicas”. En conclusión, siguiendo la teoría 
genética de las infecciones, cualquier infección primaria severa en la infancia puede deberse a 
defectos heredados en el sistema inmunitario, es decir, a una IDP [10].  
La MSMD es una IDP de las consideradas “atípicas”, causada por defectos genéticos en 
la vía IL-12/IFN-γ; confiere predisposición a infecciones causadas principalmente por 
micobacterias poco virulentas, como son las micobacterias no tuberculosas y la cepa vacunal 
BCG (bacilos vivos atenuados de una cepa de Mycobacterium bovis), pero también por 
Mycobacterium tuberculosis [4,5,11]; más raramente, se han reportado también infecciones 
graves por otras bacterias intracelulares, hongos y parásitos (como la leishmaniasis [12,13]) que 
debutan habitualmente en la infancia [4]. Se considera hoy en día una enfermedad de base 
mendeliana (formas autosómicas recesivas, dominantes o ligadas al cromosoma X), en la cual se 
conocen diez defectos genéticos: IFNGR1, IFNGR2, STAT1, IRF8, CYBB, IL12B, IL12RΒ1, NEMO, 
ISG15 [4] y TYK2 [14]. Dichos defectos genéticos tienen en común un fallo en la inmunidad 
mediada por IFN-γ, ya sea completo o parcial según si la mutación es deletérea o hipomórfica, 
respectivamente.  
La gravedad de las manifestaciones clínicas en los pacientes con MSMD depende en gran 
parte del genotipo: los defectos completos de IL-12 y su receptor y los defectos parciales del 
receptor de IFN-γ habitualmente predisponen a infecciones menos graves en comparación con 
los defectos completos del receptor de IFN-γ que predisponen a infecciones devastadoras a 
edades tempranas. Dentro del mismo genotipo, existe igualmente gran variabilidad en la 
expresividad clínica: pacientes con el mismo defecto genético pueden tener formas clínicas con 
severidad dispar, como ha podido objetivarse en amplias series de pacientes con los defectos 
de IL-12Rβ1 [15] y de IFN-γR1 [16], en los que aparecen infecciones recurrentes junto a 
asintomáticas, incluso dentro de la misma familia. Ello sugiere que mecanismos patogénicos 
adicionales, potencialmente determinados por factores ambientales, pueden determinar la 
presentación de la enfermedad, y la forma en que ésta progresa [4,5].  
El estudio de posibles defectos causantes de MSMD se debe realizar en niños o adultos 
que desarrollen infecciones severas/diseminadas por micobacterias o Salmonella sin otras 
alteraciones hemato-inmunológicas, infección por el virus de la inmunodeficiencia humana o 
exposición a fármacos inmunosupresores (incluyendo los fármacos biológicos anti-TNF-α). El 
diagnóstico de la MSMD se basa en la realización de pruebas funcionales sobre la vía IL-12/IFN-
γ, en concreto, la medición de la producción de IFN-γ e IL-12 tras estimulación de sangre total 
con BCG (+/- IL-12 e IFN-γ), junto a la medición por citometría de flujo de la expresión del 
receptor de IL-12 (IL-12Rβ1) y de IFN-γ (IFN-γR1 e IFN-γR2), así como la fosforilación de STAT1 
en respuesta a IFN-γ, seguido del estudio genético dirigido [4,17–19]. Con el desarrollo de las 
nuevas tecnologías para el estudio genético, el algoritmo diagnóstico ha variado en algunos 
centros, de manera que la realización de estudios de secuenciación masiva es el primer paso 




los pacientes depende del defecto genético: por ejemplo, en los defectos completos que afecten 
al receptor de IFN-γ, la administración de IFN-γ exógeno no será eficaz y serán candidatos a 
trasplante de progenitores hematopoyéticos [20]; en cambio, el resto de formas de MSMD se 
benefician del tratamiento con IFN-γ exógeno. La identificación de los pacientes afectos de 
MSMD, con la consiguiente indicación de un tratamiento específico marcarán el pronóstico de 
los pacientes.  
 
2.1.3.Inmunidad a infecciones intramacrofágicas 
Dado que los macrófagos forman parte de la primera línea de defensa contra los 
patógenos, las infecciones por microorganismos intramacrofágicos representan un reto para el 
sistema inmunitario. Comúnmente, estos patógenos han desarrollado estrategias para evadir 
los mecanismos innatos para su destrucción, por lo que la cooperación entre el sistema 
inmunitario adaptativo y el innato es imprescindible. Esta colaboración se da principalmente a 
través de la vía de IL-12/IFN-γ. En resumen, tras la fagocitosis de la micobacteria o patógeno 
intramacrofágico se activa la célula fagocítica, que producirá IL-12p70 e ISG15. Estas citocinas 
son detectadas por las células T y natural killer que, a su vez, se van a activar y a producir IFN-γ 
causando la sobre activación de las células fagocíticas induciendo la producción de TNF-α, IL-
12p70 y la activación de la respuesta oxidativa que permitirá la destrucción de los patógenos. 
De esta manera se crea un círculo de retroalimentación positiva que es necesario para el control 
de la infección [21–25]. 
 
Figura 1. Esquema de la vía de IL-12/IFN-γ en respuesta a micobacterias 
El mecanismo de señalización principal de IL-12 e IFN-γ se basa en eje Janus associated 
kinase (JAK) – signal transducers and activation of transcription (STAT). Este eje es usado por 
diversas citocinas que comparten el mecanismo de acción. Existen 4 miembros de la familia de 
JAK (JAK1, JAK2, JAK2 y TYK2) y 7 miembros de la familia de STAT (STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B, STAT6). Las moléculas JAK se encuentran asociadas con las cadenas de los 
receptores de citocinas. Tras la unión de la citocina con su receptor hay una agregación del 




proximidad física activa a sus dominios quinasa, de manera que se da fosforilación de los 
receptores y fosforilación de las JAKs. Estas fosforilaciones van a crear sitios de unión para los 
STATs que, a su vez, serán también fosforilados y dimerizarán formando homo o heterodímeros 
para migrar al núcleo y, allí, realizar su función como factores de transcripción [26,27]. La 
señalización de IFN-γ se da tras la agregación de sus dos receptores, IFN-γR1 e IFN-γR2, que se 
encuentran asociados a JAK1 y JAK2 respectivamente; similarmente, la IL-12 se une a su receptor 
formado por las cadenas IL-12Rβ1 e IL-12Rβ2 que se encuentran asociadas a TYK2 y JAK2. La 
agregación de los receptores y la fosforilación de los adaptadores JAK creará un lugar de unión 
para STAT1 en el caso del IFN-γ y para STAT4 en el caso de la IL-12p70 [28–33] 
La tuberculosis es la manifestación clínica de la infección por Mycobacterium 
tuberculosis. Esta enfermedad es un problema global y una de las primeras causas de muerte en 
el mundo, sobre todo en países empobrecidos; de hecho, un 20% de los nuevos casos se pueden 
atribuir a la malnutrición [34]. La inmunidad frente a la tuberculosis depende principalmente en 
la vía de IL-12/IFN-γ con un gran papel del TNF-α. La respuesta inmunitaria es compleja y lleva 
normalmente al control de la infección, pero muy raramente da lugar a una inmunidad 
“esterilizante” [35–37]. Pese a su potencial patogénico, solo aproximadamente un 5% de los 
individuos infectados por Mycobacterium tuberculosis va a desarrollar tuberculosis primaria 
(con formas extrapulmonares, principalmente en la infancia) y, del resto, un 5% va a desarrollar 
tuberculosis secundaria (forma pulmonar “clásica” en adultos) [11,38]. A parte de la 
malnutrición o la co-infección con el virus de la inmunodeficiencia humana, existen IDPs que 
confieren susceptibilidad aumentada a este patógeno como son la inmunodeficiencia 
combinada severa, la enfermedad granulomatosa crónica y los defectos autosómicos 
dominantes de GATA2 entre otros. Además, se han descrito 26 pacientes con mutaciones en 
genes de la vía IL-12/IFN-γ causantes de MSMD [4,11,39–43]. 
La leishmaniasis es una enfermedad parasitaria que se da en las zonas tropicales, 
subtropicales y en el área del Mediterráneo, siendo endémica en España. La organización 
mundial de la salud la ha catalogado como una enfermedad “descuidada”, afectando 
principalmente en zonas en situación de pobreza. Se transmite tras la picada de flebótomos 
hembra y tiene un ciclo de vida complejo con forma de promastigota en el insecto y de 
amastigota en el huésped humano [44–46]. Hay cuatro formas clínicas de leishmaniasis, la 
cutánea, la cutánea difusa, la muco-cutánea y la leishmaniasis visceral. La leishmaniasis visceral, 
también conocida como Kala-Azar, es una forma grave de la infección por Leishmania spp que, 
sin tratamiento, es letal. La respuesta inmunitaria a Leishmania es, como en el caso de la 
tuberculosis, dependiente de la vía de IL-12/IFN-γ para conseguir la activación del macrófago y, 
así, la destrucción del patógeno. Dada la casuística de la enfermedad, se han descrito sobre todo 
causas secundarias de susceptibilidad a leishmaniasis; además, se han descrito 12 pacientes con 
IDP asociada a leishmaniasis, de los cuales 5 tenían mutaciones en genes causantes de MSMD 
[12,42,47–49]  
2.1.4.Tratamiento con fármacos biológicos anti-TNF-α 
La enfermedad inflamatoria intestinal (EII), mayoritariamente representada por la 
enfermedad de Crohn y la colitis ulcerosa, es potencialmente invalidante y se da 
mayoritariamente en mujeres en edad fértil. Al contrario que otras enfermedades inflamatorias, 




enfermedad un riesgo tanto para el feto en desarrollo como para la madre. El uso de fármacos 
biológicos ha proporcionado un gran avance en el tratamiento de los pacientes afectos. En 
concreto, en la EII se emplean fármacos anti-TNF-α (infliximab, adalimumab golimumab y 
certolizumab pegol) [50–53], una molécula que participa en diversos procesos, incluyendo la 
inflamación, la inmunidad frente patógenos intracelulares y el desarrollo del sistema 
inmunitario durante la gestación [54].  
Por su rol en la inmunidad frente a patógenos intracelulares, los pacientes adultos 
tratados con fármacos biológicos anti-TNF-α tienen un riesgo infeccioso aumentado frente a 
estos patógenos, incluyendo la leishmaniasis [55,56] y, como elemento principal, la tuberculosis 
[8,57]. En el caso de la tuberculosis, se observa la reactivación de infecciones latentes con formas 
extrapulmonares que recuerdan a las infecciones observadas en niños con MSMD; este hecho 
hace que antes de administrar un tratamiento biológico anti-TNF-α se deba contemplar la 
posibilidad de la presencia de tuberculosis latente, que deberá ser tratada antes de empezar el 
tratamiento biológico [58,59]. El TNF-α es una molécula clave para la inmunidad frente a 
tuberculosis, tanto en su acción sinérgica con el IFN-γ para la estimulación de la respuesta 
oxidativa en los macrófagos como el reclutamiento de células T, la activación de las células T 
citotóxicas y la promoción de la maduración del monocito, siendo crucial para la formación y el 
mantenimiento del granuloma [35,58,59]. 
Los AcMos anti-TNF-α más usados hasta el momento en EII, adalimumab e infliximab, 
son AcMos IgG que atraviesan la barrera placentaria sobre todo a partir de la semana 30 de 
gestación, existiendo niveles detectables en el suero del niño hasta 6-7 meses después del 
nacimiento [60]. En los casos en que las pacientes con EII no pueden suspender el tratamiento 
durante la gestación, se ha observado que estos fármacos no tienen un efecto teratogénico. Sin 
embargo, no se conoce el alcance de los efectos sobre el sistema inmunitario en desarrollo para 
poder determinar el riesgo infeccioso real del lactante y la necesidad de tomar medidas 
específicas al respecto [61]. Por ello, existe gran controversia sobre la necesidad o no de 
interrumpir dicho tratamiento en caso de embarazo [62,63]. Los efectos a largo plazo de la 
exposición a anti-TNF-α del sistema inmunológico en desarrollo son todavía desconocidos 
[54,64]. En base a datos limitados provenientes de casos reportados, los bebés que nacen con 
niveles detectables de anticuerpos anti-TNF-α no parecen tener un mayor riesgo de infecciones 
en su primer año de vida y tienen una respuesta normal a las vacunas inactivadas [61]. Sin 
embargo, un caso mortal de infección diseminada por BCG fue reportada en un niño cuya madre 
había sido tratada con infliximab durante el embarazo y que recibió la vacuna BCG a los 3 meses 
de edad [65].  
 
2.1.5.El sistema inmunitario en el neonato 
El sistema inmunitario tiene un papel crucial en la transición del feto entre el útero 
materno, estéril y alogénico, y el mundo exterior. Al nacer, especialmente tras el parto vaginal, 
el neonato es masivamente colonizado por diferentes microorganismos. La mayoría de éstos 
serán no-patogénicos, pero algunos podrán ser dañinos. Por esta razón, es necesario un balance 
entre la respuesta antimicrobiana hacia microorganismos patogénicos y la tolerancia para los 
nuevos antígenos inocuos. Los mecanismos de control del sistema inmunitario neonatal incluyen 




antimicrobianos no inflamatorios, la transferencia transplacentaria de anticuerpos maternos, un 
sesgo de la inmunidad adaptativa hacia células T colaboradoras tipo 2 a expensas de las células 
T colaboradoras tipo 1, baja respuesta a receptores tipo toll, entre otros mecanismos. Con esto, 
las infecciones intramacrofágicas en edad neonatal son especialmente peligrosas, destacando 
especialmente los casos de Listeria monocytogenes, Salmonella spp. y Mycobacterium spp. [66–
70].   
El establecimiento de la tolerancia periférica necesita diferentes estrategias reguladoras 
o supresoras. En los últimos años se ha ido desvelando el papel regulador de las células B en 
humanos [71,72]. Las células B reguladoras en humanos no tienen un fenotipo único definido, 
si no que se han descrito diferentes poblaciones con actividad reguladora, siendo las células 
CD24hiCD38hi las más estudiadas, también conocidas como células B reguladoras inmaduras. 
Estas células hacen su función reguladora mediante la producción de IL-10 y el contacto directo 
entre células principalmente; de esta manera, pueden bloquear la diferenciación de las células 
Th1 y Th17 y promover la diferenciación de las células T reguladoras [73–76]. Se ha visto la 
importancia de estas células en diferentes situaciones como las infecciones crónicas, la 
autoinmunidad y, recientemente, sobre el embarazo. Se ha observado que, tanto en modelos 
murinos como en humanos, estas células están reguladas por las hormonas del embarazo y que 
son claves para el establecimiento y el mantenimiento del embarazo [77].  
 
2.2.Hipótesis y objetivos:  
Esta tesis se enmarca en el concepto que la vía IL-12/IFN-γ es fundamental para el 
control de las infecciones intracelulares. Con esto, disfunciones, heredadas o adquiridas, en este 
eje pueden ser detectadas en condiciones clínicas no exploradas en la actualidad. 
Concretamente, hipotetizamos que pacientes con infecciones severas/extrapulmonares por 
Mycobacterium tuberculosis o con leishmaniasis visceral tienen una disfunción primaria de la vía 
de IL-12/IFN-γ, de manera que el estudio de estos pacientes va a llevar a la detección de nuevos 
casos de MSMD, en los que se podrá realizar un manejo específico. Además, que la exposición a 
anticuerpos anti-TNF-α durante el embarazo afecta al desarrollo del sistema inmunitario, 
pudiendo generar una inmunodeficiencia secundaria a esta exposición que incluiría la disfunción 
del eje de IL-12/IFN-γ. 
Con esto, el objetivo principal de esta tesis doctoral: entender los defectos de la vía IL-
12-IFN-γ causados por defectos heredados y secundarios a la exposición a anti-TNF-α durante el 
embarazo. Del objetivo general se derivan los siguientes objetivos específicos:   
Objetivo 1. Elucidar si los pacientes con infecciones intramacrofágicas severas como la 
tuberculosis severa/extrapulmonar o la leishmaniasis visceral tienen defectos en la vía 
IL-12/IFN-  
Objetivo 2. Definir el efecto del tratamiento de la madre con enfermedad inflamatoria 
intestinal con anti-TNF-α durante el embarazo en el desarrollo del sistema inmune del 
niño expuesto.  
Objetivo 2.1. Determinar si la vía IL-12/IFN-γ se encuentra afectada en los niños 




Objetivo 2.2. Caracterizar las diferentes poblaciones linfocitarias en los niños 
expuestos. 
Objetivo 3: Establecer valores de normalidad para las diferentes poblaciones 
linfocitarias en sangre de cordón umbilical, especialmente en el subgrupo de células B 
reguladoras y la integridad del eje IL-12/IFN-γ  
 
2.3.Resultados 
2.3.1.Estudio del eje IL-12/IFN-γ en pacientes con tuberculosis severa/extrapulmonar y leishmaniasis 
visceral 
Para el reclutamiento de pacientes hemos establecido colaboraciones con diferentes 
centros autonómicos, estatales e internacionales incluyendo el Hospital Sant Joan de Déu y el 
Hospital Vall d’Hebron en Barcelona, el Hospital Joan XXIII (Tarragona), el Hospital General 
(Granollers), el Hospital La Fe (Valencia), el Hospital Gregorio Marañón y 12 de Octubre en 
Madrid, el Hospital Son Espases (Mallorca) y el Instituto Nacional del Niño (Lima, Perú). Hemos 
recogido 25 pacientes con infección por Mycobacterium tuberculosis y 23 con leishmaniasis 
visceral, así como 41 controles sanos, de los cuales 23 están relacionados con los pacientes 
(mayoritariamente padres) y 18 no están relacionados. Uno de los pacientes de la cohorte de 
tuberculosis tuvo que ser excluido del estudio dado que primeramente se catalogó como una 
infección por Mtb para luego confirmarse que se trataba de una infección por BCG. 
Los pacientes con infección por Mycobacterium tuberculosis presentaron una mayor 
variación étnica mientras que los pacientes con leishmaniasis visceral eran mayoritariamente de 
origen caucásico. Cabe destacar que los pacientes con leishmaniasis visceral eran más pequeños 
en el momento de la infección (mediana: 1,58 años, rango: 0.25 a 8 años en leishmaniasis 
visceral y mediana: 3 años, rango: 0,47 a 16 años en Mycobacterium tuberculosis). Por otro lado, 
estas diferencias desaparecieron cuando se compara la edad en el momento del estudio 
(mediana: 7,42 años, rango: 0,42 a 12,54 años en leishmaniasis visceral y mediana: 7,28 años, 
rango: 0,62 a 18 años en Mycobacterium tuberculosis). En los pacientes con infección 
extrapulmonar por Mycobacterium tuberculosis, la localización de la infección fue 
mayoritariamente diseminada (33%), con (12%) o sin (21%) meningitis, adenopática (21%) o 
meníngea (17%). Dos de las familias reportaron consanguineidad. Se descartó la presencia de 
inmunodeficiencia combinada severa y enfermedad granulomatosa crónica mediante el estudio 
de las poblaciones celulares, proliferación en respuesta a mitógenos y respuesta oxidativa. 
También resultaron sin alteraciones evidentes las pruebas citométricas específicas para la 
MSMD que incluyeron la detección de IFN-γR1 e IFN-γR2 en monocitos y de IL-12Rβ1 en 
linfocitos activados, así como la fosforilación de STAT1 en respuesta a IFN-γ.  
La técnica gold-standard para el diagnóstico de pacientes con MSMD es la detección de 
la producción de citocinas tras el cultivo de sangre entera con BCG con o sin co-estimulación con 
IL-12p70 o IFN-γ exógeno. Esta técnica permite observar cómo es la respuesta a micobacterias 
en el paciente ex-vivo, siendo muy útil para la detección de defectos completos. Sin embargo, 
existe una gran variabilidad en controles sanos que dificulta la detección de defectos parciales. 
Observamos esta gran variabilidad en la producción de citocinas tanto en los controles sanos 




ratios de co-estimulación (producción de citocinas con “BCG + co-estímulo” / ”BCG”) se observó 
una disminución del coeficiente de variación en los controles sanos no-relacionados que no se 
observó en la cohorte de controles relacionados.  
Se observó un patrón de producción de citocinas diferente entre los dos grupos de 
controles, habiendo una menor producción de IFN-γ y mayor producción de IL-6, IL-10 y TNF-α 
en los controles relacionados en los que, además, observamos una disminución de la ratio de 
co-estimulación de IL-6, y TNF-α en respuesta a IL-12 y de IL-12p70 en respuesta a IFN-γ. En los 
pacientes con infección por Mycobacterium tuberculosis o leishmaniasis visceral no detectamos 
defectos completos en la vía de IL-12/IFN-γ, pero si detectamos una función alterada de esta 
vía. Los pacientes con infecciones por Mycobacterium tuberculosis destacaron por una respuesta 
a IFN-γ alterada, acompañada de un aumento de la producción de IL-10 y TNF-α tras la 
estimulación con BCG. Por el otro lado, los pacientes con infecciones por Leishmania se 
caracterizaron por la baja producción de IFN-γ, en respuesta a BCG. Cabe destacar que todos los 
grupos presentaron una ratio de IFN-γ/IL-10 en respuesta a BCG disminuida en relación con los 
controles no relacionados, especialmente evidente en los pacientes con leishmaniasis visceral. 
Con estos datos, concluimos que tanto los pacientes con tuberculosis severa/extrapulmonar 
como los pacientes con leishmaniasis visceral tienen alterada la vía de IL-12/IFN-γ.  
El caso sacado de la cohorte de tuberculosis por un error en el diagnóstico 
microbiológico es de especial interés. Se trató de una niña de 6 años peruana diagnosticada con 
tuberculosis recurrente, severa y diseminada. Con esta evolución se decidió estudiar la 
integridad de la vía IL-12/IFN-γ, de manera que se nos remitió el caso. Al realizar las pruebas 
funcionales y genéticas diagnosticamos un defecto completo de IL-12Rβ1 caracterizado por la 
ausencia de la expresión de IL-12Rβ1, así como de fosforilación de STAT-4 tras la estimulación 
con IL-12p70. La producción de IFN-γ tras la estimulación con BCG fue muy reducida y no se 
rescató con la co-estimulación con IL-12p70. Los estudios genéticos confirmaron una mutación 
en IL12RB1 en p. (Arg211*; c.631C>T), siendo la primera paciente con diagnóstico genético de 
MSMD en Perú. Al tiempo del diagnóstico la paciente empeoró y fue trasladada al National 
Institute of Health en Estados Unidos para su tratamiento con IFN-γ exógeno. Una vez allí los 
estudios microbiológicos confirmaron que había habido un error en el diagnóstico inicial, siendo 
la infección derivada de la vacunación por BCG recibida en la infancia. Con esto se optimizó el 
tratamiento micobactericida acompañado de IFN-γ exógeno. La paciente se encuentra ahora 
estable y sin clínica infecciosa. 
 
2.3.2.Estudio del efecto de la exposición a fármacos anti-TNF-α en el desarrollo del sistema 
inmunitario del niño expuesto.  
Para el estudio del efecto de los fármacos anti-TNF-α administrado a mujeres con EII 
embrazadas sobre el desarrollo del sistema inmunitario del niño expuesto se enrolaron 7 
pacientes de las 8 pacientes que cumplieron los criterios de inclusión. De éstas, 2 dejaron el 
seguimiento analítico después del nacimiento, 4 lo han completado hasta los 12 meses y 1 hasta 
los 18 meses. El tamaño de la cohorte de debe a que, en el momento de realización del estudio, 





Hemos encontrado niveles de fármaco detectables en todos los pacientes al nacimiento 
(media 11,42 µg/ml, rango: 5,87 – 42,52 µg/ml), siendo el clearance de éstos el propio que 
corresponde a la vida media esperada de las inmunoglobulinas. Pudimos detectar fármaco hasta 
los 6 meses. No observamos cambios en las principales poblaciones leucocitarias y linfocitarias. 
De todas maneras, al nacimiento encontramos un sistema inmunitario inmaduro 
(subpoblaciones linfocitarias B y T) comparado con controles sanos no expuestos a los fármacos. 
Al año de vida las subpoblaciones linfocitarias B y T se encontraron dentro de los rangos 
definidos para la edad. La inmadurez inicial no tiene consecuencias a nivel de producción de 
inmunoglobulinas o de respuesta a vacunas. Por otro lado, observamos una disminución de las 
células T reguladoras que correlacionó de manera inversa con el nivel valle de fármaco anti-TNF-
α de la madre durante el embarazo. Este nivel de células T reguladoras también correlacionó 
inversamente con la proliferación de las células T a un estímulo débil. De esta manera, a más 
alto es el nivel de fármaco valle de la madre durante el embarazo, menos células T reguladoras 
se encuentran en el neonato y mayor es la proliferación de sus células T a un estímulo débil.  
La respuesta a micobacterias fue menor en los recién nacidos expuestos al fármaco 
durante el embarazo, con una reducción de la expresión de la molécula de activación temprana 
CD69 y de HLA-DR, recuperadas parcialmente después de lavar el fármaco de la sangre para el 
cultivo. Además, la ratio de estimulación (RE) para IL-17 y TNF-α se encontró disminuida, así 
como para la producción de IL-1β, aunque no alcanzó significancia estadística. De igual manera 
la RE de IL-6 y de IL-1RA se encontró aumentada sin obtener significancia estadística. 
Observamos que, con el paso del tiempo, y coincidiendo con la desaparición del fármaco en 
sangre existió un aumento en la producción de IFN-γ, IL-12p70 y TNF-α, mientras que la 
producción de IL-6 se mantuvo estable. 
Clínicamente, ninguno de los niños sufrió infecciones severas, solo uno de los niños 
expuestos (en este caso a adalimumab + azatioprina) tuvo un aumento de las infecciones entre 
los 6 y los 12 meses. 4 de los 7 niños expuestos desarrollaron dermatitis atópica. Con todo, 
podemos concluir que la exposición a fármacos anti-TNF-α durante el embarazo no tiene 
consecuencias clínicas severas durante el primer año de vida, pero que es necesario ampliar el 
número de niños expuestos con estudios inmunológicos y ampliar su seguimiento clínico para 
otros defectos. Es importante sobre todo el control de estos pacientes en países endémicos para 
micobacterias y evitar la su vacunación con BCG, al menos en los primeros meses de vida. 
 
2.3.3.Estudio de las células B reguladoras y la vía IL-12/IFN-γ en neonatos sanos 
Dado que el TNF-α es un factor clave para el desarrollo de las células B, decidimos incluir 
el estudio de las células B reguladoras que, en el momento de realización del estudio, no se 
había descrito en el neonato. Estudiamos las células B reguladoras definidas como 
CD19+CD24hiCD38hi en sangre de cordón umbilical de neonatos sanos (hUCB) y en sangre 
periférica de individuos adultos sanos (hAPB). La frecuencia de células Breg estaba incrementada 
en hUCB en comparación con hAPB (34,39% vs. 9,49%; p=0,0002), especialmente en la 
subpoblación B de células de la zona marginal circulantes, donde se observó la mayor diferencia 
entre hUCB y hAPB (60,80% vs. 4,94%). Las células B reguladoras en hUCB fueron capaces de 
producir IL-10 e inhibir la producción de IFN-γ (1,63 vs. 0,95 RE p=0.004) e IL-4 (1,66 vs. 0,86 RE; 




IgMhiIgDhiCD5+CD10+CD27-, siendo similar al descrito en hAPB con algunas diferencias. Se 
encontró un aumento de la concentración por célula de IgM y un descenso de la expresión de 
los marcadores CD22 y CD73. Nuestro trabajo ha caracterizado la frecuencia, fenotipo y función 
de las células Breg en hUCB, lo que puede contribuir en el conocimiento de la tolerancia 
inmunitaria durante el embarazo, abriendo una puerta a nuevos acercamientos a las 
enfermedades inmuno-mediadas en el feto y el recién nacido.  
Además de las células B reguladoras estudiamos el estado de la vía de IL-12/IFN-γ en 
neonatos. Observamos que, en general, la respuesta tras el estímulo con BCG estaba disminuida, 
concretamente observamos una menor producción de IFN-γ (p=0.001) y de IL-6 (p=0.005), así 
como una menos frecuencia de células CD69+ y un nivel de CD69 por célula más bajo. Por otro 
lado, la respuesta a IL-12 e IFN-γ no se encontraba disminuida. Al estudiar la relación entre la 
producción de citocinas y las células B reguladoras descubrimos una asociación entre la 




Este trabajo aborda el estudio de la integridad de la vía IL-12/IFN-γ en dos situaciones 
de posible inmunodeficiencia: por un lado, pacientes con sospecha de inmunodeficiencia 
primaria por el tipo y gravedad de las infecciones que padecen y, por el otro, el estudio de una 
posible inmunodeficiencia secundaria en el neonato, derivada de la exposición a un fármaco 
biológico anti-TNF-α durante el embarazo. Para desentrañar el efecto de la exposición a 
fármacos anti-TNF-α durante el embarazo era necesario establecer valores de normalidad en un 
grupo control, especialmente respecto a la vía IL-12/IFN-γ. Además, dado el papel del TNF-α en 
el desarrollo de las células B y del papel de las células B reguladoras en salud y enfermedad, 
decidimos incluir su estudio en el neonato. 
2.4.1.Fortalezas y limitaciones:  
Diferentes fortalezas y limitaciones condicionan la interpretación de este trabajo, 
incluyendo el tamaño de las cohortes, los grupos controles y la variación intrínseca de la 
producción de citocinas. Dadas las características de las cohortes estudiadas, el tamaño 
muestral es reducido en todos los casos, especialmente en el estudio del efecto de los fármacos 
anti-TNF-α en niños de madres con EII. Aunque los resultados deben ser interpretados teniendo 
en cuenta esta limitación, valoramos que provienen de cohortes altamente valiosas y son 
robustos.  
Por otro lado, el grupo control ideal pareado por edad no se pudo reclutar debido a 
limitaciones éticas. Por tanto, en el estudio de pacientes pediátricos con tuberculosis 
severa/extrapulmonar o leishmaniasis visceral, éstos se compararon con controles adultos. Para 
el estudio del efecto de los inhibidores del TNF-α en el neonato expuesto se compararon los 
valores obtenidos en sangre de cordón con una cohorte de neonatos nacidos de madres sanas, 
dado que virtualmente todas las madres con EII moderada a severa reciben tratamientos 
inmunomoduladores que nos impedirían evaluar el efecto del fármaco separadamente de la 
patología materna. Al no poder disponer de una cohorte control pediátrica, los resultados del 




en la evolución cuando no existían valores de normalidad establecidos. Cabe destacar la valía de 
la cohorte control de sangre de cordón de madres sanas, que nos permitió establecer valores de 
normalidad y, además, el estudio de la población de células B reguladoras que, en el momento 
del estudio no se había explorado en neonatos. Desafortunadamente, otro grupo trabajando en 
trasplante de progenitores hematopoyéticos de sangre de cordón publicó por primera vez la 
presencia de la población CD24hiCD38hi en sangre de cordón umbilical 9 meses antes [78].  
El cultivo sangre entera del paciente con BCG, en presencia o no de co-estímulos, es una 
de las mejores simulaciones de lo que ocurre en el paciente después de una infección 
intramacrofágica. Es considerado gold standard para el diagnóstico de la MSMD aunque 
presenta una gran variabilidad interindividual como demuestran los datos de los controles 
sanos, y como también han descrito otros grupos [15,18,42]. Esta variabilidad hace que 
mediante esta técnica sea complejo distinguir los defectos parciales de los controles sanos. 
Mediante el uso de ratios de co-estimulación se puede reducir esta variabilidad en controles 
sanos no relacionados con los pacientes. Hemos observado que esta disminución de la 
variabilidad no se observa en controles sanos relacionados con los pacientes. Creemos que al 
estar relacionados con un grupo niños con posibles defectos parciales de respuesta o producción 
de IFN-γ, la variabilidad se mantiene aun realizando ratios de respuesta a los co-estímulos, 
reforzando la hipótesis de que existe un componente familiar/genético en la susceptibilidad a 
dichas infecciones.  
2.4.2.Estudio de la vía de IL-12/IFN-γ en pacientes con tuberculosis severa/extrapulmonar y 
leishmaniasis visceral  
Siguiendo la teoría genética de las infecciones, que postula que infecciones severas en 
la infancia, en pacientes sin predisposición adquirida, se deben a defectos heredados en un 
único gen [79], hemos estudiado dos cohortes de pacientes con infecciones no típicas en la 
MSMD: pacientes con infección extrapulmonar por Mycobacterium tuberculosis y pacientes con 
leishmaniasis visceral como única infección. Estas infecciones son más graves de lo común en 
niños con un estado de salud general normal, sugiriendo un defecto en el control de estos 
patógenos.  
Ya en controles sanos relacionados con los pacientes observamos un patrón de 
producción de citocinas alterado, sugiriendo una afectación de la vía. Los pacientes con infección 
tuberculosa presentaron una producción de IFN-γ comparable a los controles sanos pero una 
respuesta a éste disminuida, incluyendo la producción de IL-12p70, TNF-α e IL-1β. Por otro lado, 
la producción de IFN-γ estaba disminuida en los pacientes con infección por leishmaniasis 
visceral comparado con los demás grupos estudiados. Se conoce que durante la infección por 
Leishmania, las células de los pacientes tienen una menor capacidad de producción de IFN-γ que 
se recuera tras la desaparición de la infección [80,81], por lo que dado que todas las muestras 
se procesaron al menos un mes después de la infección no debería afectar a los resultados. Por 
otro lado, la teoría de la inmunidad innata entrenada sostiene que, al nacer, la inmunidad innata 
es inmadura y que va adquiriendo la capacidad para generar respuestas inflamatorias con el 
tiempo y la exposición a antígenos debido a cambios principalmente epigenéticos [82–84], con 
esto, podría ser posible que la infección con leishmaniasis en edades muy tempranas previniera 
estas modificaciones epigenéticas o que fuera debido a errores heredados. El estudio genético 




epigenética, podría dilucidar el origen de la susceptibilidad de estos pacientes y, así, optimizar 
su tratamiento y manejo.  
Hasta el momento no hay publicado ningún trabajo en que se estudie la integridad de la 
vía IL-12/IFN-γ en busca de defectos en pacientes con leishmaniasis visceral; sin embargo, hay 
un estudio describiendo que 2 de 50 niños estudiados presentaron mutaciones en IL-12RΒ1en 
el pacientes con infecciones severas por Mycobacterium tuberculosis en una zona endémica de 
tuberculosis con alta consanguinidad [48]; por otro lado, otro estudio de genes causantes de 
MSMD en pacientes adultos y pediátricos con infecciones severas por Mtb realizado en una zona 
de baja consanguinidad no detectó ninguna mutación causante [85]. En el estudio presentado 
no hemos detectado ningún paciente con un defecto completo, lo que sugiere que defectos 
completos en genes conocidos causantes de MSMD no deberían ser sospechados a priori en 
pacientes con estas infecciones en zonas de baja consanguineidad; de todas maneras, es 
necesario seguir estudiando la alteración observada en la integridad de la vía de IL-12/IFN-γ.  
La baja frecuencia de pacientes diagnosticados de MSMD en nuestro medio se puede 
deber a la baja consanguinidad presente y, también, al hecho que no exista la vacunación con 
BCG, el signo de alarma principal de esta entidad. El desarrollo de enfermedad infecciosa tras la 
vacunación con BCG es muy raro [86] y es signo de inmunodeficiencia [4], ya sea adquirida o 
congénita. Al derivar de Mycobacterium bovis, la diferenciación entre una infección por 
Mycobacterium tuberculosis y BCG es compleja y puede llevar a confusión en áreas endémicas 
para Mycobacterium tuberculosis [86–88]. La correcta identificación del elemento infeccioso, así 
como la sospecha de inmunodeficiencia es básica para el correcto manejo del paciente. En el 
caso de la paciente diagnosticada de una deficiencia de IL-12Rβ1 no se sospechó la presencia de 
una inmunodeficiencia hasta la diseminación y recurrencia de la mal diagnosticada infección por 
Mycobacterium tuberculosis. Si la sospecha de inmunodeficiencia se hubiera realizado desde el 
principio, se hubiera podido aplicar el tratamiento adecuado y, posiblemente, haber reducido la 
severidad de la enfermedad.  
 
2.4.3.El diagnóstico de la MSMD, de la investigación a la práctica clínica 
El diagnóstico de la MSMD es complejo y se realiza en laboratorios de inmunología 
especializada. Gracias al desarrollo de la metodología necesaria para el estudio de la vía de IL-
12/IFN-γ en pacientes con leishmaniasis visceral o tuberculosis severa/extrapulmonar hemos 
podido establecer la metodología necesaria para el diagnóstico de MSMD. Concretamente 
proponemos un algoritmo diagnóstico que incluye, tras la sospecha diagnóstica: 1) descartar 
otras inmunodeficiencias que, además de otras características, causan susceptibilidad a 
micobacterias, 2) determinar mediante citometría de flujo la presencia de los receptores de IFN-
γ y el receptor de IL-12R así como la fosforilación de STAT1 en respuesta a IFN-γ para descartar 
de manera rápida los defectos completos de la vía más frecuentes, 3) estudios genéticos, o bien 
enfocados tras las pruebas citométricas o mediante secuenciación masiva (con el uso de paneles 
o secuenciación del exoma) y 4) si se ha encontrado una posible mutación causante de 
enfermedad se deberá realizar la validación funcional que suele ser realizada en el contexto de 
un laboratorio de investigación. El diagnóstico final de MSMD puede reducir la morbi-mortalidad 




2.4.4.La exposición prenatal a fármacos anti-TNF-α tiene un impacto en la maduración del sistema 
inmunitario de los niños expuestos  
Existe una proporción elevada de familias que escogen no tener hijos entre las pacientes 
con EII, principalmente por el miedo a la reactivación de la enfermedad o al efecto de los 
fármacos en el niño. En los niños expuestos a anti-TNF-α prenatalmente observamos que, como 
se había publicado anteriormente [89,90], existía presencia del fármaco en sangre detectable 
hasta, aproximadamente, los seis meses de vida. La exposición al fármaco afectó a la maduración 
del sistema inmunitario durante el embarazo, normalizándose a los 12 meses de vida, 
incluyendo una respuesta vacunal adecuada respecto a la edad. A los tres meses de edad, 3 de 
los 5 niños expuestos que seguían realizando seguimiento analítico desarrollaron neutropenia. 
Previamente se había asociado el uso de fármacos anti-TNF-α durante el embarazo con 
neutropenia severa en el neonato expuesto al nacimiento [91], por este motivo. Aunque en la 
cohorte incluida en el estudio ninguno de los niños desarrolló las infecciones cutáneas 
observadas previamente, creemos que el conteo de neutrófilos debería incluirse en el 
seguimiento de esta población. 
Cabe destacar que observamos un descenso de células T reguladoras que no se recupera 
a los 12 meses. Se ha descrito en algunos trabajos que la exposición a fármacos anti-TNF-α 
aumenta la frecuencia de células T reguladoras en pacientes respondedores [92–94]. Una 
posible explicación de estas diferencias es que las células que aumentan en los pacientes adultos 
parecen ser células T reguladoras inducidas [93]. Dado que las células T reguladoras inducidas 
se diferencian tras un insulto antigénico, en el cordón umbilical esperaríamos que la mayoría de 
las células reguladoras sean naturales [95]. Además, el efecto del fármaco anti-TNF-α en el 
desarrollo de las células Treg inducidas es difícil de cuantificar dado que el nivel de fármaco 
presente en sangre disminuye de manera significativa a los 3 meses de edad. Es destacable en 
este contexto que observamos que 4 de los 7 niños estudiados presentaron atopia. Por estas 
razones creemos aconsejable realizar un seguimiento clínico de estos niños para valorar la 
aparición de alergias, atopia u otros eventos relacionados.  
La exposición a fármacos anti-TNF-α durante todo el embarazo produce una disminución 
transitoria de la respuesta a micobacterias. En adultos, los tratamientos con fármacos biológicos 
son considerados causantes de fenotipos tipo inmunodeficiencia [96]; esto se puede aplicar 
también a los neonatos que, además, tienen una respuesta sesgada hacia las células T 
colaboradoras tipo 2 [97]. En adultos con enfermedad inflamatoria, estos fármacos producen 
disminución de la producción de IL-12 [98], así como un descenso en las células T CD8 
productoras de IFN-γ y en las subpoblaciones Th1/Th17 [99]. Los resultados obtenidos en 
neonatos no corresponden totalmente con los observados en adultos, presumiblemente 
explicable por el hecho de que el sistema inmunitario del neonato y el del adulto con 
enfermedad inflamatoria son diferentes [70,97,100–103]. La respuesta disminuida a 
micobacterias al nacimiento es de especial importancia en el contexto de la vacunación con BCG.  
Recientemente han aparecido en el mercado los biosimilares anti-TNF-α, de manera que 
se va a poder ampliar el tratamiento con este tipo de fármacos biológicos en países con menos 
recursos económicos, donde la vacunación con BCG está regulada justo al nacer. Hasta que se 
realicen más investigaciones, la vacunación con BCG está totalmente contraindicada en estos 




durante el embarazo y vacunado con BCG [104], así como la práctica en pacientes con EII 
tratados con fármacos inmunomoduladores [105], llevaron a la decisión de evitar las vacunas 
vivas en estos niños hasta, al menos, los 12 meses [89,106]. Tras observar que no hubo 
reacciones adversas tras la administración de la vacuna del rotavirus en 4 pacientes, la correcta 
maduración de las poblaciones linfocitarias, la proliferación en respuesta a mitógenos y la 
respuesta a vacunas, cumpliendo los criterios para poder administrar vacunas atenuadas en 
pacientes con inmunodeficiencia celular [107], especulamos que la política de vacunación de los 
niños expuestos a fármacos anti-TNF-α durante el embarazo podría ser revisada, siempre 
teniendo en cuenta la evitación de la vacunación con BCG u otras vacunas con microorganismos 
de vida intramacrofágica atenuados.  
2.4.5.Las células B reguladoras pueden jugar un papel principal en la inmunidad neonatal 
El sistema inmunitario se ha adaptado para mediar la transición entre el útero materno, 
estéril y alogénico, y el mundo exterior donde será masivamente colonizado por 
microorganismos y atacado por patógenos. En sangre de cordón de neonatos sanos, las células 
con fenotipo CD19+CD24hiCD38hi se encuentran en una mayor frecuencia y son capaces de 
producir IL-10 así como de inhibir la producción de citocinas inflamatorias como el IFN-γ con un 
fenotipo similar al de las células B reguladoras en el adulto. Cabe destacar que encontramos una 
asociación entre el nivel de células B reguladoras y la producción de IFN-γ tras la estimulación 
con BCG, estando ésta disminuida en los neonatos.  
La inhibición de la producción de IFN-γ por las células B reguladoras no se da con las 
células “no B reguladoras” (subpoblación definida con los marcadores CD24intCD38int). En el otro 
estudio publicado estudiando las células B reguladoras en sangre de cordón ratificaron que eran 
capaces de inhibir la producción de IFN-γ por las células T, pero que la subpoblación de células 
no B reguladoras también era capaz de hacerlo [78], estas diferencias no son irreconciliables y 
se pueden deber a diferentes aproximaciones experimentales. La proporción de células B 
reguladoras entre la población de células circulantes de la zona marginal llama la atención. Cabe 
destacar que las células de la zona marginal se caracterizan por ser de rápida respuesta tras el 
insulto con bacterias encapsuladas, incluyendo la microbiota comensal [108–110]. El aumento 
de células con función reguladora dentro de esta población, así como la disminución de la 
molécula CD22, que podría resultar en una reducción del umbral de activación, podría ser uno 
de los mecanismos mediante los cuales el sistema inmunitario del neonato previene una 
respuesta inflamatoria exagerada en respuesta al gran rango de antígenos encontrados. 
Además, observamos un aumento de la cantidad de IgM por célula en las células B 
reguladoras en cordón umbilical, que especulamos podría estar implicado en el mecanismo de 
acción de éstas. Los anticuerpos IgM anti-leucocitarios son definidos como anticuerpos 
“naturales”, que tienen capacidad de inhibir la activación de las células T y su quimiotaxis 
[111,112]. Estos anticuerpos se encuentran presentes al nacimiento [112] y son capaces de 
inhibir la producción de IFN-γ e IL-17 por las células T en respuesta a aloantígenos en ratón [111]. 
Especulamos que este puede ser un nuevo mecanismo independiente de IL-10 por el cual las 
células B reguladoras neonatales serían capaces de ejercer su función reguladora. 
Las células B podrían ser un arma de doble filo en el trasplante de progenitores 
hematopoyéticos de sangre de cordón, por un lado, parece que favorecen la tolerancia [78] y, 




y la correlación de la producción de IFN-γ con la frecuencia de células B reguladoras, 
hipotetizamos que también podrían estar implicadas en la aumentada susceptibilidad a 
infecciones observada en los pacientes trasplantados con sangre de cordón [113]. Esta 
asociación merece una investigación más exhaustiva para determinar el papel de estas células 
en el trasplante de células de cordón, así como para estudiar el papel de estas células en 
situaciones especiales del embarazo.  
2.4.6.Implicaciones del trabajo y expectativas de futuro 
El trabajo presentado es el resultado de un proyecto traslacional, por lo que los 
resultados obtenidos tienen implicaciones en la práctica clínica. La consecución de los diferentes 
objetivos ha generado más preguntas de las que ha resuelto.  
Ninguno de los pacientes con algún episodio de leishmaniasis visceral o tuberculosis 
severa/extrapulmonar presentó defectos completos con las pruebas funcionales disponibles. De 
todas maneras, estos pacientes presentaron una alteración de la vía de IL-12/IFN-γ, por lo que 
se deberían estudiar, al menos, los genes conocidos con mutaciones causantes de MSMD. De 
todas maneras, existe un gran número de pacientes con cuadros compatibles con MSMD, sin 
defecto genético conocido aún tras la realización de estudios de secuenciación masiva, 
incluyendo el exoma [4]. Es probable que genes candidatos y vías cruciales para la inmunidad 
micobacterias aún no se hayan identificado; así como la existencia de otros mecanismos 
causantes de enfermedad todavía no explorados como las mutaciones somáticas o las 
variaciones epigenéticas. Complementariamente al estudio de mecanismos de enfermedad 
alternativos, la técnica gold standard actual tiene todavía rango de mejora, sobre todo en la 
variabilidad existente en los resultados obtenidos en controles sanos, el análisis de los 
resultados mediante técnicas bioinformáticas avanzadas podría ayudar a reducir esta 
variabilidad y, así, facilitar la interpretación de los resultados.  
En el efecto de la exposición con fármacos anti-TNF-α sobre el sistema inmunitario del 
niño expuesto destaca el efecto sobre la frecuencia de células T reguladoras. Por esto, estudiar 
en profundidad los cambios que se producen en estas células, así como su funcionalidad sería 
de gran ayuda para poder entender los efectos y las consecuencias del uso de estos fármacos 
sobre éstas. En la misma línea, dado que existe una respuesta alterada a micobacterias que no 
se recupera totalmente tras limpiar el fármaco de la sangre para el cultivo, sería muy interesante 
estudiar la posibilidad que se produzcan cambios epigenéticos por la exposición al fármaco 
durante la fase final del desarrollo intra-uterino del sistema inmunitario que expliquen esta 
reducida respuesta a micobacterias. Dada la importancia de las condiciones maternas en el 
desarrollo del sistema inmunitario, creemos que es recomendable estudiar los efectos del 
fármaco en las diferentes enfermedades en que se quiera implementar su uso durante esta 
etapa.  
Finalmente, la observación de una población expandida de células B reguladoras en 
sangre de cordón abre la puerta a ahondar en el estudio de estas células en diferentes 
situaciones, incluyendo la posibilidad de estudiar un nuevo mecanismo de acción mediante la 
producción de anticuerpos IgM anti-leucocitarios, el estudio de las células B reguladoras en 
diferentes condiciones como las infecciones neonatales y su importancia en el trasplante de 
células hematopoyéticas cordón umbilical, evaluando en qué casos podría ser beneficioso y en 






1. No detectamos ningún caso de inmunodeficiencia primaria en los pacientes estudiados 
con leishmaniasis visceral o tuberculosis severa/extrapulmonar en nuestra área, 
incluyendo defectos T, enfermedad granulomatosa crónica y defectos completos de la 
vía IL-12/IFN-γ o MSMD. 
2. Sin embargo, el eje IL-12/IFN-γ estaba parcialmente alterado en pacientes pediátricos 
con leishmaniasis visceral y con tuberculosis severa/extrapulmonar, sugiriendo una 
susceptibilidad intrínseca a infecciones intramacrofágicas. Para la definición de los 
mecanismos concretos de susceptibilidad son necesarias nuevas estrategias de 
estudio, incluyendo el uso de técnicas de secuenciación masiva y estudios 
epigenéticos. 
3.  El diagnóstico temprano de la MSMD, basado en el desarrollo de signos de alarma 
específicos y de la metodología diagnóstica de MSMD, es primordial ya que la 
confirmación genética e inmunológica de MSMD va a condicionar el tratamiento del 
paciente. 
4. La exposición prenatal a anti-TNF-α, usado para el tratamiento de mujeres 
embarazadas con enfermedad inflamatoria intestinal, puede considerarse segura, sin 
eventos clínicos significantes 
5. Sin embargo, cambios en el sistema inmunitario del neonato expuesto se han 
observado, especialmente teniendo en cuenta el eje IL-12/IFN-γ que se encuentra 
parcialmente defectuoso, posiblemente aumentando la susceptibilidad a 
micobacterias. Por este motivo, la vacunación con BCG debe ser evitada al nacimiento 
6. Los niños expuestos a anti-TNF-α, usado para el tratamiento de mujeres embarazadas 
con enfermedad inflamatoria intestinal, deberían ser seguidos a largo término para 
controlar la aparición de eventos alérgicos, autoinmunes o autoinflamatorios. 
7. Las células B reguladoras se encuentran expandidas en sangre de cordón de neonatos 
sanos, con una función regulatoria confirmada. Esta observación podría tener un rol 
importante explicando las particularidades tanto de la respuesta neonatal a 
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